
<html lang="en"     class="pb-page"  data-request-id="0d8e283a-a27a-4336-a973-d6af5f6a5c67"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00972;issue:issue:10.1021/jmcmar.2019.62.issue-18;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor" /></meta><meta name="dc.Creator" content="Chiara  Borsari" /></meta><meta name="dc.Creator" content="Denise  Rageot" /></meta><meta name="dc.Creator" content="Alix  Dall’Asen" /></meta><meta name="dc.Creator" content="Thomas  Bohnacker" /></meta><meta name="dc.Creator" content="Anna  Melone" /></meta><meta name="dc.Creator" content="Alexander M.  Sele" /></meta><meta name="dc.Creator" content="Eileen  Jackson" /></meta><meta name="dc.Creator" content="Jean-Baptiste  Langlois" /></meta><meta name="dc.Creator" content="Florent  Beaufils" /></meta><meta name="dc.Creator" content="Paul  Hebeisen" /></meta><meta name="dc.Creator" content="Doriano  Fabbro" /></meta><meta name="dc.Creator" content="Petra  Hillmann" /></meta><meta name="dc.Creator" content="Matthias P.  Wymann" /></meta><meta name="dc.Description" content="The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have..." /></meta><meta name="Description" content="The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 29, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00972" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00972" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00972" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00972" /></link>
        
    
    

<title>A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00972" /></meta><meta property="og:title" content="A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0011.jpeg" /></meta><meta property="og:description" content="The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure–activity relationship (SAR) studies led to the identification of compound 12b with a ∼450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00972"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00972">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00972&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00972&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00972&amp;href=/doi/10.1021/acs.jmedchem.9b00972" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8609-8630</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00963" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01003" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chiara Borsari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chiara Borsari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chiara++Borsari">Chiara Borsari</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4688-8362" title="Orcid link">http://orcid.org/0000-0002-4688-8362</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Denise Rageot</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Denise Rageot</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Denise++Rageot">Denise Rageot</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2833-5481" title="Orcid link">http://orcid.org/0000-0002-2833-5481</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alix Dall’Asen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alix Dall’Asen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alix++Dall%E2%80%99Asen">Alix Dall’Asen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Bohnacker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Bohnacker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Bohnacker">Thomas Bohnacker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Melone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Melone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Melone">Anna Melone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexander M. Sele</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexander M. Sele</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+M.++Sele">Alexander M. Sele</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4903-7934" title="Orcid link">http://orcid.org/0000-0002-4903-7934</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eileen Jackson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eileen Jackson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eileen++Jackson">Eileen Jackson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jean-Baptiste Langlois</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jean-Baptiste Langlois</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Baptiste++Langlois">Jean-Baptiste Langlois</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Florent Beaufils</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Florent Beaufils</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Florent++Beaufils">Florent Beaufils</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Hebeisen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Hebeisen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Hebeisen">Paul Hebeisen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Doriano Fabbro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Doriano Fabbro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Doriano++Fabbro">Doriano Fabbro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Petra Hillmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Petra Hillmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Petra++Hillmann">Petra Hillmann</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Matthias P. Wymann</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthias P. Wymann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#e38e8297978b8a8290cd949a8e828d8da3968d8a818290cd808b"><span class="__cf_email__" data-cfemail="a4c9c5d0d0cccdc5d78ad3ddc9c5cacae4d1cacdc6c5d78ac7cc">[email protected]</span></a>. Phone: +41 61 207 5046. Fax: +41 61 207 3566.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthias+P.++Wymann">Matthias P. Wymann</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3349-4281" title="Orcid link">http://orcid.org/0000-0003-3349-4281</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00972&amp;href=/doi/10.1021%2Facs.jmedchem.9b00972" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8609–8630</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 29, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 June 2019</li><li><span class="item_label"><b>Published</b> online</span>29 August 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 September 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00972" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00972</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by-nc text">with CC-BY-NC-ND<a href="/page/policy/authorchoice_ccbyncnd_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00972"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4596</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00972" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chiara&quot;,&quot;last_name&quot;:&quot;Borsari&quot;},{&quot;first_name&quot;:&quot;Denise&quot;,&quot;last_name&quot;:&quot;Rageot&quot;},{&quot;first_name&quot;:&quot;Alix&quot;,&quot;last_name&quot;:&quot;Dall’Asen&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Bohnacker&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Melone&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;M. Sele&quot;},{&quot;first_name&quot;:&quot;Eileen&quot;,&quot;last_name&quot;:&quot;Jackson&quot;},{&quot;first_name&quot;:&quot;Jean-Baptiste&quot;,&quot;last_name&quot;:&quot;Langlois&quot;},{&quot;first_name&quot;:&quot;Florent&quot;,&quot;last_name&quot;:&quot;Beaufils&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Hebeisen&quot;},{&quot;first_name&quot;:&quot;Doriano&quot;,&quot;last_name&quot;:&quot;Fabbro&quot;},{&quot;first_name&quot;:&quot;Petra&quot;,&quot;last_name&quot;:&quot;Hillmann&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;P. Wymann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;8609-8630&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00972&quot;},&quot;abstract&quot;:&quot;The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure–activity relationship (SAR) studies led to the identification of compound 12b with a ∼450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00972&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00972" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00972&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00972" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00972&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00972" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00972&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00972&amp;href=/doi/10.1021/acs.jmedchem.9b00972" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00972" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00972" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00972%26sid%3Dliteratum%253Aachs%26pmid%3D31465220%26genre%3Darticle%26aulast%3DBorsari%26date%3D2019%26atitle%3DA%2BConformational%2BRestriction%2BStrategy%2Bfor%2Bthe%2BIdentification%2Bof%2Ba%2BHighly%2BSelective%2BPyrimido-pyrrolo-oxazine%2BmTOR%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D18%26spage%3D8609%26epage%3D8630%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (7)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/jmcmar.2019.62.issue-18/20190926/jmcmar.2019.62.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure–activity relationship (SAR) studies led to the identification of compound <b>12b</b> with a ∼450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of <b>12b</b>. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63364" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63364" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The mechanistic target of rapamycin (mTOR, also mammalian TOR) is a key signaling node in the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathway and operates downstream of PI3K. mTOR is a serine/threonine protein kinase and is part of two functionally distinct multiprotein complexes, mammalian target of rapamycin complex 1 (mTORC1) and mammalian target of rapamycin complex 2 (mTORC2).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> TORC1 integrates inputs from cell surface receptors, cellular energy, stress levels, availability of oxygen and amino acids. Cell surface receptors activate PI3K to produce PtdIns(3,4,5)<i>P</i><sub>3</sub>, which serves as a docking site for protein kinase B (PKB/Akt) and phosphoinositide-dependent protein kinase 1 (PDK1). This results in phosphorylation of PKB/Akt at two regulatory sites, Thr308 by PDK1 and Ser473 by mTORC2, and other hydrophobic motif kinases.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a></div><div class="NLM_p">Through the activation of S6 kinase (S6K), TORC1 promotes phosphorylation of ribosomal protein S6, which is a key regulator of protein and lipid synthesis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> TORC1 also regulates lysosome function and autophagy, while TORC2 promotes cytoskeletal rearrangement, cell survival, and cell cycle entry.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The PI3K/mTOR axis is involved in many cellular processes including cell growth, proliferation, and metabolism, and it has been found to be dysregulated in fatal diseases, such as cancer, metabolic, cardiovascular, and neurological disorders.<a onclick="showRef(event, 'ref5 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref5 ref9 ref10 ref11 ref12">(5,9−12)</a></div><div class="NLM_p">The pivotal role of mTOR in numerous human cancers has made this Ser/Thr-kinase a therapeutic target for cancer treatment.</div><div class="NLM_p">Rapamycin and its analogs (rapalogs) are allosteric inhibitors of TORC1 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and form a TORC1/rapalog/FK506 binding protein 12 (FKBP12) complex.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Rapalogs have been extensively investigated in clinical trials in oncology<a onclick="showRef(event, 'ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17">(14−17)</a> and have been approved for a number of cancer treatments such as lung, gastrointestinal neuroendocrine, noncancerous kidney, and advanced pancreatic tumors, advanced ER+/HER2-negative breast and endometrial cancer, mantle cell lymphoma, tuberous sclerosis complex (TSC), and pediatric subependymal giant cell astrocytoma (SEGA).<a onclick="showRef(event, 'ref16 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref18 ref19">(16,18,19)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of rapamycin and rapalogs and a selection of ATP-competitive mTOR kinase inhibitor (TORKi) compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Their efficacy as single agents in major solid tumors, however, has turned out to be limited.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This might be explained by the selective allosteric inhibition of TORC1, which (i) leaves mTORC2 intact and (ii) suppresses TORC1-dependent feedback loops.<a onclick="showRef(event, 'ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24">(21−24)</a> Small molecule ATP-competitive TORKi compounds target both mTORC1 and mTORC2. Hence, these inhibitors efficiently block two branches of PI3K downstream signaling: (i) one via PKB/Akt to tuberous sclerosis complex (TSC) and Ras homolog enriched in brain (Rheb1) controlling TORC1 and (ii) the PtdIns(3,4,5)<i>P</i><sub>3</sub>-medited Sin1-dependent TORC2 activation,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> explaining their robust antitumor efficacy.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> However, by targeting the ATP-binding site of mTOR, TORKi compounds potentially inhibit other protein and lipid kinases at elevated doses, especially the structurally related PI3Ks. Thus, the development of highly selective TORKi is an ongoing challenge. Structurally distinct mTOR-selective inhibitors have been reported and evaluated in a wide range of malignancies. Among the most noteworthy examples, CC-223 (<b>55</b>),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> sapanisertib (INK128, MLN0128, <b>56</b>),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and vistusertib (AZD2014, <b>57</b>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> have been explored in clinical trials and were found superior to rapalogs in terms of cytostatic and cytotoxic potential (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> for chemical structures).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">Very recently, we have reported on PQR620 (<b>58</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a highly selective and potent ATP-competitive mTOR inhibitor, targeting both mTORC1 and mTORC2 kinase activities.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> PQR620 (<b>58</b>) had been discovered through chemical modification of PQR309 (<b>1</b>), a pan-PI3K and moderate mTOR inhibitor currently in clinical trials for the treatment of lymphoma and solid tumors.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35">(32−35)</a></div><div class="NLM_p last">Here, we report the discovery of conformationally restricted compounds as a novel scaffold for the development of highly selective TORKi compounds. The design of conformationally constrained analogs is often used to minimize the entropic loss associated with target binding, to enhance the potency for the target, and to increase the selectivity.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> This conformational restriction approach explores a novel chemical space and secured intellectual property.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> An extensive structure–activity relationship (SAR) study led us to the identification of a highly selective and potent ATP-competitive inhibitor <b>12b</b>. Compound <b>12b</b> is orally bioavailable, metabolically stable and has a minimal brain permeability, an advantage in the treatment of systemic tumors. Our results disclose the tricyclic pyrimido-pyrrolo-oxazine moiety as an innovative scaffold for selectively targeting mTOR kinase.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Rigidification Strategy</h3><div class="NLM_p">In our rigidification strategy, we started from PQR309 (<b>1</b>) and introduced a methylene bridge between one of the morpholines and the aromatic core (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). This led to the conversion of the triazine ring into a pyrimidine core. Moreover, we have removed the trifluoromethyl group from the 2-aminopyridine moiety (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) to alter lipophilicity, increase solubility, and change electronic and steric parameters.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Strategy for the development of mTOR selective inhibitors starting from PQR309 (<b>1</b>): rigidification strategy (red dotted lines) and removal of trifluoromethyl group from the 2-aminopyridine moiety (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For the designed compounds, two different regioisomers exist, each with two enantiomers (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <b>2a</b> /<b>2b</b> and <b>2c</b>/<b>2d</b>). To evaluate the rigidification effect on compounds activity, compounds <b>2a</b>–<b>d</b> were evaluated for in vitro binding [<i>K</i><sub>i</sub> for mTOR and PI3Kα (p110α)] and for PI3K/mTOR signaling in A2058 cells (IC<sub>50</sub> for phosphorylated S6 to detect mTORC1 activity, and protein kinase B (PKB/Akt) phosphorylation on Ser473 to detect mTORC2 activity). One regioisomer is more potent both in cells and in vitro, as highlighted by comparing <b>2a</b> with <b>2c</b> and <b>2b</b> with <b>2d</b>. Compound <b>2a</b> was >9-fold more potent in cells and >11-fold more potent in vitro than <b>2c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Conformationally Restricted Regioisomers <b>2a/2b</b> and <b>2c/2d</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0007.gif" alt="" id="gr3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">cellular assay, IC<sub>50</sub> [nM]<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">in vitro binding assay, <i>K</i><sub>i</sub> [nM]<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">pPKB S473</th><th class="colsep0 rowsep0" align="center" char=".">pS6 S235/236</th><th class="colsep0 rowsep0" align="center" char=".">p110α</th><th class="colsep0 rowsep0" align="center" char=".">mTOR</th><th class="colsep0 rowsep0" align="center" char=".">selectivity <i>K</i><sub>i</sub>(p110α)/<i>K</i><sub>i</sub>(mTOR)</th><th class="colsep0 rowsep0" align="center" char=".">clogP<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR309 (<b>1</b>)</td><td class="colsep0 rowsep0" align="char" char=".">139</td><td class="colsep0 rowsep0" align="char" char=".">205</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="char" char=".">3.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char=".">194</td><td class="colsep0 rowsep0" align="char" char=".">164</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">2.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char=".">118</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">432</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">18.3</td><td class="colsep0 rowsep0" align="char" char=".">2.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="char" char=".">1871</td><td class="colsep0 rowsep0" align="char" char=".">1790</td><td class="colsep0 rowsep0" align="char" char=".">867</td><td class="colsep0 rowsep0" align="char" char=".">812</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">2.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char=".">1560</td><td class="colsep0 rowsep0" align="char" char=".">1857</td><td class="colsep0 rowsep0" align="char" char=".">541</td><td class="colsep0 rowsep0" align="char" char=".">1279</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">2.65</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">PKB phosphorylation on Ser473 and ribosomal S6 phosphorylation on Ser235/236 were analyzed in A2058 cells exposed to the indicated inhibitors and subsequent detection of phosphoproteins in an in-cell Western assay. Each experiment was performed with <i>n</i> = 2. The log IC<sub>50</sub> values and standard errors are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S7 in the Supporting Information</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Compounds were tested for the in vitro binding to the ATP-binding site of p110α and mTOR using a commercially available time-resolved FRET (TR-FRET) displacement assay (LanthaScreen). Each experiment was performed with <i>n</i> = 2. IC<sub>50</sub> values and log IC<sub>50</sub> values and standard errors are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S7 in the Supporting Information</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Marvin/JChem 16.10.17 was used for calculation of log <i>P</i> (partition coefficient) values.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Elucidation of Binding Modes to PI3K and mTOR</h3><div class="NLM_p">To explain activity differences of the regioisomers, we considered the possible interactions of the inhibitors within the ATP-binding site of the kinases. As previously reported for PQR309 (<b>1</b>)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and other morpholino-substituted PI3K inhibitors,<a onclick="showRef(event, 'ref32 ref39'); return false;" href="javascript:void(0);" class="ref ref32 ref39">(32,39)</a> a crucial interaction for PI3K binding is the hydrogen bond formation in the hinge region between the backbone amide of Val882 residue in PI3Kγ (Val851 in PI3Kα) and the morpholine oxygen atom. Herein, we started from the conformationally restricted PQR309 (<b>1</b>) analogs (<b>3a</b> and <b>3b</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) and replaced the morpholine with a piperidine (<b>4a</b>,<b>b</b> and <b>5a</b>,<b>b</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) to investigate whether the methylene-bridged morpholine or the unrestricted morpholine points toward and interacts with the hinge region Val of the ATP-binding pocket. The obtained <i>K</i><sub>i</sub> values for PI3Kα suggested that the methylene-bridged morpholine is located in the solvent exposed region, since only the compounds with a methylene-bridged piperidine (<b>4a</b> and <b>4b</b>) displayed a strong affinity for PI3Kα (<i>K</i><sub>i</sub> = 22 and 48 nM, respectively). The in vitro potency of <b>4a</b> and <b>4b</b> is comparable to that of the dimorpholine-substituted parental compounds (<b>3a</b> and <b>3b</b>). On the contrary, replacement of the unrestricted morpholine with a piperidine (<b>5a</b> and <b>5b</b>) led to a drop in PI3K binding affinity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Binding Mode: Morpholine vs Piperidine in Unrestricted and Restricted Positions</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0008.gif" alt="" id="gr4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">PKB phosphorylation on Ser473 and ribosomal S6 phosphorylation on Ser235/236 were analyzed in A2058 cells exposed to the indicated inhibitors and subsequent detection of phosphoproteins in an in-cell Western assay. Each experiment was performed with <i>n</i> = 2. The log IC<sub>50</sub> values and standard errors are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S8</a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Compounds were tested for the in vitro binding to the ATP-binding site of p110α and mTOR using a commercially available time-resolved FRET (TR-FRET) displacement assay (LanthaScreen). Each experiment was performed with <i>n</i> = 2. IC<sub>50</sub> values, logIC<sub>50</sub> values, and standard errors are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S8</a>.</p></div></div><div></div></div><div class="NLM_p">We thus concluded that the unrestricted morpholine binds to the hinge region and establishes a H-bond with the Val backbone amide. We exploited the 2.48 Å resolution X-ray structure of PIKiN3 in PI3Kγ (see ref <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB">5JHB</a>), and substituted PIKiN3 for compound <b>3a</b> to confirm its binding mode. Energy minimization calculations of the resulting PI3Kγ-<b>3a</b> complex maintained important interactions such as H-bonds between the aminopyridine and Asp836/964 as well as the interaction of the oxygen atom of the unrestricted morpholine and the backbone amide of Val882 (as present in the parental structure with PIKiN3; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Moreover, the interaction of the core nitrogen of compound <b>3a</b> with the structured water molecule allows stabilization of the inhibitor binding through a H-bond network. In PI3Kγ, this interaction had been proved to play a pivotal role in inhibitor binding (see ref <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB">5JHB</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Docking of compound <b>3a</b> (plum) into PI3Kγ (gray) starting from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB">5JHB</a> (see ref <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>). Structural water molecules are shown in red, and water-mediated H-bonds are depicted as dashed black lines. (B) Docking of compound <b>2a</b> (gold) and (C) compound <b>2b</b> (green) into mTOR (turquoise) starting from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>. The important features for mTOR selectivity are depicted in a ball and stick representation. (D) Docking of compound <b>2a</b> (gold) and (E) compound <b>2b</b> (green) into PI3Kα (gray) starting from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZIM">3ZIM</a>. The exit vector from the restricted morpholine oxygen is shown as a black arrow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the high homology of the ATP-binding pocket of class I PI3Ks and mTOR, a similar binding mode and orientation in mTOR and all PI3K isoforms can be assumed. Computational modeling studies were performed to elucidate the binding mode of the conformationally restricted compounds <b>2a</b> and <b>2b</b> in mTOR starting from the PI103-mTOR complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>). In analogy to PI3K, the higher mTOR potency of the compounds bearing the unrestricted morpholine in the 4-position of the pyrimidine core (<b>2a</b> and <b>2b</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B) could be derived from the interaction of a pyrimidine core nitrogen with a putative structured water molecule, even though the 3.6 Å structural resolution of mTOR did not reveal such structured water molecules. Thus, the position of N-1 of the pyrimidine core (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> for numbering) in the ATP-binding pocket is an essential parameter for mTOR affinity. The binding affinity data of compounds <b>2a</b>–<b>d</b> suggest a similar structured water network in mTOR, which is only maintained by binding of regioisomer <b>2a</b> and <b>2b</b> but not with <b>2c</b> and <b>2d</b> (<i>K</i><sub>i</sub><b>2a</b>, <b>2b</b> = 69, 24 nM vs <i>K</i><sub>i</sub><b>2c</b>, <b>2d</b> = 812, 1279 nM). An additional stabilization of <b>2a</b>/<b>2b</b>-mTOR complex is provided by hydrophobic interactions between the methylene bridge and Met2345 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). The important features for mTOR selectivity are depicted in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C in a ball and stick representation.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>c</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Prepared according to ref  <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>.</p><p><span class="fn-label"><sup>b</sup></span>Prepared according to procedure vii. After the reaction, the two regioisomers (<b>26</b> and <b>32</b>) were separated by column chromatography.</p><p class="last"><span class="fn-label"><sup>c</sup></span>(A) Reagents and conditions: (i) (1) benzaldehyde, 2 M NaOH, rt, 30 min; (2) NaBH<sub>4</sub>, 5 °C → rt, 1 h; (ii) (1) chloroacetyl chloride, K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 0 °C, 1 h; (2) NaOH, 5 °C, 2 h; (iii) borane–dimethyl sulfide complex, Et<sub>3</sub>N, THF, 0 °C → 65 °C, 5 h; (iv) Pd/C, H<sub>2</sub>, 2.8 bar, 48 h; (v) thionyl chloride, imidazole, DCM, −5 °C → rt → 0 °C, 2 h; (vi) ruthenium(IV) oxide hydrate, NaIO<sub>4</sub>, rt, o/n. (B) Reagents and conditions: (vii) morpholine derivative (M<sub>n</sub>–H), DIPEA, DCM, 0 °C → rt, o/n; (viii) (1) <i>n</i>-BuLi, CuI, −78 °C → rt, o/n; (2) HCl conc, MeOH, 45 °C, 4–6 h; (3) NaOH, H<sub>2</sub>O, rt, 1–16 h; (ix) (1) boronic ester <b>38</b> or <b>41</b>, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2–16 h; (2) HCl, dioxane/H<sub>2</sub>O, 60 °C, 3–16 h (for <b>2a</b>, <b>2b</b>, <b>2c</b>, <b>2d</b>, <b>6a</b>, <b>6b</b>, <b>7a</b>, <b>7b</b>, <b>8a</b>, <b>8b</b>, <b>9a</b>, <b>9b</b>, <b>10a</b>, <b>10b</b>, and <b>14b</b>); (x) 2-aminopyridine-5-boronic acid pinacol ester, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C (for <b>11b</b>), o/n; (xi) boronic ester <b>39</b>, Pd(dppf)Cl<sub>2</sub> (cat.), CsCO<sub>3</sub>, THF, Δ, o/n (for <b>12b</b>); (xii) (1) boronic ester generated in situ, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 3–3.5 h; (2) HCl, 80 °C, o/n (for <b>13b</b> and <b>15b</b>); (xiii) (1) boronic ester generated in situ, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2–16 h (isolated intermediates <b>18b</b> and <b>19b</b>); (2) <b>18b</b> or <b>19b</b>, TFA, DCM, 0 °C → rt, 1–3 h (for <b>16b</b> and <b>17b</b>).</p></p></figure><div class="NLM_p last">Within one regioisomer pair (<b>2a</b> and <b>2b</b>), the (<i>R</i>)-enantiomer <b>2b</b> displayed a stronger affinity for mTOR, together with an 18-fold selectivity for mTOR kinase over PI3Kα (<i>K</i><sub>i</sub> for mTOR = 24 nM and <i>K</i><sub>i</sub> for PI3Kα = 432 nM). In contrast, the (<i>S</i>)-enantiomer <b>2a</b> is a dual mTOR/PI3Kα inhibitor (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The 6-fold difference in PI3K inhibitory activity between compound <b>2a</b> and <b>2b</b> (<i>K</i><sub>i</sub> for PI3Kα = 76 and 432 nM, respectively) might be related to the different orientation of the morpholine due to scaffold rigidification. In the (<i>S</i>)-configured compound <b>2a</b>, the oxygen of the restricted morpholine points toward the amide side chain of Gln859 (4 Å) and a weak H-bond could stabilize the binding of <b>2a</b> in PI3Kα (see exit vector in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). In the (<i>R</i>)-tricyclic pyrimido-pyrrolo-oxazine <b>2b</b> the morpholine oxygen is rotated by 1 Å with respect to the oxygen atom of <b>2a</b> and the exit vector does not point toward Gln859 (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E). Therefore, no H-bond can be established.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Chemistry</h3><div class="NLM_p last">Procedures for library synthesis are depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. First, sulfamidates <b>33a</b> and <b>33b</b> were prepared (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A). Typically, sulfamidates are made from chiral amino alcohols in several steps.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The 3-hydroxymethyl morpholines (<b>34a</b> and <b>34b</b>) were synthesized by a chiral synthesis starting from serine enantiomers. As for <b>34a</b>, the amino group of (<i>R</i>)-serine was protected with a benzyl group (compound <b>37b</b>) since the ring closure has been described to proceed in higher yields when a protecting group is present.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a><i>N</i>-Benzyl-(<i>R</i>)-serine (<b>37b</b>) underwent ring closure in the presence of chloroacetyl chloride to give (<i>R</i>)-4-benzyl-5-oxomorpholine-3-carboxylic acid (<b>36b</b>) in 71% yield. Reduction of <b>36b</b> using borane–dimethyl sulfide complex in tetrahydrofuran (THF) gave intermediate <b>35a</b> with an 82% yield. Hydrogenolysis of <i>N</i>-benzyl derivative (<b>35a</b>) over palladium on charcoal (Pd/C, H<sub>2</sub>) yielded (<i>S</i>)-morpholin-3-ylmethanol (<b>34a</b>). Subsequent two-step cyclic sulfamidate formation was performed by treating the amino alcohol (<b>34a</b>) with thionyl chloride to give the corresponding cyclic sulfamidite, followed by oxidation using NaIO<sub>4</sub> and catalytic amounts of ruthenium(IV) oxide hydrate to give sulfamidate <b>33b</b> in 52% yield. The (<i>S</i>)-enantiomer (<b>33a</b>) was synthesized from (<i>S</i>)-serine following the procedure described for <b>33b</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A). The dichloropyrimidines (<b>26</b>–<b>31</b>) were prepared according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B starting from the commercially available 2,4,6-trichloropyrimidine. Morpholines M<sub>0</sub>–M<sub>5</sub> were introduced as M<sub>n</sub> substituents by nucleophilic aromatic substitution reaction. Following this procedure, both regioisomers were generated and separated by column chromatography. The desired regioisomers (<b>27</b>–<b>31</b>) were isolated in moderate to high yields (46–86%). The (<i>S</i>)-tricyclic intermediates (<b>20a</b>–<b>25a</b>) were synthesized by sequential alkylation and nucleophilic aromatic substitution reactions of dichloropyrimidines (<b>26</b>–<b>31</b>) with (<i>R</i>)-sulfamidate <b>33b</b> using <i>n</i>-BuLi in THF at −78 °C and a catalytic amount of copper(I) iodide followed by acidic hydrolysis of the intermediary sulfaminic acid and ring closure mediated by base treatment.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The same procedure was followed for the preparation of (<i>R</i>)-tricyclic intermediates (<b>20b</b>–<b>25b</b>), starting from (<i>S</i>)-sulfamidate <b>33a</b>. A subsequent palladium catalyzed Suzuki coupling between choloropyrimidine intermediates (<b>20a</b>–<b>25a</b> and <b>20b</b>–<b>25b</b>) and protected 2-aminopyridine-5-boronic acid pinacol ester (<b>38</b>, see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Supporting Information</a>) afforded compounds <b>2a</b>, <b>6a</b>–<b>10a</b>, and <b>2b</b>, <b>6b</b>–<b>10b</b> in moderate to high yields (49–88%; <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B). In addition, the chlorine of intermediate <b>22b</b> was displaced by heteroaryl moieties using Suzuki cross-coupling reaction with boronic acid pinacol esters to give compounds <b>11b</b>–<b>17b</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B). For not commercially available boronic acid pinacol esters or corresponding bromo derivatives, the synthesis is reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Schemes S1 and S2 in Supporting Information</a>. The regioisomer bearing the unrestricted morpholine in the 2-position of the pyrimidine core (enantiomers <b>2c</b> and <b>2d</b>) was synthesized starting from dichloropyrimidine <b>32</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>C) following the procedure described for <b>2a</b> and <b>2b</b>. The synthesis of the conformationally restricted PQR309 (<b>1</b>) analogs <b>3a</b> and <b>3b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) is depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Scheme S3A in Supporting Information</a>, and the synthetic procedure is analogous to that described for <b>2a</b> and <b>2b</b>. The procedure for the preparation of the compounds bearing a piperidine instead of a morpholine (<b>4a</b>,<b>b</b> and <b>5a</b>,<b>b</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) is reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Scheme S3B and Scheme S3C in Supporting Information</a>.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Determination of Cellular Potency and PI3K vs mTOR Kinase Activities</h3><div class="NLM_p">In the search for novel mTOR inhibitors, we selected the regioisomer bearing the unrestricted morpholine in the 4-position of the pyrimidine core (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B) and built up a structure–activity relationship (SAR) study to investigate (i) the influence of the stereogenic center on mTOR selectivity and (ii) the effect of substitution on the unrestricted morpholine. We prepared a series of compounds introducing different morpholine derivatives (M<sub>n</sub> substituents, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B), such as 3-methylmorpholine [M<sub>1</sub>, (<i>S</i>); M<sub>2</sub>, (<i>R</i>)], 8-oxa-3-azabicyclo[3.2.1]octane (M<sub>3</sub>), 3-oxa-8-azabicyclo[3.2.1]octane (M<sub>4</sub>), and 3,3-dimethylmorpholine (M<sub>5</sub>). Morpholines with increased steric demand had already been shown to increase selectivity for mTOR over PI3K.<a onclick="showRef(event, 'ref31 ref43'); return false;" href="javascript:void(0);" class="ref ref31 ref43">(31,43)</a> For each conformationally restricted compound both (<i>S</i>)- (<b>2a</b>, <b>6a</b>–<b>10a</b>) and (<i>R</i>)-enantiomers (<b>2b</b>, <b>6b</b>–<b>10b</b>) were synthesized and tested in kinase binding and cellular assays. For all the regioisomer pairs, the (<i>R</i>)-enantiomer had higher affinity for mTOR than the (<i>S</i>)-configured compound (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), confirming the results of compounds <b>2a</b> and <b>2b</b>. Also the cellular potency of the (<i>R</i>)-configured compounds was 2- to 7-fold higher than that of their corresponding enantiomers (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The introduction of sterically hindered morpholines in the hinge region of (<i>R</i>)-configured tricyclic pyrimido-pyrrolo-oxazines (<b>6b</b>–<b>10b</b>) did not affect the potency for mTOR but led to a significant improvement in mTOR selectivity. With the exception of compound <b>10b</b>, the selectivity of (<i>R</i>)-configured tricyclic compounds for mTOR versus PI3Kα was higher than 35-fold [<i>K</i><sub>i</sub>(p110α)/<i>K</i><sub>i</sub>(mTOR) <b>6b</b> = 43; <b>7b</b> = 165; <b>8b</b> = 53; <b>9b</b> = 36]. The (<i>S</i>)-3-methylmorpholine (M<sub>1</sub>) only slightly increased the compound potency and selectivity for mTOR if compared with the morpholine (M<sub>0</sub>) [<i>K</i><sub>i</sub> for mTOR <b>2b</b> = 24 nM; <b>6b</b> = 9.1 nM; selectivity <i>K</i><sub>i</sub>(p110α)/<i>K</i><sub>i</sub>(mTOR) for <b>2b</b> was 18-fold and for <b>6b</b> 43-fold]. On the contrary, the presence of a (<i>R</i>)-3-methylmorpholine (M<sub>2</sub>) on the (<i>R</i>)-configured tricyclic pyrimido-pyrrolo-oxazine scaffold yielded the highest selectivity of the series [<i>K</i><sub>i</sub>(p110α)/<i>K</i><sub>i</sub>(mTOR) for <b>7b</b> was 165-fold]. In cells, compound <b>7b</b> displayed good activity (IC<sub>50</sub> for phosphorylated PKB/Akt = 133 nM and for phosphorylated S6 = 61 nM) and was therefore selected for further optimization.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Study on the Unrestricted Morpholine of Tricyclic Pyrimido-pyrrolo-oxazines<a class="ref internalNav" href="#t3fn1" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0009.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn2"><div class="footnote" id="t3fn2"><sup><sup>a</sup></sup><p class="last">PKB phosphorylation on Ser473 and ribosomal S6 phosphorylation on Ser235/236 were analyzed in A2058 cells exposed to the indicated inhibitors and subsequent detection of phosphoproteins in an in-cell Western assay. Each experiment was performed with <i>n</i> = 2. The log IC<sub>50</sub> values and standard errors are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S7 in the Supporting Information</a>.</p></div><div class="footnote" id="t3fn3"><sup><sup>b</sup></sup><p class="last">Compounds were tested for the in vitro binding to the ATP-binding site of p110α and mTOR using a commercially available time-resolved FRET (TR-FRET) displacement assay (LanthaScreen). Each experiment was performed with <i>n</i> = 2. IC<sub>50</sub> values, log IC<sub>50</sub> values, and standard errors are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S7 in the Supporting Information</a>.</p></div><div class="footnote" id="t3fn4"><sup><sup>c</sup></sup><p class="last">Marvin/JChem 16.10.17 was used for calculation of log <i>P</i> (partition coefficient) values.</p></div><div class="footnote" id="t3fn1"><sup><sup>d</sup></sup><p class="last">Chemical structures of M<sub>0</sub>–M<sub>5</sub> are depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</p></div></div><div></div></div><div class="NLM_p">To further improve the potency and selectivity for mTOR and to modulate the physicochemical properties of compound <b>7b</b>, we investigated the role of the aryl moiety (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). First, we replaced the pyridine ring with a pyrimidine (<b>11b</b>) and a pyrazine (<b>12b</b>) to assess the effect of the polarity of the heteroaromatic ring. Afterward, we introduced a methyl (<b>13b</b> and <b>14b</b>), a methoxy (<b>15b</b>), or a dimethoxymethyl substituent (<b>16b</b> and <b>17b</b>) on the 2-amino-substituted aryl group. The presence of a pyrimidine or a pyrazine ring slightly increased mTOR potency, selectivity, and cellular activity (see comparison between <b>11b</b>/<b>12b</b> and <b>7b</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compound <b>13b</b>, bearing a methyl substituent in position 4 of the 2-aminopyridine ring, had a moderate activity toward mTOR (<i>K</i><sub>i</sub> = 85 nM), and was poorly active in cells (IC<sub>50</sub> for phosphorylated PKB/Akt and for phosphorylated S6 was >800 nM, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In contrast, compound <b>14b</b>, with a 3-methyl-substituted aminopyridine, maintained a moderate activity in cells (IC<sub>50</sub> for phosphorylated PKB/Akt was 488 nM and 289 nM for phosphorylated S6). The introduction of a methoxy (<b>15b</b>) and a dimethoxymethyl substituent (<b>16b</b>) on the pyridine ring reduced cellular potency and binding to both PI3Kα and mTOR. Compound <b>17b</b>, bearing a dimethoxymethyl substituent on the pyrimidine ring, is a dual PI3Kα/mTOR inhibitor (<i>K</i><sub>i</sub> for p110α = 66 nM; <i>K</i><sub>i</sub> for mTOR = 34 nM) but showed a limited potency in cells (IC<sub>50</sub>(pPKB) > 500 nM and IC<sub>50</sub>(pS6) > 300 nM, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). With respect to compound <b>7b</b>, the introduction of an additional nitrogen on the heteroaromatic ring decreased the clogP value (compound <b>11b</b> = 2.22 and <b>12b</b> = 2.15), leading to compounds with predicted optimal physicochemical and ADME properties for oral drugs.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Moreover, the polar surface area (PSA) of > 90 Å of compounds <b>11b</b> and <b>12b</b> is indicative that they might not cross the blood–brain barrier (BBB). Limited brain uptake of mTOR inhibitors, normally used to treat systemic tumors, is an advantage because inhibition of the mTOR pathway in the brain could lead to neurological side effects.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Study on the Aryl Moiety of Tricyclic Pyrimido-pyrrolo-oxazines<a class="ref internalNav" href="#t4fn1" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0010.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn3"><div class="footnote" id="t4fn3"><sup><sup>a</sup></sup><p class="last">PKB phosphorylation on Ser473 and ribosomal S6 phosphorylation on Ser235/236 were analyzed in A2058 cells exposed to the indicated inhibitors and subsequent detection of phosphoproteins in an in-cell Western assay. Each experiment was performed with <i>n</i> = 2. The log IC<sub>50</sub> values and standard errors are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S7 in the Supporting Information</a>. *PQR620 data are from ref  <a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> for comparison.</p></div><div class="footnote" id="t4fn4"><sup><sup>b</sup></sup><p class="last">Compounds were tested for the in vitro binding to the ATP-binding site of p110α and mTOR using a commercially available time-resolved FRET (TR-FRET) displacement assay (LanthaScreen). Each experiment was performed with <i>n</i> = 2. IC<sub>50</sub> values, log IC<sub>50</sub> values, and standard errors are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S7 in the Supporting Information</a>.</p></div><div class="footnote" id="t4fn5"><sup><sup>c</sup></sup><p class="last">Marvin/JChem 16.10.17 was used for calculation of log <i>P</i> (partition coefficient) values.</p></div><div class="footnote" id="t4fn1"><sup><sup>d</sup></sup><p class="last">Chemical structures of Ar<sub>0</sub>–Ar<sub>7</sub> are depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</p></div></div><div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacological Parameters</h3><div class="NLM_p">To assess the oral availability and to determine BBB permeability, pharmacokinetic (PK) studies were carried out for compounds <b>7b</b> and <b>12b</b>. Compounds <b>7b</b> and <b>12b</b> were administered orally (5 mg/kg po) in male Sprague Dawley rats, and compound concentrations in plasma and brain were determined after a single dose (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B, respectively; see also <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Tables S1–S4 in Supporting Information</a>). Both compounds showed plasma exposure sufficient to efficiently inhibit mTOR kinase, and brain levels remined minimal. After 8 h, the total exposure AUC<sub>0–8</sub> was 5730 ng·h/mL in plasma and 104 ng·h/g in brain for compound <b>12b</b>.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma and brain concentration of (A) compound <b>7b</b> and (B) compound <b>12b</b> after po dosing at 5 mg/kg in male Sprague Dawley rats. Stability of compound <b>11b</b> (5 μM) with primary hepatocytes from (C) mice (green) and rats (turquoise) and (D) dogs (red) and humans (black) (<i>n</i> = 2). All values are the mean ± SEM. Error bars are not shown when smaller than the symbols.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To predict the metabolic stability of our restricted scaffold, in vitro assays were performed for compound <b>11b</b>, using hepatocyte cultures of different origin (CD-1 mice, Sprague Dawley rats, beagle dogs, and humans). Compound <b>11b</b> was only minimally metabolized when incubated with mouse, rat, dog, and human hepatocytes, as indicated by 81.2%, 93.6%, 93.0%, and 93.2% remaining compound after 3 h of incubation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D, and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S5 in Supporting Information</a>). As compound <b>11b</b> was highly stable across species, neither half-lives nor intrinsic clearance could be determined under the experimental conditions.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> CYP450 Reactive Phenotyping for Compounds <b>7b</b>, <b>11b</b>, and <b>12b</b></h3><div class="NLM_p">CYP450 reactive phenotyping was performed to evaluate the involvement of different human hepatic CYP isoenzymes (CYP1A1 and CYP1A2) in the metabolism of compounds <b>7b</b>, <b>11b</b>, and <b>12b</b>. All three compounds turned out to be moderate CYP1A1 substrates, as indicated by <77% parental compound remaining after 60 min of incubation (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Compounds <b>7b</b> and <b>11b</b> were partially stable toward CYP1A1 (44% and 51% compound remaining, respectively), while the lowest turnover was observed with compound <b>12b</b> (77% remaining). A low metabolization by CYP1A2 was observed with <b>11b</b> (73% remaining). On the other hand, compounds <b>7b</b> and <b>12b</b> remained stable (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), indicating that they are not substrates of CYP1A2.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. CYP1A1 and CYP1A2 Reactive Phenotyping of <b>7b</b>, <b>11b</b>, and <b>12b</b> (1 μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">remaining test item with cofactors</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">% remaining in corresponding negative control without cofactors</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">test item</th><th class="colsep0 rowsep0" align="center" char=".">mean %</th><th class="colsep0 rowsep0" align="center" char=".">SD</th><th class="colsep0 rowsep0" align="center" char=".">mean</th><th class="colsep0 rowsep0" align="center" char=".">SD</th><th class="colsep0 rowsep0" align="center" char=".">mean (%)<sub>corr</sub><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="center">CYP1A1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">109</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="center">CYP1A2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">104</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">101</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Compounds remaining after 60 min of incubation with Supersomes at 25 pmol/mL (<i>n</i> = 2), calculation based on absolute amounts (nM).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">mean (%)<sub>corr</sub> = (100 – % remaining negative control) + % remaining sample.</p></div></div></div><div class="NLM_p">On the basis of these results, compound <b>11b</b> was further investigated to identify metabolites formed in vitro by CYP1A1 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) and CYP1A2 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Upon incubation of <b>11b</b> with human recombinant CYP1A1, the highest peak areas were observed for metabolite M2 (9.3% of total peak areas, hydrolysis of the 3<i>R</i>-methylmorpholinyl residue and oxidation to corresponding aldehyde) and its secondary products M5 (7.5%, introduction of a C–C double bond (desaturation) at the tricyclic backbone of M2; <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Other minor metabolites were observed, highlighting that the preferred site of oxidative metabolism of compound <b>11b</b> was the 3<i>R</i>-methyl-substituted morpholinyl moiety (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S6 and Figures S1–S5 in Supporting Information</a>). In CYP1A2 incubates, M2 was the only metabolite (0.3%) suggesting that compound <b>11b</b> is not a substrate of CYP1A2.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pie chart showing the percentage of compound <b>11b</b> and its metabolites after 60 min of incubation with human recombinant (A) CYP1A1 and (B) CYP1A2. (C) Major metabolites observed upon incubation of <b>11b</b> with CYP1A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Enzymatic Profiling and Determination of Selectivity</h3><div class="NLM_p">According to our SAR studies, compounds <b>7b</b>, <b>11b</b>, and <b>12b</b> were the most potent and selective mTOR inhibitors showing high potency in cellular assays and good pharmacokinetic profile. Therefore, <b>7b</b>, <b>11b</b>, and <b>12b</b> were chosen for further characterization using the KINOMEScan platform of DiscoverX (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). DiscoverX KdELECT assays confirmed the excellent mTOR selectivity of compound <b>12b</b> over class I and class III PI3K and PI4K: <b>12b</b> was ∼450-fold more potent for mTOR than for class I PI3K isoforms. The selectivity of <b>12b</b> for mTOR over PI3K exceeds competitor compounds such as CC223 (<b>55</b>)<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (∼80×), INK128 (<b>56</b>) (∼40×), and AZD2104 (<b>57</b>) (∼230×) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Moreover, compound <b>12b</b> showed negligible off-target effects when screened against a DiscoverX scanMAX kinase assay panel containing a set of 468 protein and lipid kinases (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Supporting Information, Figure S6 and Table S10</a>). At a concentration of 10 μM, compound <b>12b</b> and PQR620 (<b>58</b>) reached outstanding selectivity scores [<i>S</i>(10) was 0.005 for both compounds; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Supporting Information, Table S9</a>], while the same value for INK128 (<b>56</b>) reached 0.14 (corresponding to 55 hits, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">Table S9</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. mTOR and Lipid Kinase Binding Constants of <b>7b</b>, <b>11b</b>, <b>12b</b>, and Reference Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center">inhibitor binding constant,<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a><i>K</i><sub>d</sub> [nM]</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">mTOR</th><th class="colsep0 rowsep0" align="center">PI3Kα</th><th class="colsep0 rowsep0" align="center">PI3Kβ</th><th class="colsep0 rowsep0" align="center">PI3Kδ</th><th class="colsep0 rowsep0" align="center">PI3Kγ</th><th class="colsep0 rowsep0" align="center">PI4Kβ</th><th class="colsep0 rowsep0" align="center">VPS34</th><th class="colsep0 rowsep0" align="center">most sensitive PI3K/mTOR,<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> fold selectivity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left"><b>610</b></td><td class="colsep0 rowsep0" align="left">4100</td><td class="colsep0 rowsep0" align="left">6200</td><td class="colsep0 rowsep0" align="left">8700</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">2100</td><td class="colsep0 rowsep0" align="left">17.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left"><b>120</b></td><td class="colsep0 rowsep0" align="left">1400</td><td class="colsep0 rowsep0" align="left">1900</td><td class="colsep0 rowsep0" align="left">1800</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">980</td><td class="colsep0 rowsep0" align="left">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left"><b>1600</b></td><td class="colsep0 rowsep0" align="left">7500</td><td class="colsep0 rowsep0" align="left">12000</td><td class="colsep0 rowsep0" align="left">11000</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">3200</td><td class="colsep0 rowsep0" align="left">457</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CC223 (<b>55</b>)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left"><b>2300</b></td><td class="colsep0 rowsep0" align="left">18000</td><td class="colsep0 rowsep0" align="left">6200</td><td class="colsep0 rowsep0" align="left">7100</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">2500</td><td class="colsep0 rowsep0" align="left">>80×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INK128 (<b>56</b>)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.092</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left"><b>3.7</b></td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">8200</td><td class="colsep0 rowsep0" align="left">>40×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD2014 (<b>57</b>)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">3300</td><td class="colsep0 rowsep0" align="left">1500</td><td class="colsep0 rowsep0" align="left">8400</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">23000</td><td class="colsep0 rowsep0" align="left">>230×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR620 (<b>58</b>)</td><td class="colsep0 rowsep0" align="left">0.27</td><td class="colsep0 rowsep0" align="left"><b>1000</b></td><td class="colsep0 rowsep0" align="left">22000</td><td class="colsep0 rowsep0" align="left">23000</td><td class="colsep0 rowsep0" align="left">18000</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">2750</td><td class="colsep0 rowsep0" align="left">>3700×</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Dissociation constants (<i>K</i><sub>d</sub>) were determined using ScanMax technology (DiscoveRx) with 11-point 3-fold serial dilutions of the indicated compounds. <i>K</i><sub>d</sub> is the mean value from experiments performed in duplicate and was calculated from standard dose–response curves using the Hill equation. nd = not determined.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Dissociation constants (<i>K</i><sub>d</sub>) of CC223 (<b>55</b>), INK128 (<b>56</b>), AZD2014 (<b>57</b>), and PQR620 (<b>58</b>) are from ref <a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a>.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Fold selectivity: ratio of <i>K</i><sub>d</sub> of the most sensitive class I PI3K isoform (displayed in bold type) over <i>K</i><sub>d</sub> for mTOR.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have exploited a conformational restriction strategy to enlarge the chemical space around PQR309 (<b>1</b>), a pan-PI3K and moderate mTOR inhibitor. Our rigidification strategy allowed us to enhance potency and selectivity for mTOR. Molecular modeling elucidated interactions of the tricyclic pyrimido-pyrrolo-oxazine scaffold in the ATP-binding pocket of PI3Ks and mTOR and explained the difference in potency between the regioisomers. An extensive SAR study led to the discovery of compound <b>12b</b>, with a selectivity for mTOR higher than competitor compounds such as CC223 (<b>55</b>), INK128 (<b>56</b>), and AZD2014 (<b>57</b>). The selectivity of PQR620 (<b>58</b>) for mTOR over PI3Ks exceeds that of <b>12b</b>; however <b>12b</b> explores a novel chemical space and paves the way for additional chemical modifications. A lead optimization process of the tricyclic pyrimido-pyrrolo-oxazine scaffold could lead to further improvement of the mTOR potency and selectivity of <b>12b</b>. Compound <b>12b</b> efficiently inhibited mTOR signaling in cells and showed plasma drug exposure after oral dosing that is expected to fully inhibit mTOR in vivo. The minimal brain permeability of compounds <b>7b</b> and <b>12b</b> suggests the tricyclic pyrimido-pyrrolo-oxazine as a novel scaffold for the development of highly selective and potent ATP-competitive mTOR inhibitors to be exploited for the treatment of systemic tumors. PQR620 (<b>58</b>) and the tricyclic pyrimido-pyrrolo-oxazine derivatives span along the different therapeutic applications of mTOR inhibitors. PQR620 (<b>58</b>) showed an excellent brain penetration and could be exploited in the treatment of neurological disorders. On the contrary, the conformationally restricted compounds have a limited brain uptake and could find an optimal application in the treatment of systemic cancers, with the advantage of avoiding neurological side effects. Our novel scaffold was also characterized for CYP450 related metabolism to assess the substrate specificity toward CYP1A1 and CYP1A2. The tricyclic pyrimido-pyrrolo-oxazines <b>7b</b>, <b>11b</b>, and <b>12b</b> were metabolically stable, with compound <b>12b</b> showing the lowest turnover in CYP450 reactive phenotyping. On the basis of its remarkable mTOR potency/selectivity and favorable pharmacokinetic profile, compound <b>12b</b> represents a promising starting point for the development of a novel mTOR candidate in oncology.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Information</h3><div class="NLM_p last">Reagents were purchased at the highest commercial quality from Acros, Sigma-Aldrich, or Fluorochem and used without further purification. Solvents were purchased from Acros Organics in AcroSeal bottles over molecular sieves. Cross-coupling reactions were carried out under nitrogen atmosphere in anhydrous solvents, and glassware was oven-dried prior to use. Thin layer chromatography (TLC) plates were purchased from Merck KGaA (Polygram SIL/UV254, 0.2 mm silica with fluorescence indicator), and UV light (254 nm) was used to visualize the compounds. Column chromatographic purifications were performed on Merck KGaA silica gel (pore size 60 Å, 230–400 mesh particle size). Alternatively, flash chromatography was performed with Isco CombiFlash Companion systems using prepacked silica gel columns (40–60 μm particle size RediSep). <sup>1</sup>H, <sup>19</sup>F, and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance 400 spectrometer. NMR spectra were obtained in deuterated solvents, such as CDCl<sub>3</sub>, (CD<sub>3</sub>)<sub>2</sub>SO, or CD<sub>3</sub>OD. The chemical shifts (δ values) are reported in ppm and corrected to the signal of the deuterated solvents (7.26 ppm (<sup>1</sup>H NMR) and 77.16 ppm (<sup>13</sup>C NMR) for CDCl<sub>3</sub>; 2.50 ppm (<sup>1</sup>H NMR) and 39.52 ppm (<sup>13</sup>C NMR) for (CD<sub>3</sub>)<sub>2</sub>SO; and 3.31 ppm (<sup>1</sup>H NMR) and 49.00 ppm (<sup>13</sup>C NMR) for CD<sub>3</sub>OD). <sup>19</sup>F NMR spectra are calibrated relative to CFCl<sub>3</sub> (δ = 0 ppm) as external standard. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), td (triplet of doublets), q (quartet), m (multiplet), br (broadened). Coupling constants, when given, are reported in hertz (Hz). High resolution mass spectra (HRMS) were recorded on a Bruker maxis 4G, high resolution ESI-QTOF. All analyses were carried out in positive ion mode and in MeOH + 0.1% formic acid as solvent. Sodium formate was used as calibration standard. MALDI-ToF mass spectra were obtained on a Voyager-De Pro measured in <i>m</i>/<i>z</i>. The chromatographic purity of final compounds was determined by high performance liquid chromatography (HPLC) analyses on an Ultimate 3000SD system from ThermoFisher with LPG-3400SD pump system, ACC-3000 autosampler and column oven, and DAD-3000 diode array detector. An Acclaim-120 C18 reversed-phase column from ThermoFisher was used as stationary phase. Gradient elution (5:95 for 0.2 min, 5:95 → 100:0 over 10 min, 100:0 for 3 min) of the mobile phase consisting of CH<sub>3</sub>CN/MeOH:H<sub>2</sub>O<sub>(10:90)</sub> was used at a flow rate of 0.5 mL/min at 40 °C. The purity of all final compounds was >95%. Optical rotations ([α]<sub class="stack">D</sub><sup class="stack">23</sup>) were measured on a PerkinElmer polarimeter 341 (in a cuvette (<i>l</i> = 1 dm)) at 23 °C at 589 nm.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedure 1</h3><div class="NLM_p last">A flask was charged with the corresponding boronic acid pinacol ester (1 equiv), <i>N</i>,<i>N</i>-dimethylformamide–dimethyl acetal (DMF–DMA, 1.3–1.5 equiv), and THF (5 mL). The mixture was stirred at 70 °C overnight. After completion of the reaction monitored by NMR, the solvents were evaporated and the compound was dried under vacuum.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure 2</h3><div class="NLM_p">To a solution of the desired morpholine (1.05 equiv) in DCM (approximately 1 mL/0.6 mmol) at 0 °C, <i>N</i>,<i>N</i>-diisopropylethylamine (2.1 equiv) was added, followed by 2,4,6-trichloropyrimidine (1.0 equiv). The reaction mixture was allowed to warm up to rt and was stirred overnight. The reaction mixture was washed with aqueous saturated NaHSO<sub>4</sub> solution (2×). The aqueous layer was extracted with DCM, and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude was purified by column chromatography on silica gel.</div><div class="NLM_p last">Using this procedure, both regioisomers were generated and separated by column chromatography. Only the characterization of the desired regioisomer is reported.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure 3</h3><div class="NLM_p last">Under nitrogen atmosphere, a 1.6 M <i>n</i>-BuLi solution (1.0 mL, 1.52 mmol, 1.2 equiv) in THF (approximately 1 mL/1.5 mmol) was cooled down to −78 °C and a solution of the corresponding morpholine (1 equiv) in THF (approximately 1 mL/0.4 mmol) was added dropwise. The mixture was stirred at −78 °C for 35 min. CuI (0.05 equiv) and a solution of the corresponding sulfamidate (1–1.2 equiv) in THF (approximately 1 mL/0.5 mmol) were added. The mixture was stirred at −78 °C for 15 min, then allowed to warm to rt and stirred overnight. The reaction was quenched by addition of water. Conc HCl and methanol were added, and the mixture was heated at 45 °C for 4–6 h. The reaction mixture was cooled down to 0 °C, and a 6 M NaOH solution was added until pH 10 was obtained. The reaction mixture was stirred at rt for 1–16 h, then transferred to a separatory funnel. The layers were separated, and the aqueous layer was extracted with EtOAc (2×). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure 4</h3><div class="NLM_p last">Chloropyrimidine derivative (1.0 equiv) and boronic acid pinacol ester (1.0 equiv) were charged in a flask. Under nitrogen atmosphere, 1,4-dioxane (approximately 1 mL/0.2 mmol) was added, followed by an aqueous K<sub>3</sub>PO<sub>4</sub> solution (2 equiv) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 0.05 equiv). The resulting mixture was stirred at 95 °C for 2–16 h. After completion of the reaction monitored by TLC, a 3 M aqueous HCl solution (10 equiv) was added and the mixture was stirred at 60 °C for 3–16 h. A 2 M aqueous NaOH solution was added until pH 9–10 was obtained. The aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure 5</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Step 1</h4><div class="NLM_p last">The corresponding di-Boc protected bromo derivative <b>44</b> or <b>49</b> (1.0 equiv), bis(pinacolato)diboron (1.5 equiv), and KOAc (3.0 equiv) were charged into a flask. Under nitrogen atmosphere, 1,4-dioxane (approximately 1 mL/0.2 mmol) was added, followed by [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl<sub>2</sub>, 0.1 equiv). The reaction mixture was stirred at 100 °C for 2 h.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Step 2</h4><div class="NLM_p last">After completion of the reaction monitored by TLC, the chloropyrimidine derivative <b>22b</b> (200 mg, 0.65 mmol, 1 equiv) and K<sub>3</sub>PO<sub>4</sub> (3.0 equiv) in water (approximately 1 mL/0.3 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 0.05 equiv) were added. The reaction mixture was stirred at 95 °C for 2–16 h. A 15% NH<sub>4</sub>Cl solution was added, and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure 6</h3><div class="NLM_p last">To a cold solution (0 °C) of the corresponding Boc-protected compound (1 equiv) in DCM (approximately 1 mL/0.1 mmol), trifluoroacetic acid (TFA, 40 equiv) was added dropwise. The reaction mixture was allowed to warm up to room temperature and was stirred for 1–3 h. After completion of the reaction monitored by TLC, a saturated NaHCO<sub>3</sub> solution was slowly added. The aqueous layer was extracted with DCM (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>S</i>)-5-(4-Morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>2a</b>)</h3><div class="NLM_p last"><b>2a</b> was prepared according to general procedure 4 from (<i>S</i>)-2-chloro-4-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>20a</b> (131 mg, 0.44 mmol, 1 equiv) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide <b>38</b> (121 mg, 0.44 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>2a</b> as a colorless solid (102 mg, 0.29 mmol, 65%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.83 (d, <i>J</i> = 2.3 Hz, 1 H), 8.18 (dd, <i>J</i> = 8.7, 2.3 Hz, 1 H), 6.45 (d, <i>J</i> = 8.6 Hz, 1 H), 6.27 (br s, 2 H), 4.04 (dd, <i>J</i> = 13.5, 2.6 Hz, 1 H), 3.87 (ddt, <i>J</i> = 10.5, 8.8, 4.3 Hz, 1 H), 3.79–3.71 (m, 3 H), 3.68–3.54 (m, 7 H), 3.35–3.28 (m, 1 H), 3.22–3.10 (m, 3 H), 2.63 (dd, <i>J</i> = 15.3, 4.7 Hz, 1 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.71 (s, 1 C), 161.20 (s, 1 C), 160.90 (s, 1 C), 158.28 (s, 1 C), 148.91 (s, 1 C), 136.73 (s, 1 C), 122.60 (s, 1 C), 107.34 (s, 1 C), 93.55 (s, 1 C), 70.07 (s, 1 C), 66.64 (s, 2 C), 66.17 (s, 1 C), 56.91 (s, 1 C), 45.90 (s, 2 C), 42.07 (s, 1 C), 29.14 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub> 355.1877; found, 355.1880. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 4.98 min (98.7% purity).</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>R</i>)-5-(4-Morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>2b</b>)</h3><div class="NLM_p last"><b>2b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>2a</b> starting from (<i>R</i>)-2-chloro-4-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>20b</b> (150 mg, 0.51 mmol, 1 equiv) and boronic acid pinacol ester <b>38</b> in a 76% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub> 355.1877; found, 355.1883. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 4.95 min (97.4% purity).</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-5-(2-Morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-4-yl)pyridin-2-amine (<b>2c</b>)</h3><div class="NLM_p last"><b>2c</b> was prepared according to general procedure 4 from (<i>S</i>)-4-chloro-2-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>20c</b> (80 mg, 0.27 mmol, 1 equiv) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide <b>38</b> (81.5 mg, 0.30 mmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>2c</b> as a colorless solid (45 mg, 0.13 mmol, 47%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.46 (d, <i>J</i> = 2.4 Hz, 1 H), 7.93 (dd, <i>J</i> = 8.7, 2.4 Hz, 1 H), 6.50 (d, <i>J</i> = 8.7 Hz, 1 H), 6.31 (br s, 2 H), 3.96–3.89 (m, 2 H), 3.81–3.75 (m, 2 H), 3.69–3.61 (m, 8 H), 3.34–3.27 (m, 1 H), 3.24–3.11 (m, 3 H), 2.62 (dd, <i>J</i> = 15.9, 4.5 Hz, 1 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.88 (s, 1 C), 161.13 (s, 1 C), 160.00 (s, 1 C), 152.84 (s, 1 C), 147.95 (s, 1 C), 136.12 (s, 1 C), 122.01 (s, 1 C), 107.22 (s, 1 C), 102.42 (s, 1 C), 70.07 (s, 1 C), 66.11 (s, 2 C), 65.54 (s, 1 C), 56.92 (s, 1 C), 44.23 (s, 2 C), 41.31 (s, 1 C), 27.75 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub> 355.1877; found, 355.1881. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 3.57 min (99.8% purity).</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>R</i>)-5-(2-Morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-4-yl)pyridin-2-amine (<b>2d</b>)</h3><div class="NLM_p last"><b>2d</b> was prepared as described for its (<i>S</i>)-enantiomer <b>2c</b> starting from (<i>R</i>)-4-chloro-2-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>20d</b> (100 mg, 0.34 mmol, 1 equiv) and boronic acid pinacol ester <b>38</b> in a 57% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub> 355.1877; found, 355.1880. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 3.61 min (99.2% purity).</div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-5-(4-Morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>3a</b>)</h3><div class="NLM_p last"><b>3a</b> was prepared according to general procedure 4 from (<i>S</i>)-2-chloro-4-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>20a</b> (544 mg, 1.83 mmol, 1.0 equiv) and boronic acid pinacol ester <b>50</b> (818 mg, 2.38 mmol, 1.3 equiv). Purification by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/methanol 1:0 → 20:1) gave compound <b>3a</b> as a colorless solid (503 mg, 1.19 mmol, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.62 (s, 1 H), 6.77 (s, 1 H), 4.75 (br s, 2 H), 4.10 (dd, <i>J</i> = 14.0, 2.5 Hz, 1 H), 4.01–3.93 (m, 1 H), 3.86–3.70 (m, 6 H), 3.70–3.58 (m, 4 H), 3.47 (td, <i>J</i> = 12.0, 2.8 Hz, 1 H), 3.35 (t, <i>J</i> = 11 Hz, 1 H), 3.27–3.17 (m, 2 H), 2.62 (dd, <i>J</i> = 15.0, 4.8 Hz, 1 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −60.2 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 167.70 (s, 1 C), 161.65 (s, 1 C), 158.91 (s, 1 C), 158.33 (s, 1 C), 152.29 (s, 1 C), 138.0 (q, <i>J</i> = 32 Hz, 1 C), 123.91–123.81 (m, 1 C), 123.1 (q, <i>J</i> = 274 Hz, 1 C), 105.2 (q, <i>J</i> = 5.6 Hz, 1 C), 93.59 (s, 1 C), 70.44 (s, 1 C), 66.96 (s, 2 C), 66.59 (s, 1 C), 56.97 (s, 1 C), 45.94 (s, 2 C), 42.05 (s, 1 C), 29.66 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> 423.1751; found, 423.1743. HPLC: <i>t</i><sub>R</sub> = 6.74 min (97.5% purity). (<i>S</i>)-enantiomer: [α]: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −13.2 (<i>c</i> = 2.0, CHCl<sub>3</sub>).</div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>R</i>)-5-(4-Morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>3b</b>)</h3><div class="NLM_p last"><b>3b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>50a</b> starting from (<i>R</i>)-2-chloro-4-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>20b</b> (552 mg, 1.86 mmol, 1.0 equiv) and boronic acid pinacol ester <b>50</b> (83 mg, 2.42 mmol, 1.3 equiv) in a 62% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> 423.1751; found, 423.1744. HPLC: <i>t</i><sub>R</sub> = 6.73 min (98.9% purity). (<i>R</i>)-enantiomer: [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +13.5 (<i>c</i> = 1.6, CHCl<sub>3</sub>).</div></div><div id="sec4_7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>S</i>)-5-(4-Morpholino-5,5a,6,7,8,9-hexahydropyrimido[5,4-<i>b</i>]indolizin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>4a</b>)</h3><div class="NLM_p last"><b>4a</b> was prepared according to general procedure 4 from intermediate <b>51a</b> (150 mg, 0.51 mmol, 1.0 equiv) and boronic acid pinacol ester <b>50</b> (175 mg, 0.51 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 3:2) gave compound <b>4a</b> as a yellowish solid (90 mg, 0.21 mmol, 42%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 8.42 (s, 1 H), 6.76 (s, 1 H), 6.67 (br s, 2 H), 4.05 (dd, <i>J</i> = 13, 4.2 Hz, 1 H), 3.67–3.49 (m, 9 H), 3.25 (dd, <i>J</i> = 15.0, 9.1 Hz, 1 H), 2.78–2.64 (m, 2 H), 1.83–1.67 (m, 2 H), 1.63–1.55 (m, 1 H), 1.51–1.37 (m, 1 H), 1.37–1.20 (m, 2 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, DMSO): δ −59.1 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO): δ 167.2 (s, 1 C), 160.7 (s, 1 C), 160.2 (s, 1 C), 157.5 (s, 1 C), 151.8 (s, 1 C), 135.7 (q, <i>J</i> = 31 Hz, 1 C), 123.3 (q, <i>J</i> = 274 Hz, 1 C), 121.2–121.1 (m, 1 C), 104.1 (q, <i>J</i> = 5.9 Hz, 1 C), 99.3 (s, 1 C), 66.1 (s, 2 C), 58.9 (s, 1 C), 45.5 (s, 2 C), 41.3 (s, 1 C), 33.6 (s, 1 C), 31.5 (s, 1 C), 24.4 (s, 1 C), 23.6 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O 421.1958; found, 421.1962. HPLC: <i>t</i><sub>R</sub> = 8.44 min (97.8% purity).</div></div><div id="sec4_7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>R</i>)-5-(4-Morpholino-5,5a,6,7,8,9-hexahydropyrimido[5,4-<i>b</i>]indolizin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>4b</b>)</h3><div class="NLM_p last"><b>4b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>4a</b> starting from <b>51b</b> (150 mg, 0.51 mmol, 1.0 equiv) and boronic acid pinacol ester <b>50</b> (175 mg, 0.51 mmol, 1.0 equiv) in a 47% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O 421.1958; found, 421.1966. HPLC: <i>t</i><sub>R</sub> = 8.45 min (98.7% purity).</div></div><div id="sec4_7_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>S</i>)-5-(4-(Piperidin-1-yl)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>5a</b>)</h3><div class="NLM_p last"><b>5a</b> was prepared as described for its (<i>R</i>)-enantiomer <b>5b</b> starting from <b>52a</b> (100 mg, 0.34 mmol, 1.0 equiv) and boronic acid pinacol ester <b>50</b> (128 mg, 0.37 mmol, 1.1 equiv) in a 75% yield. The spectroscopic data agree with those reported for the (<i>R</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O 421.1958; found, 421.1966. HPLC: <i>t</i><sub>R</sub> = 8.55 min (98.3% purity).</div></div><div id="sec4_7_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>R</i>)-5-(4-(Piperidin-1-yl)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>5b</b>)</h3><div class="NLM_p last"><b>5b</b> was prepared according to general procedure 4 from intermediate <b>52b</b> (100 mg, 0.34 mmol, 1.0 equiv) and boronic acid pinacol ester <b>50</b> (128 mg, 0.38 mmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 3:2) gave compound <b>5b</b> as a colorless solid (114 mg, 0.27 mmol, 80%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 8.43 (s, 1 H), 6.76 (s, 1 H), 6.69 (br s, 2 H), 3.95–3.80 (m, 2 H), 3.77–3.67 (m, 2 H), 3.63–3.50 (m, 4 H), 3.29 (td, <i>J</i> = 12.0, 2.4 Hz, 1 H), 3.23–3.14 (m, 2 H), 3.08 (td, <i>J</i> = 13.0, 3.6 Hz, 1 H), 2.61 (dd, <i>J</i> = 15.0, 4.6 Hz, 1 H), 1.64–1.57 (m,. Two H), 1.53–1.44 (m, 4 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, DMSO): δ −58.9 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO): δ 167.10 (s, 1 C), 160.88 (s, 1 C), 160.18 (s, 1 C), 157.47 (s, 1 C), 151.81 (s, 1 C), 135.70 (q, <i>J</i> = 31 Hz, 1 C), 123.30 (q, <i>J</i> = 274 Hz, 1 C), 121.16 (s, 1 C), 104.12 (q, <i>J</i> = 5.7 Hz, 1 C), 92.47 (s, 1 C), 69.51 (s, 1 C), 65.62 (s, 1 C), 56.31 (s, 1 C), 45.88 (s, 2 C), 41.61 (s, 1 C), 29.11 (s, 1 C), 25.57 (s, 2 C), 24.43 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O 421.1958; found, 421.1963. HPLC: <i>t</i><sub>R</sub> = 8.55 min (98.9% purity).</div></div><div id="sec4_7_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 5-((<i>S</i>)-4-((<i>S</i>)-3-Methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>6a</b>)</h3><div class="NLM_p last"><b>6a</b> was prepared according to general procedure 4 from (<i>S</i>)-2-chloro-4-((<i>S</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>21a</b> (84 mg, 0.27 mmol, 1 equiv) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide <b>38</b> (275 mg, 0.27 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>6a</b> as a colorless solid (76 mg, 0.21 mmol, 76%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.82 (d, <i>J</i> = 2.2 Hz, 1 H), 8.17 (dd, <i>J</i> = 8.7, 2.3 Hz, 1 H), 6.45 (dd, <i>J</i> = 8.7, 0.8 Hz, 1 H), 6.28 (br s, 2 H), 4.36–4.30 (m, 1 H), 4.09–4.02 (m, 2 H), 3.93–3.84 (m, 2 H), 3.79–3.63 (m, 4 H), 3.48 (td, <i>J</i> = 11.7, 2.9 Hz, 1 H), 3.35–3.29 (m, 1 H), 3.26–3.10 (m, 4 H), 2.65 (dd, <i>J</i> = 15.3, 4.7 Hz, 1 H), 1.18 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.63 (s, 1 C), 161.19 (s, 1 C), 160.88 (s, 1 C), 157.80 (s, 1 C), 148.91 (s, 1 C), 136.70 (s, 1 C), 122.69 (s, 1 C), 107.33 (s, 1 C), 93.14 (s, 1 C), 70.86 (s, 1 C), 70.10 (s, 1 C), 66.98 (s, 1 C), 66.17 (s, 1 C), 56.77 (s, 1 C), 47.58 (s, 1 C), 42.02 (s, 1 C), 40.11 (s, 1 C), 29.18 (s, 1 C), 14.23 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> 369.2034; found, 369.2033. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.39 min (99.2% purity).</div></div><div id="sec4_7_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 5-((<i>R</i>)-4-((<i>S</i>)-3-Methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>6b</b>)</h3><div class="NLM_p last"><b>6b</b> was prepared as described for its (<i>S</i>,<i>R</i>)-enantiomer <b>7a</b> starting from (<i>R</i>)-2-chloro-4-((<i>S</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>21b</b> (120 mg, 0.39 mmol, 1 equiv) and boronic acid pinacol ester <b>38</b> in a 64% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>,<i>R</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> 369.2034; found, 369.2033. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.37 min (98.9% purity).</div></div><div id="sec4_7_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 5-((<i>S</i>)-4-((<i>R</i>)-3-Methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>7a</b>)</h3><div class="NLM_p last"><b>7a</b> was prepared according to general procedure 4 from (<i>S</i>)-2-chloro-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>22a</b> (84 mg, 0.27 mmol, 1 equiv) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide <b>38</b> (75 mg, 0.27 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>7a</b> as a colorless solid (72 mg, 0.20 mmol, 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.82 (d, <i>J</i> = 2.4 Hz, 1 H), 8.17 (dd, <i>J</i> = 8.7, 2.3 Hz, 1 H), 6.45 (d, <i>J</i> = 8.7 Hz, 1 H), 6.27 (br s, 2 H), 4.35–4.30 (m, 1 H), 4.13–4.02 (m, 2 H), 3.92–3.81 (m, 2 H), 3.79–3.72 (m, 2 H), 3.69–3.61 (m, 2 H), 3.48 (td, <i>J</i> = 11.8, 2.9 Hz, 1 H), 3.36–3.29 (m, 1 H), 3.25–3.09 (m, 4 H), 2.57 (dd, <i>J</i> = 15.3, 4.7 Hz, 1 H), 1.21 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.25 (s, 1 C), 160.73 (s, 1 C), 160.40 (s, 1 C), 157.20 (s, 1 C), 148.43 (s, 1 C), 136.23 (s, 1 C), 122.22 (s, 1 C), 106.87 (s, 1 C), 92.50 (s, 1 C), 70.41 (s, 1 C), 69.53 (s, 1 C), 66.53 (s, 1 C), 65.68 (s, 1 C), 56.38 (s, 1 C), 47.12 (s, 1 C), 41.64 (s, 1 C), 28.84 (s, 1 C), 13.88 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> 369.2034; found, 369.2034. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.42 min (99.3% purity).</div></div><div id="sec4_7_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 5-((<i>R</i>)-4-((<i>R</i>)-3-Methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>7b</b>)</h3><div class="NLM_p last"><b>7b</b> was prepared as described for its (<i>S</i>,<i>S</i>)-enantiomer <b>6a</b> starting from (<i>R</i>)-2-chloro-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>22b</b> (150 mg, 0.48 mmol, 1 equiv) and boronic acid pinacol ester <b>38</b> in a 49% yield. The spectroscopic data are in agreement with those reported for the (<i>S,S</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> 369.2034; found, 369.2035. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.35 min (99.6% purity).</div></div><div id="sec4_7_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 5-[(9<i>S</i>)-6-{8-Oxa-3-azabicyclo[3.2.1]octan-3-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-trien-4-yl]pyridin-2-amine (<b>8a</b>)</h3><div class="NLM_p last"><b>8a</b> was prepared according to general procedure 4 from (9<i>S</i>)-4-chloro-6-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-triene <b>23a</b> (150 mg, 0.46 mmol, 1 equiv) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide <b>38</b> (128 mg, 0.46 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>8a</b> as a colorless solid (118 mg, 0.31 mmol, 67%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81 (dd, <i>J</i> = 2.3, 0.8 Hz, 1 H), 8.15 (dd, <i>J</i> = 8.6, 2.3 Hz, 1 H), 6.44 (dd, <i>J</i> = 8.7, 0.8 Hz, 1 H), 6.26 (br s, 2 H), 4.38–4.34 (m, 2 H), 4.09–3.95 (m, 3 H), 3.87–3.80 (m, 1 H), 3.77–3.69 (m, 2 H), 3.34–3.27 (m, 1 H), 3.22–3.05 (m, 5 H), 2.63 (dd, <i>J</i> = 15.3, 4.8 Hz, 1 H), 1.84–1.74 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.09 (s, 1 C), 160.72 (s, 1 C), 160.25 (s, 1 C), 158.61 (s, 1 C), 148.43 (s, 1 C), 136.26 (s, 1 C), 122.22 (s, 1 C), 106.86 (s, 1 C), 92.56 (s, 1 C), 73.16 (s, 1 C), 73.15 (s, 1 C), 69.60 (s, 1 C), 65.70 (s, 1 C), 56.38 (s, 1 C), 50.70 (s, 1 C), 50.48 (s, 1 C), 41.59 (s, 1 C), 28.84 (s, 1 C), 27.56 (s, 1 C), 27.52 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> 381.2034; found, 381.2033. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.34 min (98.2% purity).</div></div><div id="sec4_7_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 5-[(9<i>R</i>)-6-{8-Oxa-3-azabicyclo[3.2.1]octan-3-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-trien-4-yl]pyridin-2-amine (<b>8b</b>)</h3><div class="NLM_p last"><b>8b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>8a</b> starting from (9<i>R</i>)-4-chloro-6-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-triene <b>23b</b> (200 mg, 0.62 mmol, 1 equiv) and boronic acid pinacol ester <b>38</b> in a 86% yield. The spectroscopic data agree with those reported for the (<i>S</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> 381.2034; found, 381.2036. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.17 min (96.4% purity).</div></div><div id="sec4_7_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 5-[(9<i>S</i>)-6-{3-Oxa-8-azabicyclo[3.2.1]octan-8-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-trien-4-yl]pyridin-2-amine (<b>9a</b>)</h3><div class="NLM_p last"><b>9a</b> was prepared according to general procedure 4 from (9<i>S</i>)-4-chloro-6-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-triene <b>24a</b> (150 mg, 0.46 mmol, 1 equiv) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide <b>38</b> (128 mg, 0.46 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>9a</b> as a colorless solid (122 mg, 0.32 mmol, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.04 (d, <i>J</i> = 2.2 Hz, 1 H), 8.35 (dd, <i>J</i> = 8.6, 2.2 Hz, 1 H), 6.50 (d, <i>J</i> = 8.6 Hz, 1 H), 4.61–4.51 (m, 4 H), 4.20 (dd, <i>J</i> = 13.4, 2.8 Hz, 1 H), 4.01–3.93 (m, 1 H), 3.88–3.77 (m, 4 H), 3.58 (d, <i>J</i> = 10.7 Hz, 2 H), 3.50 (td, <i>J</i> = 11.7, 3.0 Hz, 1 H), 3.36–3.23 (m, 2 H), 3.09 (dd, <i>J</i> = 14.9, 9.5 Hz, 1 H), 2.48 (dd, <i>J</i> = 14.9, 4.9 Hz, 1 H), 2.12–1.97 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.92 (s, 1 C), 160.96 (s, 1 C), 160.72 (s, 1 C), 155.76 (s, 1 C), 148.43 (s, 1 C), 136.26 (s, 1 C), 122.23 (s, 1 C), 106.86 (s, 1 C), 93.44 (s, 1 C), 70.42 (s, 1 C), 70.38 (s, 1 C), 69.71 (s, 1 C), 65.74 (s, 1 C), 56.46 (s, 1 C), 55.11 (s, 1 C), 55.04 (s, 1 C), 41.51 (s, 1 C), 28.03 (s, 1 C), 26.52 (s, 1 C), 26.45 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> 381.2034; found, 381.2036. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.39 min (97.2% purity).</div></div><div id="sec4_7_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 5-[(9<i>R</i>)-6-{3-Oxa-8-azabicyclo[3.2.1]octan-8-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-trien-4-yl]pyridin-2-amine (<b>9b</b>)</h3><div class="NLM_p last"><b>9b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>9a</b> starting from (9<i>S</i>)-4-chloro-6-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-triene <b>24b</b> (200 mg, 0.62 mmol, 1 equiv) and boronic acid pinacol ester <b>38</b> in a 88% yield. The spectroscopic data agree with those reported for the (<i>S</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> 381.2034; found, 381.2040. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.35 min (96.7% purity).</div></div><div id="sec4_7_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>S</i>)-5-(4-(3,3-Dimethylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>10a</b>)</h3><div class="NLM_p last"><b>10a</b> was prepared according to general procedure 4 from (<i>S</i>)-2-chloro-4-(3,3-dimethylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>25a</b> (150 mg, 0.46 mmol, 1 equiv) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide <b>38</b> (127 mg, 0.46 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 3:7) gave compound <b>10a</b> as a colorless solid (124 mg, 0.32 mmol, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.83 (d, <i>J</i> = 2.2 Hz, 1 H), 8.16 (dd, <i>J</i> = 8.7, 2.3 Hz, 1 H), 6.47 (d, <i>J</i> = 8.7 Hz, 1 H), 6.29 (br s, 2 H), 4.01 (dd, <i>J</i> = 13.4, 2.6 Hz, 1 H), 3.90–3.83 (m, 1 H), 3.79–3.65 (m, 4 H), 3.36–3.29 (m, 3 H), 3.20–3.04 (m, 4 H), 2.97 (dd, <i>J</i> = 16.0, 9.1 Hz, 1 H), 2.40 (dd, <i>J</i> = 15.9, 5.0 Hz, 1 H), 1.47 (s, 3 H), 1.43 (s, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.29 (s, 1 C), 160.72 (s, 1 C), 160.67 (s, 1 C), 159.98 (s, 1 C), 148.38 (s, 1 C), 136.03 (s, 1 C), 122.33 (s, 1 C), 107.05 (s, 1 C), 101.51 (s, 1 C), 77.82 (s, 1 C), 69.73 (s, 1 C), 67.12 (s, 1 C), 65.57 (s, 1 C), 56.91 (s, 1 C), 53.80 (s, 1 C), 43.68 (s, 1 C), 41.57 (s, 1 C), 27.77 (s, 1 C), 21.74 (s, 1 C), 20.72 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub> 383.2190; found, 383.2192. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.58 min (98.1% purity).</div></div><div id="sec4_7_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>R</i>)-5-(4-(3,3-Dimethylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>10b</b>)</h3><div class="NLM_p last"><b>10b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>10a</b> starting from (<i>S</i>)-2-chloro-4-(3,3-dimethylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>25b</b> (150 mg, 0.46 mmol, 1 equiv) and boronic acid pinacol ester <b>38</b> in a 88% yield. The spectroscopic data agree with those reported for the (<i>S</i>)-enantiomer. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub> 383.2190; found, 383.2193. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.61 min (99.5% purity).</div></div><div id="sec4_7_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 5-((<i>R</i>)-4-((<i>R</i>)-3-Methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyrimidin-2-amine (<b>11b</b>)</h3><div class="NLM_p last">Chloropyrimidine derivative <b>22b</b> (100 mg, 0.32 mmol, 1.0 equiv) and 2-aminopyridine-5-boronic acid pinacol ester (71.2 mg, 0.32 mmol, 1.0 equiv) were charged in a flask. Under nitrogen atmosphere, 1,4-dioxane (2 mL) was added, followed by K<sub>3</sub>PO<sub>4</sub> (137 mg, 0.65 mmol, 2 equiv) aqueous solution (1 mL) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 12.7 mg, 0.016 mmol, 0.05 equiv). The resulting mixture was stirred at 95 °C overnight. After completion of the reaction monitored by TLC, a 15% NH<sub>4</sub>Cl solution (15 mL) was added and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>11b</b> as a colorless solid (100 mg, 0.27 mmol, 84%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.98 (s, 2 H), 7.00 (br s, 2 H), 4.35–4.29 (m, 1 H), 4.07–4.02 (m, 2 H), 3.92–3.85 (m, 2 H), 3.79–3.61 (m, 4 H), 3.46 (td, <i>J</i> = 11.7, 2.9 Hz, 1 H), 3.35–3.29 (m, 1 H), 3.26–3.09 (m, 4 H), 2.66 (dd, <i>J</i> = 15.4, 4.8 Hz, 1 H), 1.17 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.01 (s, 1 C), 164.01 (s, 1 C), 158.80 (s, 1 C), 157.70 (s, 2 C), 157.24 (s, 1 C), 120.30 (s, 1 C), 93.09 (s, 1 C), 70.37 (s, 1 C), 69.66 (s, 1 C), 66.50 (s, 1 C), 65.73 (s, 1 C), 56.28 (s, 1 C), 47.12 (s, 1 C), 41.54 (s, 1 C), 39.63 (s, 1 C), 28.71 (s, 1 C), 13.82 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub> 370.1986; found, 370.1991. HPLC: <i>t</i><sub>R</sub> = 6.09 min (98.7% purity).</div></div><div id="sec4_7_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 5-((<i>R</i>)-4-((<i>R</i>)-3-Methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyrazin-2-amine (<b>12b</b>)</h3><div class="NLM_p last">Chloropyrimidine derivative <b>22b</b> (200 mg, 0.65 mmol, 1.0 equiv), <b>39</b> (428 mg, 1.94 mmol, 3.0 equiv), and Cs<sub>2</sub>CO<sub>3</sub> (421 mg, 1.29 mmol, 2.0 equiv) were charged in a flask. Under nitrogen atmosphere, THF (2 mL) was added, followed by [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl<sub>2</sub>, 47.2 mg, 0.065 mmol, 0.1 equiv). The resulting mixture was stirred at reflux for 6 h. After completion of the reaction monitored by TLC, a 15% NH<sub>4</sub>Cl solution (15 mL) was added and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>12b</b> as a colorless solid (163 mg, 0.44 mmol, 68%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.78 (s, 1 H), 7.91 (s, 1 H), 6.73 (br s, 2 H), 4.36–4.30 (m, 1 H), 4.09–4.00 (m, 2 H), 3.92–3.85 (m, 2 H), 3.78–3.61 (m, 4 H), 3.46 (td, <i>J</i> = 11.7, 2.9 Hz, 1 H), 3.29–3.09 (m, 5 H), 2.67 (dd, <i>J</i> = 15.4, 4.6 Hz, 1 H), 1.17 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.44 (s, 1 C), 160.37 (s, 1 C), 157.39 (s, 1 C), 155.84 (s, 1 C), 142.83 (s, 1 C), 138.67 (s, 1 C), 130.87 (s, 1 C), 93.51 (s, 1 C), 70.37 (s, 1 C), 69.64 (s, 1 C), 66.52 (s, 1 C), 65.73 (s, 1 C), 56.27 (s, 1 C), 47.11 (s, 1 C), 41.60 (s, 1 C), 39.65 (s, 1 C), 28.71 (s, 1 C), 13.84 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub> 370.1986; found, 370.1986. HPLC: <i>t</i><sub>R</sub> = 5.53 min (98.1% purity).</div></div><div id="sec4_7_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 4-Methyl-5-((<i>R</i>)-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>13b</b>)</h3><div class="NLM_p"><i>Step 1.</i> (<i>E</i>)-<i>N</i>′-(5-Bromo-4-methylpyridin-2-yl)-<i>N</i>,<i>N</i>-dimethylformimidamide <b>40</b> (281 mg, 1.16 mmol, 3.0 equiv), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos, 55.4 mg, 0.12 mmol, 0.3 equiv), KOAc (342 mg, 3.48 mmol, 9.0 equiv), and bis(pinacolato)diboron (312 mg, 3.48 mmol, 9.0 equiv) were charged into a flask. Under nitrogen atmosphere, EtOH (11.6 mL) was added and the reaction mixture was heated at 80 °C. Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 45.7 mg, 0.058 mmol, 0.15 equiv) was added, and the reaction mixture was stirred at 80 °C for 2 h.</div><div class="NLM_p"><i>Step 2.</i> Then the mixture was allowed to cool down to room temperature. The chloropyrimidine derivative <b>22b</b> (120 mg, 0.39 mmol, 1.0 equiv), 1,4-dioxane (2 mL), and a 1.8 M aqueous K<sub>2</sub>CO<sub>3</sub> solution (650 μL, 1,16 mmol, 3.0 equiv) were added. The reaction mixture was stirred at 95 °C for 3 h.</div><div class="NLM_p last"><i>Step 3.</i> After completion of the reaction, the mixture was allowed to cool down to room temperature, a 3 M HCl solution (1.3 mL, 3.87 mmol, 10.0 equiv) was added, and the reaction mixture was stirred at 80 °C overnight. A 2 M aqueous NaOH solution (15 mL) was added until pH 9–10 was obtained. The aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>13b</b> as a colorless solid (46 mg, 0.12 mmol, 31%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.64 (s, 1 H), 6.35 (s, 1 H), 4.57 (br s, 2 H), 4.34–4.27 (m, 1 H), 4.13 (dd, <i>J</i> = 13.4, 2.4 Hz, 1 H), 4.04–3.93 (m, 3 H), 3.85–3.71 (m, 4 H), 3.59 (td, <i>J</i> = 11.8, 2.9 Hz, 1 H), 3.47 (td, <i>J</i> = 11.7, 2.9 Hz, 1 H), 3.39–3.30 (m, 2 H), 3.28–3.17 (m, 2 H), 2.62 (dd, <i>J</i> = 14.9, 4.8 Hz, 1 H), 2.54 (s, 3 H), 1.28 (d, <i>J</i> = 6.8 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 167.57 (s, 1 C), 163.28 (s, 1 C), 158.42 (s, 1 C), 158.08 (s, 1 C), 150.47 (s, 1 C), 148.84 (s, 1 C), 126.18 (s, 1 C), 109.96 (s, 1 C), 92.79 (s, 1 C), 71.23 (s, 1 C), 70.57 (s, 1 C), 67.42 (s, 1 C), 66.68 (s, 1 C), 56.89 (s, 1 C), 48.07 (s, 1 C), 42.08 (s, 1 C), 40.43 (s, 1 C), 29.78 (s, 1 C), 22.04 (s, 1 C), 14.26 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub> 383.2190; found, 383.2191. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.18 min (96.7% purity).</div></div><div id="sec4_7_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 3-Methyl-5-((<i>R</i>)-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>14b</b>)</h3><div class="NLM_p last"><b>14b</b> was prepared according to general procedure 4 from (<i>R</i>)-2-chloro-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine <b>22b</b> (120 mg, 0.39 mmol, 1 equiv) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-<i>N</i>′-(3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide <b>41</b> (112 mg, 0.39 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>14b</b> as a colorless solid (98 mg, 0.26 mmol, 66%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.70 (d, <i>J</i> = 2.1 Hz, 1 H), 8.01 (s, 1 H), 6.05 (br s, 2 H), 4.34–4.28 (m, 1 H), 4.09–4.02 (m, 2 H), 3.92–3.83 (m, 2 H), 3.78–3.62 (m, 4 H), 3.47 (td, <i>J</i> = 11.8, 2.9 Hz, 1 H), 3.30–3.28 (m, 1 H), 3.26–3.09 (m, 4 H), 2.64 (dd, <i>J</i> = 15.3, 4.7 Hz, 1 H), 2.08 (s, 3 H), 1.17 (d, J = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.15 (s, 1 C), 160.53 (s, 1 C), 159.35 (s, 1 C), 157.36 (s, 1 C), 145.97 (s, 1 C), 135.92 (s, 1 C), 122.83 (s, 1 C), 114.54 (s, 1 C), 92.65 (s, 1 C), 70.41 (s, 1 C), 69.67 (s, 1 C), 66.54 (s, 1 C), 65.74 (s, 1 C), 56.29 (s, 1 C), 47.14 (s, 1 C), 41.57 (s, 1 C), 39.63 (s, 1 C), 28.74 (s, 1 C), 17.20 (s, 1 C), 13.77 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub> 383.2190; found, 383.2191. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.67 min (99.2% purity).</div></div><div id="sec4_7_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 4-Methoxy-5-((<i>R</i>)-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>15b</b>)</h3><div class="NLM_p"><i>Step 1.</i> (<i>tert</i>-Butyl (5-bromo-4-methoxypyridin-2-yl)carbamate <b>42</b> (200 mg, 0.66 mmol, 1.0 equiv), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos, 31.5 mg, 0.066 mmol, 0.1 equiv), KOAc (194 mg, 1.98 mmol, 3.0 equiv), and bis(pinacolato)diboron (178 mg, 1.98 mmol, 3.0 equiv) were charged into a flask. Under nitrogen atmosphere, EtOH (6.6 mL) was added and the reaction mixture was heated at 60 °C. Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 26 mg, 0.033 mmol, 0.05 equiv) was added, and the reaction mixture was stirred at 80 °C for 3 h.</div><div class="NLM_p"><i>Step 2.</i> Then the mixture was allowed to cool down to room temperature. The chloropyrimidine derivative <b>22b</b> (102 mg, 0.33 mmol, 0.5 equiv) and K<sub>3</sub>PO<sub>4</sub> (210 mg, 0.99 mmol, 1.5 equiv) in water (1.7 mL) were added. The reaction mixture was stirred at 80 °C for 3.5 h.</div><div class="NLM_p last"><i>Step 3.</i> After completion of the reaction monitored by TLC, a 15% NH<sub>4</sub>Cl solution (10 mL) was added and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The crude was dissolved in 1,4-dioxane (1.6 mL), a 3 M HCl solution (0.7 mL, 1.98 mmol, 3.0 equiv) was added, and the reaction mixture was stirred at 80 °C for 3 h. A 2 M aqueous NaOH solution was added until pH 9–10 was obtained. The aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>15b</b> as a colorless solid (58 mg, 0.15 mmol, 44%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.18 (s, 1 H), 6.04 (br s, 2 H), 6.02 (s, 1 H), 4.32–4.26 (m, 1 H), 4.00–3.90 (m, 2 H), 3.89–3.81 (m, 1 H), 3.75–3.69 (m, 2 H), 3.71 (s, 3 H), 3.67–3.58 (m, 2 H), 3.44 (td, <i>J</i> = 11.7, 2.9 Hz, 1 H), 3.30–3.25 (m, 2 H), 3.21–3.05 (m, 4 H), 2.64 (dd, <i>J</i> = 15.3, 4.7 Hz, 1 H), 1.16 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.05 (s, 1 C), 164.76 (s, 1 C), 161.73 (s, 1 C), 160.96 (s,1 C), 157.24 (s, 1 C), 150.54 (s, 1 C), 115.28 (s, 1 C), 92.45 (s, 1 C), 89.20 (s, 1 C), 70.45 (s, 1 C), 69.60 (s, 1 C), 66.51 (s, 1 C), 65.66 (s, 1 C), 56.24 (s, 1 C), 54.84 (s, 1 C), 47.03 (s, 1 C), 41.59 (s, 1 C), 39.70 (s, 1 C), 28.69 (s, 1 C), 13.76 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub> 399.2139; found, 399.2145. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 4.28 min (95.3% purity).</div></div><div id="sec4_7_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 4-(Dimethoxymethyl)-5-((<i>R</i>)-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyridin-2-amine (<b>16b</b>)</h3><div class="NLM_p last"><b>16b</b> was prepared according to general procedure 6 from <b>18b</b> (169 mg, 0.26 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>16b</b> as a colorless solid (88 mg, 0.20 mmol, 76%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.41 (s, 1 H), 6.66 (s, 1 H), 6.45 (s, 1 H), 6.24 (br s, 2 H), 4.33–4.26 (m, 1 H), 3.99–3.94 (m, 2 H), 3.92–3.84 (m, 2 H), 3.79–3.72 (m, 2 H), 3.69–3.61 (m, 2 H), 3.46 (td, <i>J</i> = 11.7, 2.8 Hz, 1 H), 3.35–3.26 (m, 2 H), 3.24–3.10 (m, 3 H), 3.22 (s, 3 H), 3.16 (s, 3 H), 2.68 (dd, <i>J</i> = 15.3, 4.9 Hz, 1 H), 1.19 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.97 (s, 1 C), 162.33 (s, 1 C), 159.98 (s, 1 C), 157.32 (s, 1 C), 150.47 (s, 1 C), 145.81 (s, 1 C), 122.14 (s, 1 C), 104.47 (s, 1 C), 99.62 (s, 1 C), 92.62 (s, 1 C), 70.39 (s, 1 C), 69.65 (s, 1 C), 66.49 (s, 1 C), 65.68 (s, 1 C), 56.33 (s, 1 C), 53.71 (s, 1 C), 53.26 (s, 1 C), 47.11 (s, 1 C), 41.68 (s, 1 C), 39.79 (s, 1 C), 28.74 (s, 1 C), 13.88 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>31</sub>N<sub>6</sub>O<sub>4</sub> 443.2401; found, 443.2405. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.19 min (99.5% purity).</div></div><div id="sec4_7_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 4-(Dimethoxymethyl)-5-((<i>R</i>)-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazin-2-yl)pyrimidin-2-amine (<b>17b</b>)</h3><div class="NLM_p last"><b>17b</b> was prepared according to general procedure 6 from <b>19b</b> (234 mg, 0.36 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>17b</b> as a colorless solid (122 mg, 0.28 mmol, 76%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.72 (s, 1 H), 6.97 (br s, 2 H), 6.36 (s, 1 H), 4.33–4.27 (m, 1 H), 4.01–3.85 (m, 4 H), 3.79–3.72 (m, 2 H), 3.68–3.60 (m, 2 H), 3.46 (td, <i>J</i> = 11.7, 2.8 Hz, 1 H), 3.36–3.29 (m, 1 H), 3.27 (s, 3 H), 3.25 (s, 3 H), 3.26–3.10 (m, 4 H), 2.68 (dd, <i>J</i> = 15.4, 4.9 Hz, 1 H), 1.18 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.95 (s, 1 C), 162.97 (s, 1 C), 162.76 (s, 1 C), 160.70 (s, 1 C), 160.57 (s, 1 C), 157.25 (s, 1 C), 120.35 (s, 1 C), 99.37 (s, 1 C), 92.84 (s, 1 C), 70.35 (s, 1 C), 69.66 (s, 1 C), 66.48 (s, 1 C), 65.69 (s, 1 C), 56.33 (s, 1 C), 53.94 (s, 1 C), 53.71 (s, 1 C), 47.13 (s, 1 C), 41.65 (s, 1 C), 39.68 (s, 1 C), 28.70 (s, 1 C), 13.96 (s, 1 C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>30</sub>N<sub>7</sub>O<sub>4</sub> 444.2354; found, 444.2358. HPLC: <i>t</i><sub>R</sub> = 5.88 min (98.3% purity).</div></div><div id="sec4_7_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>tert</i>-Butyl <i>N</i>-[(<i>tert</i>-Butoxy)carbonyl]-<i>N</i>-[4-(dimethoxymethyl)-5-[(9<i>R</i>)-6-[(3<i>R</i>)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-trien-4-yl]pyridin-2-yl]carbamate (<b>18b</b>)</h3><div class="NLM_p last"><b>18b</b> was prepared according to general procedure 5 from <b>44</b> (289 mg, 0.65 mmol, 1.0 equiv) and <b>22b</b> (200 mg, 0.65 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 1:1) gave compound <b>18b</b> as a colorless solid (174 mg, 0.27 mmol, 42%). The product is a mixture of mono- and di-Boc protected derivative and was used for the next step without further purification. MALDI-MS: <i>m</i>/<i>z</i> = 643.813 ([M + H]<sup>+</sup>); 543.329 ([M – Boc + H]<sup>+</sup>).</div></div><div id="sec4_7_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>tert</i>-Butyl <i>N</i>-[(<i>tert</i>-Butoxy)carbonyl]-<i>N</i>-[4-(dimethoxymethyl)-5-[(9<i>R</i>)-6-[(3<i>R</i>)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-trien-4-yl]pyrimidin-2-yl]carbamate (<b>19b</b>)</h3><div class="NLM_p last"><b>19b</b> was prepared according to general procedure 5 from <b>49</b> (289 mg, 0.65 mmol, 1.0 equiv) and <b>22b</b> (200 mg, 0.65 mmol, 1 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 1:1) gave compound <b>19b</b> as a yellowish solid (240 mg, 0.37 mmol, 57%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.20 (s, 1 H), 6.36 (s, 1 H), 4.36–4.30 (m, 1 H), 4.05–3.08 (m, 4 H), 3.81–3.76 (m, 2 H), 3.70–3.62 (m, 2 H), 3.47 (td, <i>J</i> = 11.7, 2.9 Hz, 1 H), 3.33 (s, 3 H), 3.28 (s, 3 H), 3.39–3.14 (m, 5 H), 2.76 (dd, <i>J</i> = 15.6, 5.0 Hz, 1 H), 1.42 (s, 18 H), 1.21 (d, <i>J</i> = 6.8 Hz, 3 H). MALDI-MS: <i>m</i>/<i>z</i> = 644.445 ([M + H]<sup>+</sup>).</div></div><div id="sec4_7_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>S</i>)-2-Chloro-4-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>20a</b>)</h3><div class="NLM_p last"><b>20a</b> was prepared according to general procedure 3 from 4-(2,6-dichloropyrimidin-4-yl)morpholine <b>26</b> (653 mg, 2.79 mmol, 1 equiv) and (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33b</b> (500 mg, 2.79 mmol, 1 equiv). Purification by column chromatography (cyclohexane/EtOAc 2:1 → 1:1) gave compound <b>20a</b> as a colorless solid (550 mg, 1.85 mmol, 66%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.01 (dd, <i>J</i> = 13.5, 2.9 Hz, 1 H), 3.95–3.87 (m, 1 H), 3.79–3.72 (m, 2 H), 3.68–3.65 (m, 4 H), 3.59–3.49 (m, 4 H), 3.38 (td, <i>J</i> = 11.7, 2.9 Hz, 1 H), 3.23 (t, <i>J</i> = 11.0 Hz, 1H), 3.18–3.09 (m, 2 H), 2.50 (dd, <i>J</i> = 15.0, 5.1 Hz, 1 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 167.84 (s, 1 C), 158.32 (s, 1 C), 158.24 (s, 1 C), 93.08 (s, 1 C), 70.49 (s, 1 C), 66.73 (s, 2 C), 66.58 (s, 1 C), 57.32 (s, 1 C), 45.81 (s, 2 C), 42.15 (s, 1 C), 29.06 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 297.301 ([M + H]<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 6.36 min (97.7% purity). (<i>S</i>)-enantiomer: [α<sub>D</sub>] = +4.0 (CHCl<sub>3</sub>, <i>c</i> = 1.2).</div></div><div id="sec4_7_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>R</i>)-2-Chloro-4-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>20b</b>)</h3><div class="NLM_p last"><b>20b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>20a</b> starting from (<i>S</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33a</b> (506 mg, 2.16 mmol, 1 equiv) in 73% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer. HPLC: <i>t</i><sub>R</sub> = 6.35 min (98.0% purity). (<i>R</i>)-enantiomer: [α<sub>D</sub>] = −3.3 (CHCl<sub>3</sub>, <i>c</i> = 1.5).</div></div><div id="sec4_7_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>S</i>)-4-Chloro-2-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>20c</b>)</h3><div class="NLM_p last"><b>20c</b> was prepared according to general procedure 3 from 4-(4,6-dichloropyrimidin-2-yl)morpholine <b>32</b> (298 mg, 1.27 mmol, 1 equiv) and (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33b</b> (228 mg, 1.27 mmol, 1 equiv). Purification by column chromatography (cyclohexane/EtOAc 2:1 → 1:1) gave compound <b>20c</b> as a colorless solid (286 mg, 0.96 mmol, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.02–3.94 (m, 2 H), 3.89–3.87 (m, 1 H), 3.86–3.84 (m, 1 H), 3.75–3.70 (m, 8 H), 3.44 (td, <i>J</i> = 11.7, 3.0 Hz, 1 H), 3.26 (t, <i>J</i> = 11.0 Hz, 1 H), 3.25–3.19 (m, 1 H), 2.99 (dd, <i>J</i> = 16.1, 9.4 Hz, 1 H), 2.42 (dd, <i>J</i> = 16.1, 5.0 Hz, 1 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 166.64 (s, 1 C), 161.92 (s, 1 C), 151.94 (s, 1 C), 104.19 (s, 1 C), 71.07 (s, 1 C), 66.83 (s, 2 C), 66.40 (s, 1 C), 57.11 (s, 1 C), 44.54 (s, 2 C), 41.79 (s, 1 C), 26.35 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 297.030 ([M + H]<sup>+</sup>). (<i>S</i>)-enantiomer: [α<sub>D</sub>] = −61.0 (CHCl<sub>3</sub>, <i>c</i> = 1.1).</div></div><div id="sec4_7_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>R</i>)-4-Chloro-2-morpholino-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>20d</b>)</h3><div class="NLM_p last"><b>20d</b> was prepared as described for its (<i>S</i>)-enantiomer <b>20c</b> starting from (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33a</b> (281 mg, 1.57 mmol, 1 equiv) in 24% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer. (<i>R</i>)-enantiomer: [α<sub>D</sub>] = +56.2 (CHCl<sub>3</sub>, <i>c</i> = 1.4).</div></div><div id="sec4_7_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>S</i>)-2-Chloro-4-((<i>S</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>21a</b>)</h3><div class="NLM_p last"><b>21a</b> was prepared according to general procedure 3 from (<i>S</i>)-4-(2,6-dichloropyrimidin-4-yl)-3-methylmorpholine <b>27</b> (3.68 g, 14.92 mmol, 1 equiv) and (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33b</b> (2.67 g, 14.92 mmol, 1 equiv). Purification by column chromatography (cyclohexane/ethyl acetate 1:0 → 3:2) gave compound <b>21a</b> as a yellowish solid (853 mg, 2.75 mmol, 18%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.23–4.18 (m, 1 H), 3.97–3.73 (m, 6 H), 3.66–3.57 (m, 2 H), 3.42 (td, <i>J</i> = 11.8, 3.0 Hz, 1 H), 3.34–3.29 (m, 1 H), 3.24–3.08 (m, 4 H), 2.68 (dd, <i>J</i> = 15.4, 5.1 Hz, 1 H), 1.17 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.87 (s, 1 C), 157.71 (s, 1 C), 157.48 (s, 1 C), 93.25 (s, 1 C), 70.13 (s, 1 C), 69.64 (s, 1 C), 66.27 (s, 1 C), 65.69 (s, 1 C), 56.71 (s, 1 C), 47.18 (s, 1 C), 41.55 (s, 1 C), 39.67 (s, 1 C), 28.07 (s, 1 C), 14.10 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 311.109 ([M + H]<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 7.03 min (96.5% purity).</div></div><div id="sec4_7_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (<i>R</i>)-2-Chloro-4-((<i>S</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>21b</b>)</h3><div class="NLM_p last"><b>21b</b> was prepared as described for its (<i>S,R</i>)-enantiomer <b>22a</b> starting from (<i>S</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33a</b> (1.0 g, 5.58 mmol, 1 equiv) in 24% yield. The spectroscopic data are in agreement with those reported for the (<i>S,R</i>)-enantiomer.</div></div><div id="sec4_7_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (<i>S</i>)-2-Chloro-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>22a</b>)</h3><div class="NLM_p last"><b>22a</b> was prepared according to general procedure 3 from (<i>R</i>)-4-(2,6-dichloropyrimidin-4-yl)-3-methylmorpholine <b>28</b> (1.15 g, 4.65 mmol, 1 equiv) and (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33b</b> (833 mg, 4.65 mmol, 1 equiv). Purification by column chromatography (cyclohexane/ethyl acetate 1:0 → 4:1) gave compound <b>22a</b> as a yellowish solid (1.05 g, 3.39 mmol, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.20–4.14 (m, 1 H), 3.93–3.72 (m, 6 H), 3.63 (d, <i>J</i> = 11.1 Hz, 1 H), 3.56 (dd, <i>J</i> = 11.5, 3.1 Hz, 1 H), 3.41 (td, <i>J</i> = 11.8, 2.9 Hz, 1 H), 3.34–3.27 (m, 1 H), 3.25–3.06 (m, 4 H), 2.57 (dd, <i>J</i> = 15.4, 5.0 Hz, 1 H), 1.18 (d, <i>J</i> = 6.8 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.96 (s, 1 C), 157.72 (s, 1 C), 157.40 (s, 1 C), 93.14 (s, 1 C), 70.15 (s, 1 C), 69.55 (s, 1 C), 66.29 (s, 1 C), 65.66 (s, 1 C), 56.76 (s, 1 C), 47.23 (s, 1 C), 41.62 (s, 1 C), 39.56 (s, 1 C), 28.18 (s, 1 C), 14.21 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 311.085 ([M + H]<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 7.15 min (98.9% purity).</div></div><div id="sec4_7_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>R</i>)-2-Chloro-4-((<i>R</i>)-3-methylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>22b</b>)</h3><div class="NLM_p last"><b>22b</b> was prepared as described for its (<i>S,S</i>)-enantiomer <b>21a</b> starting from (<i>S</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33a</b> (1.0 g, 5.58 mmol, 1 equiv) in 55% yield. The spectroscopic data are in agreement with those reported for the (<i>S,S</i>)-enantiomer. HPLC: <i>t</i><sub>R</sub> = 7.24 min (99.6% purity).</div></div><div id="sec4_7_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (9<i>S</i>)-4-Chloro-6-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-triene (<b>23a</b>)</h3><div class="NLM_p last"><b>23a</b> was prepared according to general procedure 3 from 3-(2,6-dichloropyrimidin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane <b>29</b> (1.21 g, 4.65 mmol, 1 equiv) and (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33b</b> (1 g, 5.58 mmol, 1.2 equiv). Purification by column chromatography (cyclohexane/ethyl acetate 1:0 → 3:2) gave compound <b>23a</b> as a yellowish solid (1.06 g, 3.28 mmol, 71%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.36–4.31 (m, 2 H), 3.92–3.71 (m, 6 H), 3.32–3.27 (m, 1 H), 3.24–3.19 (m, 2 H), 3.16–3.03 (m, 3 H), 2.65 (dd, <i>J</i> = 15.4, 5.0 Hz, 1 H), 1.83–1.69 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.75 (s, 1 C), 158.86 (s, 1 C), 157.52 (s, 1 C), 93.27 (s, 1 C), 72.89 (s, 1 C), 72.88 (s, 1 C), 69.59 (s, 1 C), 65.67 (s, 1 C), 56.75 (s, 1 C), 50.61 (s, 1 C), 50.42 (s, 1 C), 41.55 (s, 1 C), 28.20 (s, 1 C), 27.37 (s, 1 C), 27.34 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 323.162 ([M + H]<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 6.98 min (99.8% purity).</div></div><div id="sec4_7_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (9<i>R</i>)-4-Chloro-6-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-triene (<b>23b</b>)</h3><div class="NLM_p last"><b>23b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>23a</b> starting from (<i>S</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33a</b> (2.0 g, 11.17 mmol, 1 equiv) in 40% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer.</div></div><div id="sec4_7_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (9<i>S</i>)-4-Chloro-6-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-triene (<b>24a</b>)</h3><div class="NLM_p last"><b>24a</b> was prepared according to general procedure 3 from 8-(2,6-dichloropyrimidin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane <b>30</b> (1.21 g, 4.65 mmol, 1 equiv) and (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33b</b> (1 g, 5.58 mmol, 1.2 equiv). Purification by column chromatography (cyclohexane/ethyl acetate 1:0 → 3:2) gave compound <b>24a</b> as a colorless solid (893 mg, 2.77 mmol, 59%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.38–4.33 (m, 2 H), 3.94–3.89 (m, 1 H), 3.80–3.71 (m, 3 H), 3.59 (dd, <i>J</i> = 10.8, 5.8 Hz, 2 H), 3.50 (d, <i>J</i> = 10.8 Hz, 2 H), 3.36–3.29 (m, 1 H), 3.23 (t, <i>J</i> = 11.0 Hz, 1 H), 3.14–3.03 (m, 2 H), 2.54–2.48 (m, 1 H), 1.93–1.85 (m, 4 H). MALDI-MS: <i>m</i>/<i>z</i> = 323.111 ([M + H]<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 7.04 min (95.5% purity). <sup>13</sup>C NMR spectroscopic data are not available due to insufficient solubility in standard deuterated solvents.</div></div><div id="sec4_7_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (9<i>S</i>)-4-Chloro-6-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}-11-oxa-1,3,5-triazatricyclo[7.4.0.0<sup>2,7</sup>]trideca-2(7),3,5-triene (<b>24b</b>)</h3><div class="NLM_p last"><b>24b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>24a</b> starting from (<i>S</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33a</b> (2.0 g, 11.17 mmol, 1 equiv) in 26% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer.</div></div><div id="sec4_7_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (<i>S</i>)-2-Chloro-4-(3,3-dimethylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>25a</b>)</h3><div class="NLM_p last"><b>25a</b> was prepared according to general procedure 3 from 4-(2,6-dichloropyrimidin-4-yl)-3,3-dimethylmorpholine <b>31</b> (1.21 g, 4.65 mmol, 1 equiv) and (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33b</b> (1 g, 5.58 mmol, 1.2 equiv). Purification by column chromatography (cyclohexane/ethyl acetate 1:0 → 4:1) gave compound <b>25a</b> as a colorless solid (922 mg, 2.84 mmol, 61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 3.95–3.88 (m, 1 H), 3.81–3.73 (m, 3 H), 3.72–3.62 (m, 2 H), 3.35–3.27 (m, 4 H), 3.22–3.07 (m, 4 H), 2.99 (dd, <i>J</i> = 16.1, 9.5 Hz, 1 H), 2.42 (dd, <i>J</i> = 16.1, 5.3 Hz, 1 H), 1.36 (s, 3 H), 1.33 (s, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.01 (s, 1 C), 160.49 (s, 1 C), 156.25 (s, 1 C), 102.21 (s, 1 C), 77.30 (s, 1 C), 69.71 (s, 1 C), 66.75 (s, 1 C), 65.51 (s, 1 C), 57.21 (s, 1 C), 54.29 (s, 1 C), 43.33 (s, 1 C), 41.56 (s, 1 C), 27.39 (s, 1 C), 21.71 (s, 1 C), 20.86 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 325.036 ([M + H]<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 8.19 min (99.1% purity).</div></div><div id="sec4_7_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (<i>R</i>)-2-Chloro-4-(3,3-dimethylmorpholino)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>25b</b>)</h3><div class="NLM_p last"><b>25b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>25a</b> starting from (<i>S</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33a</b> (1.64 g, 9.16 mmol, 1.2 equiv) in 66% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer.</div></div><div id="sec4_7_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 4-(2,6-Dichloropyrimidin-4-yl)morpholine (<b>26</b>)</h3><div class="NLM_p last"><b>26</b> was prepared according to the literature.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec4_7_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (<i>S</i>)-4-(2,6-Dichloropyrimidin-4-yl)-3-methylmorpholine (<b>27</b>)</h3><div class="NLM_p last"><b>27</b> was prepared according to general procedure 2 from (<i>S</i>)-3-methylmorpholine (1.3 mL, 11.46 mmol, 1.05 equiv) and 2,4,6-trichloropyrimidine (1.25 mL, 10.92 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 3:1) gave compound <b>27</b> as a colorless solid (1.96 g, 7.90 mmol, 72%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.95 (s, 1 H), 4.49 (qd, <i>J</i> = 6.8, 2.9 Hz, 1 H), 4.13 (dd, <i>J</i> = 13.7, 2.8 Hz, 1 H), 3.90 (dd, <i>J</i> = 11.5, 3.8 Hz, 1 H), 3.69 (d, <i>J</i> = 11.5 Hz, 1 H), 3.56 (dd, <i>J</i> = 11.6, 3.2 Hz, 1 H), 3.44–3.37 (m, 1 H), 3.25–3.18 (m, 1 H), 1.21 (d, <i>J</i> = 6.8 Hz, 3 H). The spectroscopic data are in agreement with those reported for the (<i>R</i>)-enantiomer.</div></div><div id="sec4_7_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (<i>R</i>)-4-(2,6-Dichloropyrimidin-4-yl)-3-methylmorpholine (<b>28</b>)</h3><div class="NLM_p last"><b>28</b> was prepared according to general procedure 2 from (<i>R</i>)-3-methylmorpholine (4 g, 39.54 mmol, 1.05 equiv) and 2,4,6-trichloropyrimidine (4.55 mL, 39.54 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 3:2) gave compound <b>28</b> as a colorless solid (6.94 g, 28.10 mmol, 71%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.00 (s, 1 H), 4.46–4.32 (m, 1 H), 4.10–3.97 (m, 1 H), 3.91 (ddt, <i>J</i> = 11.5, 4.0, 1.1 Hz, 1 H), 3.70 (d, <i>J</i> = 11.6 Hz, 1 H), 3.57 (dd, <i>J</i> = 11.7, 3.0 Hz, 1 H), 3.43 (td, <i>J</i> = 11.9, 3.0 Hz, 1 H), 3.21 (td, <i>J</i> = 13.0, 3.8 Hz, 1 H), 1.21 (d, <i>J</i> = 6.7 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 163.06 (s, 1 C), 160.71 (s, 1 C), 160.06 (s, 1 C), 99.90 (s, 1 C), 70.70 (s, 1 C), 66.56 (s, 1 C), 47.94 (s, 1 C), 39.72 (s, 1 C), 14.09 (s, 1 C). The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer.</div></div><div id="sec4_7_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 3-(2,6-Dichloropyrimidin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane (<b>29</b>)</h3><div class="NLM_p last"><b>29</b> was prepared according to general procedure 2 from 8-oxa-3-azabicyclo[3.2.1]octane·HCl (2.5 g, 16.70 mmol, 1.05 equiv) and 2,4,6-trichloropyrimidine (1.83 mL, 15.90 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 4:1) gave compound <b>29</b> as a colorless solid (3.57 g, 13.73 mmol, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.94 (s, 1 H), 4.47–4.36 (m, 2 H), 4.25–4.04 (m, 1 H), 3.82–3.60 (m, 1 H), 3.26–2.95 (m, 2 H), 1.90–1.74 (m, 2 H), 1.73–1.55 (m, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 164.65 (s, 1 C), 160.53 (s, 1 C), 159.83 (s, 1 C), 99.79 (s, 1 C), 73.33 (s, 2 C), 50.30 (s, 2 C), 27.79 (s, 2 C).</div></div><div id="sec4_7_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 8-(2,6-Dichloropyrimidin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane (<b>30</b>)</h3><div class="NLM_p last"><b>30</b> was prepared according to general procedure 2 from 3-oxa-8-azabicyclo[3.2.1]octane.HCl (2.5 g, 16.70 mmol, 1.05 equiv) and 2,4,6-trichloropyrimidine (1.83 mL, 15.90 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 4:1) gave compound <b>30</b> as a colorless solid (3.33 g, 12.81 mmol, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.98 (s, 1 H), 4.68–4.62 (m, 1 H), 4.52–4.45 (m, 1 H), 3.61–3.53 (m, 4 H), 2.02–1.87 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.52 (s, 1 C), 159.36 (s, 1 C), 159.22 (s, 1 C), 102.25 (s, 1 C), 71.21 (s, 2 C), 55.97 (s, 1 C), 55.71 (s, 1 C), 26.95 (s, 1 C), 26.17 (s, 1 C).</div></div><div id="sec4_7_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 4-(2,6-Dichloropyrimidin-4-yl)-3,3-dimethylmorpholine (<b>31</b>)</h3><div class="NLM_p last"><b>31</b> was prepared according to general procedure 2 from 3,3-dimethylmorpholine (4.0 g, 34.73 mmol, 1.05 equiv) and 2,4,6-trichloropyrimidine (3.8 mL, 33.08 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 9:1) gave compound <b>31</b> as a colorless solid (4.19 g, 15.99 mmol, 46%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.04 (s, 1 H), 3.81 (t, <i>J</i> = 5.5 Hz, 2 H), 3.59 (t, <i>J</i> = 5.7 Hz, 2 H), 3.46 (s, 2 H), 1.44 (s, 6 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.40 (s, 1 C), 159.38 (s, 1 C), 157.59 (s, 1 C), 104.26 (s, 1 C), 75.62 (s, 1 C), 65.76 (s, 1 C), 57.14 (s, 1 C), 42.65 (s, 1 C), 22.57 (s, 2 C).</div></div><div id="sec4_7_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 4-(4,6-Dichloropyrimidin-2-yl)morpholine (<b>32</b>)</h3><div class="NLM_p last"><b>32</b> was prepared according to the literature.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec4_7_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (<i>S</i>)-Tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-Dioxide (<b>33a</b>)</h3><div class="NLM_p last"><b>33a</b> was prepared as described for its (<i>R</i>)-enantiomer <b>33b</b> starting from (<i>R</i>)-morpholin-3-ylmethanol <b>34b</b> (0.685 g, 5.85 mmol, 1 equiv) in 64% yield. The spectroscopic data are in agreement with those reported for the (<i>R</i>)-enantiomer. (<i>S</i>)-enantiomer: [α<sub>D</sub>] = +53.8 (CHCl<sub>3</sub>, <i>c</i> = 0.75).</div></div><div id="sec4_7_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (<i>R</i>)-Tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-Dioxide (<b>33b</b>)</h3><div class="NLM_p last">A solution of thionyl chloride (2.8 g, 1.7 mL, 23.3 mmol, 1.95 equiv) in DCM (1.7 mL) was added dropwise to a cooled (−5 °C) solution of imidazole (4.9 g, 71.7 mmol, 6 equiv) in DCM (30 mL), and the temperature was kept at −5 °C. The cooling bath was removed, and the reaction mixture was stirred for 45 min while allowing it to warm to rt. The mixture was cooled down to −10 °C, and a solution of <b>34a</b> (1.4 g, 11.9 mmol, 1 equiv) in DCM (12 mL) was added dropwise. The mixture was stirred at 0 °C for 2 h. Water (30 mL) was added, and the layers were separated. The organic layer was washed with half-concentrated brine (30 mL) and cooled to 5 °C. A NaIO<sub>4</sub> solution (7.7 g, 35.9 mmol) in water (75 mL) was added, followed by RuO<sub>2</sub>–H<sub>2</sub>O (16 mg). The mixture was allowed to warm up to rt and stirred at rt overnight. The layers were separated, and the organic layer was filtered through a silica gel column eluting with DCM. The solvent was removed under reduced pressure to give compound <b>33b</b> (1.1 g, 61.4 mmol, 52%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.59 (dd, <i>J</i> = 8.1, 6.4 Hz, 1 H), 4.31 (dd, <i>J</i> = 9.3, 8.1 Hz, 1 H), 4.02 (dd, <i>J</i> = 11.6, 3.4 Hz, 1 H), 3.88 (dt, <i>J</i> = 11.9, 3.6 Hz, 1 H), 3.85–3.79 (m, 1 H), 3.74 (ddd, <i>J</i> = 11.9, 8.9, 3.1 Hz, 1 H), 3.61 (dd, <i>J</i> = 11.6, 7.8 Hz, 1 H), 3.39–3.33 (m, 1 H), 3.15 (ddd, <i>J</i> = 12.2, 8.9, 3.4 Hz, 1 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 69.85 (s, 1 C), 66.52 (s, 1 C), 64.65 (s, 1 C), 54.21 (s, 1 C), 43.43 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 180.032 ([M + H]<sup>+</sup>). (<i>R</i>)-enantiomer: [α<sub>D</sub>] = −42.8 (CHCl<sub>3</sub>, <i>c</i> = 0.65).</div></div><div id="sec4_7_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (<i>S</i>)-Morpholin-3-ylmethanol (<b>34a</b>)</h3><div class="NLM_p last">A solution of <b>35a</b> (14 g, 67.4 mmol) in methanol (200 mL) was placed in a Parr apparatus and degassed with argon. Palladium on carbon (10 wt %, 1.5 g) was added, and the mixture was stirred under H<sub>2</sub> at 2.8 bar for 48 h. The resulting mixture was filtered through Celite, washed with MeOH, and concentrated under reduced pressure to give compound <b>34a</b> (8.0 g, 68.3 mmol, 99%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.81–3.80 (m, 1 H), 3.79–3.76 (m, 1 H), 3.60–3.47 (m, 4 H), 3.38–3.32 (m, 1 H), 3.00–2.91 (m, 4 H). The spectroscopic data are consistent with previous literature reports.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec4_7_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> (<i>R</i>)-Morpholin-3-ylmethanol (<b>34b</b>)</h3><div class="NLM_p last"><b>34b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>34a</b> starting from (<i>R</i>)-(4-benzylmorpholin-3-yl)methanol <b>35b</b> (5.2 g, 25.1 mmol, 1 equiv) in 96% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer.</div></div><div id="sec4_7_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (<i>S</i>)-(4-Benzylmorpholin-3-yl)methanol (<b>35a</b>)</h3><div class="NLM_p last">To a stirred solution of <b>36b</b> (20.6 g, 87.5 mmol, 1 equiv) in THF (320 mL), triethylamine (10.6 g, 14.7 mL, 105.1 mmol) was added. The solution was cooled to 0 °C, and borane–dimethyl sulfide complex (10 M in THF, 50 mL, 524.0 mmol) was slowly added. The reaction mixture was heated up to 65 °C for 5 h. After cooling to rt, the reaction was quenched by addition of water (60 mL). The reaction mixture was stirred at rt overnight. The organic solvents were removed under reduced pressure, and the residue was diluted with aqueous NaOH solution (20% v/v, 2×). The aqueous layer was extracted with EtOAc (2×), and the organic layer was washed with an aqueous 1 M HCl solution (2×). The combined aqueous fractions were then basified to pH 14 by addition of solid NaOH and re-extracted with EtOAc (3×). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduce pressure to give compound <b>35a</b> (15.0 g, 72.4 mmol, 82%) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.53–7.26 (m, 5 H), 4.13 (d, <i>J</i> = 13.3 Hz, 1 H), 3.96 (dd, <i>J</i> = 11.5, 4.5 Hz, 1 H), 3.84 (ddd, <i>J</i> = 11.5, 3.8, 1.1 Hz, 1 H), 3.75 (td, <i>J</i> = 3.3, 1.1 Hz, 1 H), 3.73 (td, <i>J</i> = 3.3, 1.1 Hz, 1 H), 3.67 (dd, <i>J</i> = 11.6, 9.2 Hz, 1 H), 3.56–3.49 (m, 2 H), 2.73 (dt, <i>J</i> = 12.0, 2.9 Hz, 1 H), 2.59–2.54 (m, 1 H), 2.52 (br s, 1 H), 2.34 (ddd, <i>J</i> = 12.0, 10.0, 3.3 Hz, 1 H). The spectroscopic data are consistent with previous literature reports.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec4_7_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (<i>R</i>)-(4-Benzylmorpholin-3-yl)methanol (<b>35b</b>)</h3><div class="NLM_p last"><b>35b</b> was prepared as described for its (<i>S</i>)-enantiomer <b>35a</b> starting from (<i>S</i>)-4-benzyl-5-oxomorpholine-3-carboxylic acid <b>36a</b> (7.4 g, 31.5 mmol, 1 equiv) in 81% yield. The spectroscopic data are in agreement with those reported for the (<i>S</i>)-enantiomer.</div></div><div id="sec4_7_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> (<i>S</i>)-4-Benzyl-5-oxomorpholine-3-carboxylic Acid (<b>36a</b>)</h3><div class="NLM_p last"><b>36a</b> was prepared as described for its (<i>R</i>)-enantiomer <b>36b</b> starting from <i>N</i>-benzyl-<i>S</i>-serine <b>37a</b> (12.2 g, 62.5 mmol, 1 equiv) in 51% yield. The spectroscopic data agree with those reported for the (<i>R</i>)-enantiomer.</div></div><div id="sec4_7_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> (<i>R</i>)-4-Benzyl-5-oxomorpholine-3-carboxylic Acid (<b>36b</b>)</h3><div class="NLM_p last">To a solution of <i>N</i>-benzyl-<i>R</i>-serine <b>37b</b> (25.6 g, 131.1 mmol, 1 equiv) and K<sub>2</sub>CO<sub>3</sub> (36.2 g, 262.2 mmol, 2 equiv) in THF/water (150 mL/150 mL) at 0 °C, a chloroacetyl chloride (17.8 g, 12.5 mL, 157.4 mmol, 1.2 equiv) solution in THF (13 mL) was added dropwise. The mixture was stirred at 0 °C for 1 h. Solid NaOH (15.72 g, 393 mmol, 3 equiv) was added, and the mixture was stirred at 5 °C for 2 h. After completion of the reaction, cyclohexane was added and vigorously stirred. The layers were separated and the basic aqueous layer was acidified to pH 1 with conc HCl. The mixture was kept in the fridge overnight and the solid was filtered off, washed with cold water, and dried under vacuum to give compound <b>36b</b> (21.8 g, 92.7 mmol, 71%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.37–7.26 (m, 5 H), 5.26 (d, <i>J</i> = 15.4 Hz, 1 H), 4.19–4.12 (m, 3 H), 3.96–3.90 (m, 2 H), 3.83 (d, <i>J</i> = 15.4 Hz, 1 H). The spectroscopic data are consistent with previous literature reports.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec4_7_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> <i>N</i>-Benzyl-(<i>S</i>)-serine (<b>37a</b>)</h3><div class="NLM_p last"><b>37a</b> was prepared as described for its (<i>R</i>) enantiomer <b>37b</b> starting from (<i>S</i>)-serine (29.5 g, 280.7 mmol, 1 equiv) in 63% yield. The spectroscopic data are in agreement with those reported for the (<i>R</i>) enantiomer.</div></div><div id="sec4_7_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>N</i>-Benzyl-(<i>R</i>)-serine (<b>37b</b>)</h3><div class="NLM_p last">To a stirred solution of (<i>R</i>)-serine (25 g, 237.9 mmol, 1 equiv) in aqueous 2 M NaOH (120 mL), benzaldehyde (24.7 g, 24.5 mL, 233.1 mmol, 1 equiv) was added. The reaction mixture was stirred at rt for 30 min before cooling to 5 °C. NaBH<sub>4</sub> (2.7 g, 71.4 mmol, 0.3 equiv) was added portionwise while keeping the temperature below 10 °C. After addition, the reaction mixture was allowed to warm up to rt and stirred 1 h. Additional benzaldehyde (24.7 g, 24.5 mL, 233.1 mmol, 1 equiv) was added, and the reaction mixture was stirred at rt for 30 min. The reaction mixture was cooled to 5 °C, and further NaBH<sub>4</sub> (2.7 g, 71.4 mmol, 0.3 equiv) was added portionwise while a temperature of 5–10 °C was maintained. After completion of the addition, the reaction mixture was stirred at rt for 2 h. The reaction mixture was then extracted with ether (3×), and the aqueous phase was cooled down to 0 °C and acidified to pH 5 with conc HCl. The resulting white precipitate was filtered off, washed with water, and dried under reduced pressure to give compound <b>37b</b> (25.8 g, 132.2 mmol, 55%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.45–7.30 (m, 5 H), 4.04–3.92 (m, 2 H), 3.70–3.61 (m, 3 H), 3.17 (t, <i>J</i> = 5.8 Hz, 1 H). The spectroscopic data are consistent with previous literature reports.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec4_7_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> (<i>E</i>)-<i>N</i>,<i>N</i>-Dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide (<b>38</b>)</h3><div class="NLM_p last"><b>38</b> was prepared according to general procedure 1 from 2-aminopyridine-5-boronic acid pinacol ester (500 mg, 2.27 mmol, 1 equiv) and <i>N</i>,<i>N</i>-dimethylformamide–dimethyl acetal (DMF–DMA, 395 μL, 2.95 mmol, 1.3 equiv). Compound <b>38</b> was obtained as a beige solid (538 mg, 1.96 mmol, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.57 (s, 1 H), 8.41 (dd, <i>J</i> = 2.0, 0.9 Hz, 1 H), 7.75 (dd, <i>J</i> = 8.1, 2.0 Hz, 1 H), 6.78 (dd, <i>J</i> = 8.0, 0.9 Hz, 1 H), 3.11 (s, 3 H), 3.00 (s, 3 H), 1.29 (s, 12 H).</div></div><div id="sec4_7_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazin-2-amine (<b>39</b>)</h3><div class="NLM_p last">2-Amino-5-bromopyrazine (1.50 g, 8.77 mmol, 1 equiv), bis(pinacolato)diboron (3.29 g, 12.95 mmol, 1.5 equiv), and KOAc (2.53 g, 25.82 mmol, 3.0 equiv) were charged in a flask. Under nitrogen atmosphere, 1,4-dioxane (20 mL) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl<sub>2</sub>, 605 mg, 0.86 mmol, 0.1 equiv) were added. The reaction mixture was stirred at 105 °C for 3.5 h. After completion of the reaction monitored by TLC, the mixture was filtered through Celite and the solvents were evaporated under reduced pressure. Methyl <i>tert</i>-butyl ether (MTBE) was added, and the solid was filtered off. Compound <b>39</b> was obtained as a light brownish solid (1.23 g, 5.57 mmol, 64%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.11 (d, <i>J</i> = 1.5 Hz, 1 H), 7.99 (d, <i>J</i> = 1.5 Hz, 1 H), 6.81 (br s, 2 H), 1.27 (s, 12 H).</div></div><div id="sec4_7_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> (<i>E</i>)-<i>N</i>′-(5-Bromo-4-methylpyridin-2-yl)-<i>N</i>,<i>N</i>-dimethylformimidamide (<b>40</b>)</h3><div class="NLM_p last"><b>40</b> was prepared according to general procedure 1 from 5-bromo-4-methylpyridin-2-amine (8.06 g, 43.10 mmol, 1 equiv) and DMF–DMA (6.92 mL, 51.70 mmol, 1.2 equiv). Compound <b>40</b> was obtained as a beige solid (7.6 g, 31.52 mmol, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.69 (s, 1 H), 8.54 (s, 1 H), 7.14 (s, 1 H), 3.38 (s, 3 H), 3.37 (s, 3 H), 2.62 (s, 3 H).</div></div><div id="sec4_7_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> (<i>E</i>)-<i>N</i>,<i>N</i>-Dimethyl-<i>N</i>′-(3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide (<b>41</b>)</h3><div class="NLM_p last"><b>41</b> was prepared according to general procedure 1 from 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (500 mg, 2.13 mmol, 1 equiv) and DMF–DMA (430 μL, 3.20 mmol, 1.5 equiv). Compound <b>41</b> was obtained as a brownish solid (407 mg, 1.41 mmol, 66%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.51 (s, 1 H), 8.26 (s, 1 H), 7.62 (s, 1 H), 3.11 (s, 3 H), 3.03 (s, 3 H), 2.19 (s, 3 H), 1.28 (s, 12 H).</div></div><div id="sec4_7_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> <i>tert</i>-Butyl (5-Bromo-4-methoxypyridin-2-yl)carbamate (<b>42</b>)</h3><div class="NLM_p last">To a solution of Boc anhydride (Boc<sub>2</sub>O, 4.73 g, 21.67 mmol, 2.2 equiv) in THF (20 mL) at 0 °C, 5-bromo-4-methoxypyridin-2-amine (2.0 g, 9.85 mmol, 1 equiv) was added. Then, 4-dimethylaminopyridine (DMAP, 241 mg, 1.97 mmol, 0.2 equiv) was added portionwise. The reaction mixture was stirred overnight while it was allowed to warm up to room temperature. After completion of the reaction monitored by TLC, the solvent was evaporated and DCM (200 mL) was added. The organic layer was washed with NH<sub>4</sub>Cl 15% solution (2×), and the combined aqueous layers were extracted with DCM (1×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. Purification by column chromatography (cyclohexane/EtOAc 1:0 → 1:4) gave compound <b>42</b> as a colorless solid (767 mg, 2.53 mmol, 26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.97 (s, 1 H), 8.22 (s, 1 H), 7.61 (s, 1 H), 3.92 (s, 3 H), 1.48 (s, 9 H).</div></div><div id="sec4_7_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 5-Bromo-4-(dimethoxymethyl)pyridin-2-amine (<b>43</b>)</h3><div class="NLM_p last">To a solution of 4-(dimethoxymethyl)pyridin-2-amine (2.0 g, 11.89 mmol, 1.0 equiv) in 2-methyltetrahydrofuran (24 mL) at 0 °C, <i>N</i>-bromosuccinimide (NBS, 2.23 g, 12.48 mmol, 1.05 equiv) was added portionwise. The reaction mixture was stirred at 0 °C for 1 h and then at rt overnight. After completion of the reaction monitored by TLC, the reaction mixture was washed with a Na<sub>2</sub>CO<sub>3</sub> 8% solution (3×). The combined aqueous layers were extracted with 2-methyltetrahydrofuran (1×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. Purification by column chromatography (cyclohexane/EtOAc 1:0 → 4:1) gave compound <b>43</b> as a beige solid (2.585 g, 10.46 mmol, 88%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.98 (s, 1 H), 6.65 (s, 1 H), 6.24 (br s, 2 H), 5.28 (s, 1 H), 3.29 (s, 6 H).</div></div><div id="sec4_7_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> <i>tert</i>-Butyl <i>N</i>-[5-Bromo-4-(dimethoxymethyl)pyridin-2-yl]-<i>N</i>-[(<i>tert</i>-butoxy)carbonyl]carbamate (<b>44</b>) and <i>tert</i>-Butyl <i>N</i>-[5-Bromo-4-(dimethoxymethyl)pyridin-2-yl]carbamate (<b>45</b>)</h3><div class="NLM_p last">To a solution of Boc anhydride (Boc<sub>2</sub>O, 5.02 g, 22.98 mmol, 2.2 equiv) in THF (26 mL) at 0 °C, 5-bromo-4-(dimethoxymethyl)pyridin-2-amine <b>43</b> (2.58 g, 10.44 mmol, 1 equiv) was added. Then, 4-dimethylaminopyridine (DMAP, 256 mg, 2.09 mmol, 0.2 equiv) was added portionwise. The reaction mixture was stirred overnight while it was allowed to warm up to room temperature. After completion of the reaction monitored by TLC, the reaction mixture was washed with NH<sub>4</sub>Cl 15% solution (2×) and the organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. Purification by column chromatography (cyclohexane/EtOAc 1:0 → 0:1) gave compound <b>44</b> as a yellowish oil (1.286 g, 2.87 mmol, 27%) and <b>45</b> as a white solid (2.154 g, 6.21 mmol, 59%). <b>44</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.66 (s, 1 H), 7.45 (s, 1 H), 5.51 (s, 1 H), 3.33 (s, 6 H), 1.40 (s, 18 H). <b>45</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.70 (s, 1 H), 7.51 (s, 1 H), 5.51 (s, 1 H), 3.33 (s, 6 H), 1.38 (s, 9 H).</div></div><div id="sec4_7_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> (<i>E</i>)-4-(Dimethylamino)-1,1-dimethoxybut-3-en-2-one (<b>46</b>)</h3><div class="NLM_p last"><b>46</b> was prepared as previously reported in the literature.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> A solution of methylglyoxal dimethyl acetal (26 mL, 211.6 mmol, 1.0 equiv) and DMF–DMA (37 mL, 275.1 mmol, 1.3 equiv) was stirred at 100 °C overnight. The reaction mixture was concentrated under reduced pressure. Compound <b>46</b> was obtained as a brown oil (35.7 g, 206.1 mmol, 75%) and used for the next step without further purification.</div></div><div id="sec4_7_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 4-(Dimethoxymethyl)pyrimidin-2-amine (<b>47</b>)</h3><div class="NLM_p last">Compound <b>46</b> (35.7 g, 206.1 mmol, 1.0 equiv) was dissolved in ethanol (780 mL). Potassium carbonate (71.2 g, 512.3 mmol, 2.5 equiv) and guanidine hydrochloride (23.6 g, 247.3 mmol, 1.2 equiv) were added, and the resulting suspension was heated to reflux overnight. After completion of the reaction monitored by TLC, ethanol was evaporated under reduced pressure. The residue was stirred with water for 6 h, filtered, and dried under vacuum to afford compound <b>47</b>. The filtrate was extracted with dichloromethane (3×) and the combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> sodium sulfate and concentrated under reduced pressure to give compound <b>47</b> as a brown solid (24.8 g, 146.6 mmol, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.34 (d, <i>J</i> = 5.0 Hz, 1 H), 6.84 (d, <i>J</i> = 5.0 Hz, 1 H), 5.28 (br s, 1 H), 5.14 (s, 1 H), 4.76 (br s, 1 H), 3.39 (s, 6 H).</div></div><div id="sec4_7_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 5-Bromo-4-(dimethoxymethyl)pyrimidin-2-amine (<b>48</b>)</h3><div class="NLM_p last">To a solution of 4-(dimethoxymethyl)pyrimidin-2-amine <b>47</b> (5.0 g, 29.58 mmol, 1.0 equiv) in ACN (150 mL), NBS (5.53 g, 31.06 mmol, 1.05 equiv) was added portionwise. The reaction mixture was stirred at 70 °C overnight. After completion of the reaction monitored by TLC, ACN was evaporated. The solid was dissolved in DCM (250 mL), and the organic layer was washed with a Na<sub>2</sub>CO<sub>3</sub> 8% solution (3×). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The product was recrystallized from dichloromethane/heptanes to obtain compound <b>48</b> as a beige solid (6.50 g, 26.20 mmol, 89%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.34 (s, 1 H), 7.02 (br s, 2 H), 5.27 (s, 1 H), 3.35 (s, 6 H).</div></div><div id="sec4_7_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> <i>tert</i>-Butyl <i>N</i>-[5-Bromo-4-(dimethoxymethyl)pyrimidin-2-yl]-<i>N</i>-[(<i>tert</i>-butoxy)carbonyl]carbamate (<b>49</b>)</h3><div class="NLM_p last">To a solution of Boc anhydride (Boc<sub>2</sub>O, 12.59 g, 57.66 mmol, 2.2 equiv) in THF (65 mL) at 0 °C, 5-bromo-4-(dimethoxymethyl)pyrimidin-2-amine <b>48</b> (6.50 g, 26.21 mmol, 1 equiv) was added. Then, DMAP (640 mg, 5.24 mmol, 0.2 equiv) was added portionwise. The reaction mixture was stirred overnight while it was allowed to warm up to room temperature. After completion of the reaction monitored by TLC, the reaction mixture was washed with a 0.1 M HCl solution (2×) and the organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. Recrystallization from heptanes gave compound <b>49</b> as a beige solid (10.71 g, 23.91 mmol, 91%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.12 (s, 1 H), 5.54 (s, 1 H), 3.39 (s, 6 H), 1.40 (s, 18 H).</div></div><div id="sec4_7_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> (<i>E</i>)-<i>N</i>,<i>N</i>-Dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)formimidamide (<b>50</b>)</h3><div class="NLM_p last"><b>50</b> was prepared according to the literature.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec4_7_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> (<i>S</i>)-4-(2-Chloro-5,5a,6,7,8,9-hexahydropyrimido[5,4-<i>b</i>]indolizin-4-yl)morpholine (<b>51a</b>)</h3><div class="NLM_p last"><b>51a</b> was prepared as described for its (<i>R</i>)-enantiomer <b>51b</b> starting from (<i>S</i>)-hexahydro[1,2,3]oxathiazolo[3,4-<i>a</i>]pyridine 1,1-dioxide <b>53a</b> (507 mg, 2.86 mmol, 1.2 equiv) in 43% yield. The spectroscopic data are in agreement with those reported for the (<i>R</i>)-enantiomer.</div></div><div id="sec4_7_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> (<i>R</i>)-4-(2-Chloro-5,5a,6,7,8,9-hexahydropyrimido[5,4-<i>b</i>]indolizin-4-yl)morpholine (<b>51b</b>)</h3><div class="NLM_p last"><b>51b</b> was prepared according to general procedure 3 from 4-(2,6-dichloropyrimidin-4-yl)morpholine (702 mg, 3.00 mmol, 1.0 equiv) and (<i>R</i>)-hexahydro-[1,2,3]oxathiazolo[3,4-<i>a</i>]pyridine 1,1-dioxide <b>53b</b> (638 mg, 3.60 mmol, 1.2 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 9:1) gave compound <b>51b</b> as a colorless solid (324 mg, 1.10 mmol, 36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.91 (dd, <i>J</i> = 13.0, 4.2 Hz, 1 H), 3.68–3.57 (m, 5 H), 3.52–3.44 (m, 4 H), 3.24 (dd, <i>J</i> = 15.0, 9.5 Hz, 1 H), 2.75 (td, <i>J</i> = 13.0, 3.2 Hz, 1 H), 2.66 (dd, <i>J</i> = 15.0, 6.4 Hz, 1 H), 1.82–1.67 (m, 2 H), 1.63–1.55 (m, 1 H), 1.50–1.36 (m, 1 H), 1.35–1.20 (m, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO): δ 167.84 (s, 1 C), 157.66–157.53 (m, 2 C), 93.32 (s, 1 C), 65.99 (s, 2 C), 59.15 (s, 1 C), 45.34 (s, 2 C), 41.29 (s, 1 C), 32.60 (s, 1 C), 31.62 (s, 1 C), 24.43 (s, 1 C), 23.35 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 295.267 ([M + H]<sup>+</sup>).</div></div><div id="sec4_7_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> (<i>S</i>)-2-Chloro-4-(piperidin-1-yl)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>52a</b>)</h3><div class="NLM_p last"><b>52a</b> was prepared as described for its (<i>R</i>)-enantiomer <b>52b</b> starting from (<i>R</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33b</b> in 70% yield. The spectroscopic data are in agreement with those reported for the (<i>R</i>)-enantiomer.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> (<i>R</i>)-2-Chloro-4-(piperidin-1-yl)-5a,6,8,9-tetrahydro-5<i>H</i>-pyrimido[5′,4′:4,5]pyrrolo[2,1-<i>c</i>][1,4]oxazine (<b>52b</b>)</h3><div class="NLM_p last"><b>52b</b> was prepared according to general procedure 3 from dichloropyrimidine <b>54</b> (200 mg, 0.86 mmol, 1.0 equiv) and (<i>S</i>)-tetrahydro-3<i>H</i>-[1,2,3]oxathiazolo[4,3-<i>c</i>][1,4]oxazine 1,1-dioxide <b>33a</b> (185 mg, 1.03 mmol, 1.2 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 9:1) gave compound <b>52b</b> as a colorless solid (168 mg, 0.57 mmol, 66%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.03–3.88 (m, 2 H), 3.79 (ddd, <i>J</i> = 16.0, 11.0, 3.8 Hz, 2 H), 3.60–3.53 (m, 4 H), 3.44 (td, <i>J</i> = 12.0, 2.9 Hz, 1 H), 3.29 (t, <i>J</i> = 11.0 Hz, 1 H), 3.22–3.12 (m, 2 H), 2.54 (dd, <i>J</i> = 15.0, 5.0 Hz, 1 H), 1.69–1.61 (m, 2 H), 1.61–1.53 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.44 (s, 1 C), 158.98 (s, 1 C), 158.49 (s, 1 C), 92.49 (s, 1 C), 70.55 (s, 1 C), 66.72 (s, 1 C), 57.32 (s, 1 C), 46.69 (s, 2 C), 42.11 (s, 1 C), 29.55 (s, 1 C), 26.16 (s, 2 C), 24.84 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 295.082 ([M + H]<sup>+</sup>).</div></div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> (<i>S</i>)-Hexahydro-[1,2,3]oxathiazolo[3,4-<i>a</i>]pyridine 1,1-Dioxide (<b>53a</b>)</h3><div class="NLM_p last"><b>53a</b> was prepared as described for its (<i>R</i>)-enantiomer <b>53b</b> in a 74% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.57 (dd, <i>J</i> = 7.7, 5.8 Hz, 1 H), 4.18 (dd, <i>J</i> = 9.9, 7.8 Hz, 1 H), 3.59–3.51 (m, 1 H), 3.50–3.40 (m, 1 H), 2.76 (ddd, <i>J</i> = 12.0, 11.0, 3.1 Hz, 1 H), 1.96–1.86 (m, 2 H), 1.86–1.78 (m, 1 H), 1.69–1.57 (m, 1 H), 1.50–1.27 (m, 2 H). The spectroscopic data are consistent with those reported in literature.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> (<i>R</i>)-Hexahydro-[1,2,3]oxathiazolo[3,4-<i>a</i>]pyridine 1,1-Dioxide (<b>53b</b>)</h3><div class="NLM_p last">To a solution of imidazole (1.77 g, 26.0 mmol, 6.0 equiv) in DCM (18 mL), a solution of SOCl<sub>2</sub> (610 μL, 8.36 mmol, 1.9 equiv) in DCM (6 mL) was added dropwise. The resulting colorless suspension was stirred at rt for 1 h. Then, a solution of (<i>R</i>)-piperidin-2-ylmethanol (500 mg, 4.34 mmol, 1.0 equiv) in DCM (800 μL) was added dropwise at −10 °C. The reaction mixture was allowed to warm up to rt and stirred at rt for 1.5 h. After completion of the reaction monitored by TLC, deionized H<sub>2</sub>O (35 mL) was added and the layers were separated. The organic layer was washed with brine (15 mL) and used in the next step. Under vigorous stirring, a solution of RuO<sub>2</sub>–H<sub>2</sub>O (5.80 mg, 43.6 μmol, 0.01 equiv) and NaIO<sub>4</sub> (2.38 g, 11.1 mmol, 2.6 equiv) in deionized H<sub>2</sub>O (24 mL) was added. The reaction mixture was stirred at rt for 30 min. After completion of the reaction, the layers were separated and the organic layer was filtered through a pad of silica gel (12 g) (eluent: DCM). The solvent was evaporated to give compound <b>53b</b> as a colorless liquid (638 mg, 3.60 mmol, 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.57 (dd, <i>J</i> = 7.8, 5.8 Hz, 1 H), 4.18 (dd, <i>J</i> = 9.9, 7.7 Hz, 1 H), 3.59–3.52 (m, 1 H), 3.50–3.40 (m, 1 H), 2.76 (ddd, <i>J</i> = 12.0, 11.0, 3.1 Hz, 1 H), 1.96–1.86 (m, 2 H), 1.86–1.78 (m, 1 H), 1.69–1.56 (m, 1 H), 1.51–1.27 (m, 2 H).</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 2,4-Dichloro-6-(piperidin-1-yl)pyrimidine (<b>54</b>)</h3><div class="NLM_p last"><b>54</b> was prepared according to general procedure 2 from 2,4,6-trichloropyrimidine (627 μL, 5.45 mmol, 1.0 equiv) and piperidine (566 μL, 5.72 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 4:1) gave compound <b>54</b> as a colorless solid (849 mg, 3.66 mmol, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.39 (s, 1 H), 3.79–3.36 (m, 4 H), 1.74–1.66 (m, 2 H), 1.66–1.57 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 162.82 (s, 1 C), 160.31 (s, 1 C), 160.02 (s, 1 C), 99.66 (s, 1 C), 45.81 (br s, 2 C), 25.61 (s, 2 C), 24.41 (s, 1 C).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Structure Modeling of PI3K and mTOR Kinase Complexes</h3><div class="NLM_p last">The coordinates of PIKiN3 in PI3Kγ complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB">5JHB</a>, resolution of 2.48 Å), CNX-1351 in PI3Kα (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZIM">3ZIM</a>, resolution of 2.85 Å), and mTOR kinase bound to PI103 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>; 3.6 Å) were used as starting points to dock molecules into the ATP-binding sites. Ligands in crystal structures were manually replaced using Maestro 11.1, and energy minimization was carried out. Further measurements and figures were generated in Maestro 11.1 and Chimera UCSF.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Determination of Inhibitor Dissociation Constants</h3><div class="NLM_p last">Dissociation constants of compounds (<i>K</i><sub>i</sub>) for p110α and mTOR were determined by commercial LanthaScreen (Life Technologies) and evaluated as described in ref <a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>. Briefly, AlexaFluor647-labeled kinase tracer 314 (no. PV6087) with a <i>K</i><sub>d</sub> of 2.2 nM was used at 20 nM for p110α and at a final concentration of 10 nM for mTOR (<i>K</i><sub>d</sub> of 19 nM). Recombinant N-terminally (His)<sub>6</sub>-tagged p110α was detected with biotinylated anti-(His)<sub>6</sub>-tag antibody (2 nM, no. PV6089) and LanthaScreen Eu-Steptavidin (2 nM, no. PV5899); N-terminal GST fused to truncated mTOR (amino acids 1360–2549; no. PR8683B) was detected with a LanthaScreen Eu-labeled anti-GST antibody (2 nM, no. PV5594). The p110α assay buffer was composed of 50 mM HEPES, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, and 0.01% (v/v) Brij-35, and the mTOR assay buffer contained 50 mM HEPES; 5 mM MgCl<sub>2</sub>; 1 mM EGTA; 0.01% Pluronic F-127. Further details and calculations are explained in ref <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Kinome Profiling</h3><div class="NLM_p last">The inhibitory capacity and selectivity of compound were determined using the ScanMax platform provided by DiscoverX.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In short binding of immobilized ligand to DNA-tagged kinases competed with 10 μM compound. The amount of kinase bound to the immobilized ligand was measured by quantitative PCR of the respective DNA tags and is given as percentage of control. Binding constants of compounds for kinases of interest were determined by competing the immobilized ligand kinase interactions with an 11-point 3-fold serial dilution of compound starting from 30 μM and subsequent quantitative PCR of DNA tags. Binding constants were calculated by a standard dose–response curve using the Hill equation (with Hill slope set to −1):<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_m001.gif" alt="" id="_i110" /></img></span> Selectivity cores<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> were calculated as <i>S</i> = number of hits/number of tested kinases (excluding mutant variants), where S35, S10, S1 were calculated using %Ctrl as a potency threshold (35, 10, 1%); for example <i>S</i>(35) = (number of nonmutant kinases with %Ctrl < 35)/(number of nonmutant kinases tested).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Cellular PI3K and mTOR Signaling</h3><div class="NLM_p last">Downstream signals emerging from mTORC2 (phosphorylation of Ser473 of PKB/Akt; rabbit polyclonal antibody from Cell Signaling Technology (CST), no. 4058) and mTORC1 (phosphorylation of Ser235/236 on the ribosomal protein S6; rabbit monoclonal antibody from CST, no. 4856) were measured in in-cell Western assays plating 2 × 10<sup>4</sup> A2058 cells/well in 96-well plates (Cell Carrier, PerkinElmer) for 24 h (37 °C, 5% CO<sub>2</sub>) before exposing cells for 1 h to inhibitors or DMSO. Then, cells were fixed (4% PFA in PBS for 30 min at rt), blocked (1% BSA/0.1% Triton X-100/5% goat serum in PBS for 30 min, RT), and stained with CST primary antibodies (1:500). Tubulin staining (mouse anti-α-tubulin, 1:2000, Sigma no. T9026) was assessed as internal standard. Secondary antibody [IRDye680-conjugated goat anti-mouse, and IRDye800-conjugated goat anti-rabbit antibodies (LICOR no. 926-68070 and no. 926-32211), both 1:500] fluorescence was detected on an Odyssey CLx infrared imaging scanner (LICOR). Remaining phospho-protein signals were normalized to cellular tubulin and related to DMSO controls. ICW anaylsis and determination of IC<sub>50</sub> were done as described in ref <a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> Pharmacokinetic Studies</h3><div class="NLM_p">Male Sprague Dawley rats (8 weeks old at delivery) were purchased from Janvier Labs (France). The animals were housed in a temperature-controlled room (20–24 °C) and maintained in a 12h light/12h dark cycle. Food and water were available ad libitum throughout the duration of the study. Formulations of compounds <b>7b</b> and <b>12b</b> were prepared by weighing the test items into glass vials and dissolving them by addition of Captisol (40% w/w in water) and water for injection in a proportion of 50% and 35% of the final desired volume. The pH was adjusted to 3 with 0.2 M HCl, and finally, the volume was completed with water for injection. The formulations were stirred continuously until application to the animals. At each time point (30 min, 2 h, 4 h, and 8 h), three rats were anesthetized with isoflurane and 1 mL blood was collected, via heart puncture, in tubes containing lithium-heparin. After blood sampling, the rats were euthanized and brain, liver, and skin were collected. Blood samples were stored on dry ice until centrifugation at 6000 rpm (10 min, 4 °C). Plasma supernatants and tissue samples were kept at −80 °C until being assayed. The calibration standards and quality controls were prepared in duplicates. A volume of 50 μL of unknown samples, zero samples, and blanks was spiked with 6 μL of DMSO. After 10 min of equilibration, a volume of 100 μL of acetonitrile containing the internal standard (diazepam, 300 ng/mL) was added to each calibration standard, QC, zero sample, and unknown sample, while a volume of 100 μL of plain acetonitrile was added to all blanks. Samples were vigorously shaken and centrifuged for 10 min at 6000<i>g</i> and 20 °C. The particle free supernatant was diluted 1 + 1 with water. An aliquot was transferred to 200 μL sampler vials and subsequently subjected to LC–MS. The HPLC system consisted of an Accela U-HPLC pump and an Accela autosampler (Thermo Fisher Scientific, USA). Mass spectrometry was performed on an Exactive mass spectrometer (Orbitrap technology with accurate mass) equipped with a heated electrospray (H-ESI 2) interface (Thermo Fisher Scientific, USA) connected to a PC running the standard software Xcalibur 2.1.</div><div class="NLM_p last"><i>Ethics Statement.</i> All experimental procedures were approved by and conducted in accordance with the regulations of the local animal welfare authorities (Landesamt für Gesundheit and Verbraucherschutz, Abteilung Lebensmittel- and Veterinärwesen, Saarbrücken).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Hepatocyte Stability Assay</h3><div class="NLM_p">Primary hepatocytes from mouse (CD-1), rat (Sprague Dawley, SD), dog (Beagle), and human were used. Assays were performed using cryopreserved hepatocytes in suspension. Hepatocytes were thawed according to the instructions of the supplier before seeding in 48-well cell culture plates at a density of 200 000 cells/well in 225 μL of incubation medium consisting of WME (Williams medium E) supplemented with 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine and 25 mM HEPES. Stock solution of compound <b>11b</b> was prepared with 10 mM in DMSO. A working solution was obtained by dilution of the stock solution in DMSO (first step) and in incubation medium (second step) resulting in a concentration of 10-fold higher strength (50 μM) than the final intended test concentration (5 μM) and a solvent content of 5% DMSO.</div><div class="NLM_p">Positive control incubations were performed using 7-ethoxycoumarin as substrate. A 10 mM stock solution in acetonitrile (ACN) was further diluted in ACN (first step) and in incubation medium (second step) to give a working solution in 10% ACN and of 10-fold higher strength than the final intended incubation concentration (5 μM). To 225 μL of cell suspension, 25 μL of the 10-fold concentrated working solution of test or reference item was added, resulting in a final test concentration of 5 μM for compound <b>11b</b> or 7-ethoxycoumarin, respectively, with final solvent concentrations of 0.5% DMSO (<b>11b</b>) or 1% ACN (7-ethoxycoumarin). For analysis, samples were taken after 0, 15, 60, 90, and 180 min of incubation for <b>11b</b> and after 0, 60, and 180 min for reference item. The sample preparation was performed afterward by protein precipitation using ACN (200 μL of cell suspension plus 200 μL of ACN/ISTD3). After centrifugation (5 min, 4800<i>g</i>), the particle-free supernatants were diluted with one volume of water and were analyzed by LC–MS. Negative controls were performed to exclude nonmetabolic degradation processes; i.e., the finding that the concentrations remained stable over the investigated time suggests that the decrease of the parent compound was mainly due to metabolism. Negative control incubations were performed in line with all experiments using incubation medium in absence of hepatocytes.</div><div class="NLM_p last">For quantitative analysis of compound <b>11b</b> in samples from primary human hepatocytes, the HPLC system consisted of a LC pump Surveyor Plus and an autosampler Surveyor Plus (Thermo-Fisher, USA). Mass spectrometry was performed on a TSQ Quantum Discovery Max triple quadrupole mass spectrometer equipped with an electrospray ion source (ESI) (Thermo Fisher Scientific, USA) connected to a PC running the standard software Xcalibur 2.0.7.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> CYP Reactive Phenotyping with Human Recombinant CYP1A1 and CYP1A2 Isoenzymes</h3><div class="NLM_p">Human recombinant isoenzymes from insect cells infected by baculovirus and containing cDNA of a single human CYP isoenzyme (Supersomes, Corning) were used. The test item stock solutions were diluted in DMSO/H<sub>2</sub>O (1:8, v/v) to obtain 50-fold concentrated working solutions (solvent content 12.5% DMSO/87.5% H<sub>2</sub>O) for CYP1A1 and CYP1A2. The test compound concentration applied in the CYP reactive phenotyping assay was 1 μM in the presence of 0.25% DMSO. The assays were performed in duplicate using human recombinant enzymes systems from Corning (BD Gentest P450 high throughput inhibitor screening kits). The cofactor mix, containing the NADP<sup>+</sup>-regenerating system, was prepared according to the instructions of the manufacturer. For CYP1A1 and CYP1A2, 4 μL of the 50-fold concentrated working solution was added to 96 μL of cofactor mix. Cofactor mix and test item were pipetted into the respective wells of a prewarmed 96-well plate and prewarmed for 10 min on a shaker with fitted heating block. The reactions were initiated by addition of 100 μL of prewarmed enzyme mix. By default, the final protein concentration of all CYP isoenzymes was 25 pmol/mL. Incubations with a final volume of 200 μL were performed at 37 °C. After 0 and 60 min (30 min for positive control substrates), the reactions were stopped by the addition of 200 μL of stop solution, i.e., ACN containing the internal standard. Two control groups were run in parallel for every assay: positive controls (PC, <i>n</i> = 2) using specific probe substrates for each CYP isoform as reference compounds (CYP1A1 = melatonin and CYP1A2 = phenacetin) to prove the quality of the enzyme activity of the used batches and a negative control (NC, <i>n</i> = 2), which were performed without cofactors and glucose 6-phosphate dehydrogenase to ensure that the potential loss of parent compound is due to CYP-mediated metabolism.</div><div class="NLM_p">For quantitative analysis of compounds <b>7b</b>, <b>11b</b>, and <b>12b</b>, LC–MS systems were used. (i) LC–MS: Accela U-HPLC pump and an Accela autosampler (Thermo Fisher Scientific, USA) connected to an Exactive mass spectrometer (Orbitrap with accurate mass (Thermo Fisher Scientific, USA)); data handling with the standard software Xcalibur 2.1. (ii) LC–HRMS: Accela U-HPLC pump and an Accela Open autosampler (Thermo Fisher Scientific, USA) connected to an Q-Exactive mass spectrometer (Orbitrap); data handling with the standard software Xcalibur 2.2. (iii) LC–MS: Surveyor MS Plus HPLC (Thermo Electron) HPLC system connected to a TSQ Quantum Discovery Max (Thermo Electron) triple quadrupole mass spectrometer equipped with an electrospray (ESI) or APCI interface (Thermo Fisher Scientific, USA); connected to a PC running the standard software Xcalibur 2.0.7.</div><div class="NLM_p last">The pump flow rate was set to 600 μL/min, and the analytes were separated on a Kinetex phenylhexyl analytical column 2.6 μm, 50 mm × 2.1 mm (Phenomenex, Germany).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Metabolite Identification of Compound <b>11b</b></h3><div class="NLM_p last">CYP1A1 and CYP1A2 incubates were screened for the presence of potential metabolites using LC–HRMS Q-Exactive (Thermo Scientific) instrument, combining high-performance quadrupole precursor selection with high resolution (up to 140 000) and accurate mass detection (Orbitrap). The full scan accurate mass analysis of suspected metabolites was confirmed or refused using three primary tools: (i) screening for prototypical phase I metabolites, (ii) predictive chemical formula and corresponding mass error analysis, and (iii) confirmation by product ion scan. The putative metabolites were identified based on the test item fragmentation pattern of compound <b>11b</b> and its corresponding characteristic fragments.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i116"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00972" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00972" class="ext-link">10.1021/acs.jmedchem.9b00972</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Syntheses of bromo derivative <b>44</b> (Scheme S1), bromo derivative <b>49</b> (Scheme S2), and compounds <b>3a</b>–<b>5a</b> and <b>3b</b>–<b>5b</b> (Scheme S3); plasma concentration of <b>7b</b> after a single po dose of 5 mg/kg in rats (Table S1); brain concentration of <b>7b</b> after a single po dose of 5 mg/kg in rats (Table S2); plasma concentration of <b>12b</b> after a single po dose of 5 mg/kg in rats (Table S3); brain concentration of <b>12b</b> after a single po dose of 5 mg/kg in rats (Table S4); stability of compound <b>11b</b> (5 μM) in primary mouse, rat, dog, and human hepatocytes (Table S5); CYP1A1 and CYP1A2 metabolites identification of <b>11b</b> (Table S6); proposed metabolic pathway for CYP-dependent metabolism of <b>11b</b> (Figure S1); chromatogram of compound <b>11b</b> incubated with CYP1A1 (60 min) (Figure S2); chromatogram of compound <b>11b</b> incubated with CYP1A1 (0 min) (Figure S3); chromatogram of compound <b>11b</b> incubated with CYP1A2 (60 min) (Figure S4); chromatogram of compound <b>11b</b> incubated with CYP1A2 (0 min) (Figure S5); activity data and standard errors of final compounds (Table S7); activity data and standard errors of compounds for modeling (Table S8); TREEspot data visualization of KINOMEScan interactions of compound <b>12b</b>, PQR620, and INK128 (Figure S6); selectivity profile calculated from KinomeScan data (Table S9); kinase interactions (KINOMEscan data) (Table S10); <sup>1</sup>H NMR, <sup>13</sup>C{<sup>1</sup>H} NMR, and NSI-HRMS spectra; HPLC chromatograms; chemical structures of final compounds and intermediates (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Compound <b>3a</b>-PI3Kγ (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>2a</b>-mTOR (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>2b</b>-mTOR (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>2a</b>-PI3Kα (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>2b</b>-PI3Kα (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_007.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf">jm9b00972_si_001.pdf (15.39 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_002.pdb">jm9b00972_si_002.pdb (0.99 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_003.pdb">jm9b00972_si_003.pdb (1.73 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_004.pdb">jm9b00972_si_004.pdb (1.73 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_005.pdb">jm9b00972_si_005.pdb (1.05 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_006.pdb">jm9b00972_si_006.pdb (1.07 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_007.csv">jm9b00972_si_007.csv (3.17 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB">5JHB</a> was used for docking of compound <b>3a</b> into PI3Kγ. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a> was used for docking of compounds <b>2a</b> and <b>2b</b> into mTOR kinase. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZIM">3ZIM</a> was used for docking of compounds <b>2a</b> and <b>2b</b> into PI3Kα.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00972" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias P. Wymann</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3349-4281" title="Orcid link">http://orcid.org/0000-0003-3349-4281</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f5989481819d9c9486db828c98949b9bb5809b9c979486db969d"><span class="__cf_email__" data-cfemail="204d415454484941530e57594d414e4e60554e494241530e4348">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiara Borsari</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4688-8362" title="Orcid link">http://orcid.org/0000-0002-4688-8362</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denise Rageot</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2833-5481" title="Orcid link">http://orcid.org/0000-0002-2833-5481</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alix Dall’Asen</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Bohnacker</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Melone</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander M. Sele</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4903-7934" title="Orcid link">http://orcid.org/0000-0002-4903-7934</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eileen Jackson</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Baptiste Langlois</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florent Beaufils</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Hebeisen</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doriano Fabbro</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Petra Hillmann</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60, 4057 Basel, Switzerland</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): A.D.A., F.B., P.He., P.Hi., and D.F. are current or past employees of PIQUR Therapeutics AG, Basel; and P.He., D.F., and M.P.W. are shareholders of PIQUR Therapeutics AG.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i119">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34066" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34066" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank A. Pfaltz, J. Füglistaler, C. Meyer, J. Schwarte, and E. Teillet for advice, discussions, and contributions to synthetic efforts, and we thank S. Bünger for technical assistance. This work was supported by the Swiss Commission for Technology and Innovation (CTI) by PFLS-LS Grants 14032.1, 15811.2, and 17241.1; the Stiftung für Krebsbekämpfung Grant 341; and Swiss National Science Foundation Grants 310030_153211 and 316030_133860 (to M.P.W.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mechanistical (or mammalian) target of rapamycin</p></td></tr><tr><td class="NLM_term">TORC1</td><td class="NLM_def"><p class="first last">mTOR complex 1</p></td></tr><tr><td class="NLM_term">TORC2</td><td class="NLM_def"><p class="first last">mTOR complex 2</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PKB</td><td class="NLM_def"><p class="first last">protein kinase B/Akt</p></td></tr><tr><td class="NLM_term">S6RP</td><td class="NLM_def"><p class="first last">ribosomal protein S6</p></td></tr><tr><td class="NLM_term">S6K</td><td class="NLM_def"><p class="first last">p70 S6 kinase</p></td></tr><tr><td class="NLM_term">VPS34</td><td class="NLM_def"><p class="first last">vacuolar protein sorting 34 (the class III PI3K)</p></td></tr><tr><td class="NLM_term">TORKi</td><td class="NLM_def"><p class="first last">mTOR kinase inhibitor</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved Förster resonance energy transfer</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01653" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01653" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneiter, R.</span></span> <span> </span><span class="NLM_article-title">Lipid signalling in disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nrm2335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnrm2335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18216772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=162-176&issue=2&author=M.+P.+Wymannauthor=R.+Schneiter&title=Lipid+signalling+in+disease&doi=10.1038%2Fnrm2335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid signalling in disease</span></div><div class="casAuthors">Wymann, Matthias P.; Schneiter, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-176</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling lipids such as eicosanoids, phosphoinositides, sphingolipids and fatty acids control important cellular processes, including cell proliferation, apoptosis, metab. and migration.  Extracellular signals from cytokines, growth factors and nutrients control the activity of a key set of lipid-modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase.  These enzymes and their downstream targets constitute a complex lipid signaling network with multiple nodes of interaction and cross-regulation.  Imbalances in this network contribute to the pathogenesis of human disease.  Although the function of a particular signaling lipid is traditionally studied in isolation, this review attempts a more integrated overview of the key role of these signaling lipids in inflammation, cancer and metabolic disease, and discusses emerging strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYZ1NX2T9QbVg90H21EOLACvtfcHk0liWUQDEs6ZYLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D&md5=c96aabfdfa8e93c9e98386f1a407de85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2335%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DSchneiter%26aufirst%3DR.%26atitle%3DLipid%2520signalling%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26issue%3D2%26spage%3D162%26epage%3D176%26doi%3D10.1038%2Fnrm2335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidialingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">mTOR kinase structure, mechanism and regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>497</i></span> (<span class="NLM_issue">7448</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nature12122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnature12122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=23636326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=2013&pages=217-223&issue=7448&author=H.+Yangauthor=D.+G.+Rudgeauthor=J.+D.+Koosauthor=B.+Vaidialingamauthor=H.+J.+Yangauthor=N.+P.+Pavletich&title=mTOR+kinase+structure%2C+mechanism+and+regulation&doi=10.1038%2Fnature12122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR kinase structure, mechanism and regulation</span></div><div class="casAuthors">Yang, Haijuan; Rudge, Derek G.; Koos, Joseph D.; Vaidialingam, Bhamini; Yang, Hyo J.; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">7448</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.  Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic (MgF3-) and with ATP-site inhibitors (Torin2, PP242, and PI-103).  The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases.  The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft.  MTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access.  In vitro biochem. shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site.  Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access.  The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjvPQtdm6yCbVg90H21EOLACvtfcHk0liWUQDEs6ZYLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D&md5=07809555fbdf2004819a7f2da5727baf</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature12122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12122%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRudge%26aufirst%3DD.%2BG.%26aulast%3DKoos%26aufirst%3DJ.%2BD.%26aulast%3DVaidialingam%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DmTOR%2520kinase%2520structure%252C%2520mechanism%2520and%2520regulation%26jtitle%3DNature%26date%3D2013%26volume%3D497%26issue%3D7448%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fnature12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span> (<span class="NLM_issue">5712</span>),  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&issue=5712&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0liWUQDEs6ZYLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26issue%3D5712%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">41189</span>– <span class="NLM_lpage">41196</span>, <span class="refDoi"> DOI: 10.1074/jbc.M406731200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1074%2Fjbc.M406731200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15262962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnslWms70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=41189-41196&issue=39&author=J.+Fengauthor=J.+Parkauthor=P.+Cronauthor=D.+Hessauthor=B.+A.+Hemmings&title=Identification+of+a+PKB%2FAkt+hydrophobic+motif+Ser-473+kinase+as+DNA-dependent+protein+kinase&doi=10.1074%2Fjbc.M406731200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase</span></div><div class="casAuthors">Feng, Jianhua; Park, Jongsun; Cron, Peter; Hess, Daniel; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">41189-41196</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Full activation of protein kinase B (PKB)/Akt requires phosphorylation on Thr-308 and Ser-473 by 3-phosphoinositide-dependent kinase-1 (PDK1) and Ser-473 kinase (S473K), resp.  Although PDK1 has been well characterized, the identification of the S473K remains controversial.  A major PKB Ser-473 kinase activity was purified from the membrane fraction of HEK293 cells and found to be DNA-dependent protein kinase (DNA-PK).  DNA-PK co-localized and assocd. with PKB at the plasma membrane.  In vitro, DNA-PK phosphorylated PKB on Ser-473, resulting in a ∼10-fold enhancement of PKB activity.  Knockdown of DNA-PK by small interfering RNA inhibited Ser-473 phosphorylation induced by insulin and pervanadate.  DNA-PK-deficient glioblastoma cells did not respond to insulin at the level of Ser-473 phosphorylation; this effect was restored by complementation with the human PRKDC gene.  We conclude that DNA-PK is a long sought after kinase responsible for the Ser-473 phosphorylation step in the activation of PKB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoem_keSTepy7Vg90H21EOLACvtfcHk0liQXjymWXMZfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnslWms70%253D&md5=b6bad6828d91d47e2b36f537ca6d5f85</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M406731200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M406731200%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DCron%26aufirst%3DP.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DIdentification%2520of%2520a%2520PKB%252FAkt%2520hydrophobic%2520motif%2520Ser-473%2520kinase%2520as%2520DNA-dependent%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D39%26spage%3D41189%26epage%3D41196%26doi%3D10.1074%2Fjbc.M406731200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase in disease: timing, location, and scaffolding</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2005.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.ceb.2005.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15780590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVCqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=141-149&issue=2&author=M.+P.+Wymannauthor=R.+Marone&title=Phosphoinositide+3-kinase+in+disease%3A+timing%2C+location%2C+and+scaffolding&doi=10.1016%2Fj.ceb.2005.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase in disease: timing, location, and scaffolding</span></div><div class="casAuthors">Wymann, Matthias P.; Marone, Romina</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  When PI3Ks are deregulated by aberrant surface receptors or modulators, accumulation of PtdIns(3,4,5)P3 leads to increased cell growth, proliferation and contact-independent survival.  The PI3K/PKB/TOR axis controls protein synthesis and growth, while PtdIns(3,4,5)P3-mediated activation of Rho GTPases directs cell motility.  PI3K activity has been linked to the formation of tumors, metastasis, chronic inflammation, allergy and cardiovascular disease.  Although increased PtdIns(3,4,5)P3 is a well-established cause of disease, it is seldom known which PI3K isoform is implied.  Recent work has demonstrated that PI3Kγ contributes to the control of cAMP levels in the cardiac system, where the protein acts as a scaffold, but not as a lipid kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhcm4IPHLzd7Vg90H21EOLACvtfcHk0liQXjymWXMZfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVCqtb4%253D&md5=d126dfae131b86e73e8842ec9149fd01</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2005.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2005.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DMarone%26aufirst%3DR.%26atitle%3DPhosphoinositide%25203-kinase%2520in%2520disease%253A%2520timing%252C%2520location%252C%2520and%2520scaffolding%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2005%26volume%3D17%26issue%3D2%26spage%3D141%26epage%3D149%26doi%3D10.1016%2Fj.ceb.2005.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bozulic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">PIKKing on PKB: regulation of PKB activity by phosphorylation</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2009.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.ceb.2009.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=19303758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVClu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=256-261&issue=2&author=L.+Bozulicauthor=B.+A.+Hemmings&title=PIKKing+on+PKB%3A+regulation+of+PKB+activity+by+phosphorylation&doi=10.1016%2Fj.ceb.2009.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">PIKKing on PKB: regulation of PKB activity by phosphorylation</span></div><div class="casAuthors">Bozulic, Lana; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-261</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinase B (PKB)/Akt kinase is a key regulator of a wide range of cellular processes including growth, proliferation and survival.  PKB is clearly a crucial signaling mol. and extensive research efforts aim to understand its regulation and action.  Recent studies of the regulation of PKB activity by hydrophobic motif phosphorylation have yielded several exciting findings about members of the phosphatidylinositol 3-kinase (PI3K)-like family of kinases (PIKKs) acting as PKB regulators.  Mammalian target of rapamycin complex 2 (mTORC2) and DNA-dependent protein kinase (DNA-PK) can both phosphorylate Ser-473 and activate PKB.  This review concerns PKB regulation by mTORC2 and DNA-PK in a stimulus-dependent and context-dependent manner and the possible implications of this for PKB activity, substrate specificity, and therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgDTdYbqJWtLVg90H21EOLACvtfcHk0liQXjymWXMZfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVClu7Y%253D&md5=0b7a3e6ea561f8479701a01133b5d30c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DBozulic%26aufirst%3DL.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DPIKKing%2520on%2520PKB%253A%2520regulation%2520of%2520PKB%2520activity%2520by%2520phosphorylation%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26issue%3D2%26spage%3D256%26epage%3D261%26doi%3D10.1016%2Fj.ceb.2009.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingar, D. C.</span></span> <span> </span><span class="NLM_article-title">Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>441</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1042/BJ20110892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1042%2FBJ20110892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=22168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2012&pages=1-21&issue=1&author=B.+Magnusonauthor=B.+Ekimauthor=D.+C.+Fingar&title=Regulation+and+function+of+ribosomal+protein+S6+kinase+%28S6K%29+within+mTOR+signalling+networks&doi=10.1042%2FBJ20110892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks</span></div><div class="casAuthors">Magnuson, Brian; Ekim, Bilgen; Fingar, Diane C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">441</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The ribosomal protein S6K (S6 kinase) represents an extensively studied effector of the TORC1 [TOR (target of rapamycin) complex 1], which possesses important yet incompletely defined roles in cellular and organismal physiol.  TORC1 functions as an environmental sensor by integrating signals derived from diverse environmental cues to promote anabolic and inhibit catabolic cellular functions. mTORC1 (mammalian TORC1) phosphorylates and activates S6K1 and S6K2, whose first identified substrate was rpS6 (ribosomal protein S6), a component of the 40S ribosome.  Studies over the past decade have uncovered a no. of addnl. S6K1 substrates, revealing multiple levels at which the mTORC1-S6K1 axis regulates cell physiol.  The results thus far indicate that the mTORC1-S6K1 axis controls fundamental cellular processes, including transcription, translation, protein and lipid synthesis, cell growth/size and cell metab.  In the present review we summarize the regulation of S6Ks, their cellular substrates and functions, and their integration within rapidly expanding mTOR (mammalian TOR) signalling networks.  Although our understanding of the role of mTORC1-S6K1 signalling in physiol. remains in its infancy, evidence indicates that this signalling axis controls, at least in part, glucose homeostasis, insulin sensitivity, adipocyte metab., body mass and energy balance, tissue and organ size, learning, memory and aging.  As dysregulation of this signalling axis contributes to diverse disease states, improved understanding of S6K regulation and function within mTOR signalling networks may enable the development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAHhGhhxqDTbVg90H21EOLACvtfcHk0ljsUFko86_r8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7jK&md5=5d69e3be00deef02d3fce1ed2716873d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1042%2FBJ20110892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110892%26sid%3Dliteratum%253Aachs%26aulast%3DMagnuson%26aufirst%3DB.%26aulast%3DEkim%26aufirst%3DB.%26aulast%3DFingar%26aufirst%3DD.%2BC.%26atitle%3DRegulation%2520and%2520function%2520of%2520ribosomal%2520protein%2520S6%2520kinase%2520%2528S6K%2529%2520within%2520mTOR%2520signalling%2520networks%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D441%26issue%3D1%26spage%3D1%26epage%3D21%26doi%3D10.1042%2FBJ20110892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth control and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.cell.2012.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=22500797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=274-293&issue=2&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth+control+and+disease&doi=10.1016%2Fj.cell.2012.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth control and disease</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-293</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis.  The pathway regulates many major cellular processes and is implicated in an increasing no. of pathol. conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.  Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging.  We further discuss pharmacol. approaches to treat human pathologies linked to mTOR deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjbKBX-sScfrVg90H21EOLACvtfcHk0ljsUFko86_r8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D&md5=d1adac8ec64da63358e0af26a17ceb4e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%2520control%2520and%2520disease%26jtitle%3DCell%26date%3D2012%26volume%3D149%26issue%3D2%26spage%3D274%26epage%3D293%26doi%3D10.1016%2Fj.cell.2012.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth, metabolism, and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.cell.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=28283069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=960-976&issue=6&author=R.+A.+Saxtonauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth%2C+metabolism%2C+and+disease&doi=10.1016%2Fj.cell.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth, metabolism, and disease</span></div><div class="casAuthors">Saxton, Robert A.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">960-976</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) coordinates eukaryotic cell growth and metab. with environmental inputs, including nutrients and growth factors.  Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated in the progression of cancer and diabetes, as well as the aging process.  Here, we review recent advances in our understanding of mTOR function, regulation, and importance in mammalian physiol.  We also highlight how the mTOR signaling network contributes to human disease and discuss the current and future prospects for therapeutically targeting mTOR in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvk5jg6e_MrVg90H21EOLACvtfcHk0ljsUFko86_r8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D&md5=3fdee3d04bf88d3aafc532d4e2f1e2dc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DSaxton%26aufirst%3DR.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%252C%2520metabolism%252C%2520and%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D168%26issue%3D6%26spage%3D960%26epage%3D976%26doi%3D10.1016%2Fj.cell.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivanco, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">The phosphatidylinositol 3-kinase AKT pathway in human cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1038/nrc839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&issue=7&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+phosphatidylinositol+3-kinase+AKT+pathway+in+human+cancer&doi=10.1038%2Fnrc839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lgi7wSdJJRyLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520phosphatidylinositol%25203-kinase%2520AKT%2520pathway%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26issue%3D7%26spage%3D489%26epage%3D501%26doi%3D10.1038%2Fnrc839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Targeting phosphoinositide 3-kinase: moving towards therapy</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1784</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2007.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.bbapap.2007.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=17997386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1784&publication_year=2008&pages=159-185&issue=1&author=R.+Maroneauthor=V.+Cmiljanovicauthor=B.+Gieseauthor=M.+P.+Wymann&title=Targeting+phosphoinositide+3-kinase%3A+moving+towards+therapy&doi=10.1016%2Fj.bbapap.2007.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase-Moving towards therapy</span></div><div class="casAuthors">Marone, Romina; Cmiljanovic, Vladimir; Giese, Bernd; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1784</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">159-185</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3K) orchestrate cell responses including mitogenic signaling, cell survival and growth, metabolic control, vesicular trafficking, degranulation, cytoskeletal rearrangement and migration.  Deregulation of the PI3K pathway occurs by activating mutations in growth factor receptors or the PIK3CA locus coding for PI3Kα, by loss of function of the lipid phosphatase and tensin homolog deleted in chromosome ten (PTEN/MMAC/TEP1), by the up-regulation of protein kinase B (PKB/Akt), or the impairment of the tuberous sclerosis complex (TSC1/2).  All these events are linked to growth and proliferation, and have thus prompted a significant interest in the pharmaceutical targeting of the PI3K pathway in cancer.  Genetic targeting of PI3Kγ (p110γ) and PI3Kδ (p110δ) in mice has underlined a central role of these PI3K isoforms in inflammation and allergy, as they modulate chemotaxis of leukocytes and degranulation in mast cells.  Proof-of-concept mols. selective for PI3Kγ have already successfully alleviated disease progress in murine models of rheumatoid arthritis and lupus erythematosus.  As targeting PI3K moves forward to therapy of chronic, non-fatal disease, safety concerns for PI3K inhibitors increase.  Many of the present inhibitor series interfere with target of rapamycin (TOR), DNA-dependent protein kinase (DNA-PKcs) and activity of the ataxia telangiectasia mutated gene product (ATM).  Here we review the current disease-relevant knowledge for isoform-specific PI3K function in the above mentioned diseases, and review the progress of > 400 recent patents covering pharmaceutical targeting of PI3K.  Currently, several drugs targeting the PI3K pathway have entered clin. trials (phase I) for solid tumors and suppression of tissue damage after myocardial infarction (phases I,II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwrI_aSA632bVg90H21EOLACvtfcHk0lgi7wSdJJRyLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D&md5=bf9f259b3da61067631823656658e0f7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2007.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2007.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520phosphoinositide%25203-kinase%253A%2520moving%2520towards%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2008%26volume%3D1784%26issue%3D1%26spage%3D159%26epage%3D185%26doi%3D10.1016%2Fj.bbapap.2007.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M.</span></span> <span> </span><span class="NLM_article-title">PI3Ks—Drug Targets in Inflammation and Cancer</span>. In  <i>Phosphoinositides I: Enzymes of Synthesis and Degradation</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, T.</span>, <span class="NLM_string-name">Wymann, M.</span>, <span class="NLM_string-name">York, J.
D.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Dordrecht, The Netherlands</span>, <span class="NLM_year">2012</span>; pp  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">181</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1007%2F978-94-007-3012-0_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=111-181&author=M.+Wymannauthor=T.+Balla&author=M.+Wymann&author=J.%0AD.+York&title=Phosphoinositides+I%3A+Enzymes+of+Synthesis+and+Degradation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2F978-94-007-3012-0_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-94-007-3012-0_5%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%26atitle%3DPI3Ks%25E2%2580%2594Drug%2520Targets%2520in%2520Inflammation%2520and%2520Cancer%26btitle%3DPhosphoinositides%2520I%253A%2520Enzymes%2520of%2520Synthesis%2520and%2520Degradation%26aulast%3DBalla%26aufirst%3DT.%26pub%3DSpringer%26date%3D2012%26spage%3D111%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the FKBP1 2-rapamycin complex interacting with the binding domain of human FRAP</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span> (<span class="NLM_issue">5272</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1126/science.273.5272.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&issue=5272&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP1+2-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP&doi=10.1126%2Fscience.273.5272.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0lgi7wSdJJRyLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP1%25202-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26issue%3D5272%26spage%3D239%26epage%3D242%26doi%3D10.1126%2Fscience.273.5272.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutcher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staroslawska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodrogi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacevic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesovoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Wolf, I. G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbarash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokmen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Toole, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustgarten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span> <span> </span><span class="NLM_article-title">Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2271</span>– <span class="NLM_lpage">2281</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa066838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1056%2FNEJMoa066838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=17538086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVKkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2271-2281&issue=22&author=G.+Hudesauthor=M.+Carducciauthor=P.+Tomczakauthor=J.+Dutcherauthor=R.+Figlinauthor=A.+Kapoorauthor=E.+Staroslawskaauthor=J.+Sosmanauthor=D.+McDermottauthor=I.+Bodrogiauthor=Z.+Kovacevicauthor=V.+Lesovoyauthor=I.+G.+H.+Schmidt-Wolfauthor=O.+Barbarashauthor=E.+Gokmenauthor=T.+O%E2%80%99Tooleauthor=S.+Lustgartenauthor=L.+Mooreauthor=R.+J.+Motzer&title=Temsirolimus%2C+interferon+alfa%2C+or+both+for+advanced+renal-cell+carcinoma&doi=10.1056%2FNEJMoa066838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma</span></div><div class="casAuthors">Hudes, Gary; Carducci, Michael; Tomczak, Piotr; Dutcher, Janice; Figlin, Robert; Kapoor, Anil; Staroslawska, Elzbieta; Sosman, Jeffrey; McDermott, David; Bodrogi, Istvan; Kovacevic, Zoran; Lesovoy, Vladimir; Schmidt-Wolf, Ingo G. H.; Barbarash, Olga; Gokmen, Erhan; O'Toole, Timothy; Lustgarten, Stephanie; Moore, Laurence; Motzer, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2271-2281</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability.  Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.  In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of i.v. temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) s.c. three times weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa three times weekly.  The primary end point was overall survival in comparisons of the temsirolimus group and the combination-therapy group with the interferon group.  RESULTS Patients who received temsirolimus alone had longer overall survival (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P = 0.008) and progression-free survival (P < 0.001) than did patients who received interferon alone.  Overall survival in the combination-therapy group did not differ significantly from that in the interferon group (hazard ratio, 0.96; 95% CI, 0.76 to 1.20; P = 0.70).  Median overall survival times in the interferon group, the temsirolimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 mo, resp.  Rash, peripheral edema, hyperglycemia, and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in the interferon group.  There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P = 0.02).  As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis.  The addn. of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov no., NCT00065468.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkvpThNoniLVg90H21EOLACvtfcHk0ljZ1qLWN9YUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVKkurs%253D&md5=2fc7685df067fd6ea813483610e89dc8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa066838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa066838%26sid%3Dliteratum%253Aachs%26aulast%3DHudes%26aufirst%3DG.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DTomczak%26aufirst%3DP.%26aulast%3DDutcher%26aufirst%3DJ.%26aulast%3DFiglin%26aufirst%3DR.%26aulast%3DKapoor%26aufirst%3DA.%26aulast%3DStaroslawska%26aufirst%3DE.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DMcDermott%26aufirst%3DD.%26aulast%3DBodrogi%26aufirst%3DI.%26aulast%3DKovacevic%26aufirst%3DZ.%26aulast%3DLesovoy%26aufirst%3DV.%26aulast%3DSchmidt-Wolf%26aufirst%3DI.%2BG.%2BH.%26aulast%3DBarbarash%26aufirst%3DO.%26aulast%3DGokmen%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DT.%26aulast%3DLustgarten%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DL.%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26atitle%3DTemsirolimus%252C%2520interferon%2520alfa%252C%2520or%2520both%2520for%2520advanced%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26issue%3D22%26spage%3D2271%26epage%3D2281%26doi%3D10.1056%2FNEJMoa066838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünwald, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollaender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanowitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravaud, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">9637</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)61039-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2FS0140-6736%2808%2961039-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18653228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1GmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=449-456&issue=9637&author=R.+J.+Motzerauthor=B.+Escudierauthor=S.+Oudardauthor=T.+E.+Hutsonauthor=C.+Portaauthor=S.+Bracardaauthor=V.+Gr%C3%BCnwaldauthor=J.+A.+Thompsonauthor=R.+A.+Figlinauthor=N.+Hollaenderauthor=G.+Urbanowitzauthor=W.+J.+Bergauthor=A.+Kayauthor=D.+Lebwohlauthor=A.+Ravaud&title=Efficacy+of+everolimus+in+advanced+renal+cell+carcinoma%3A+a+double-blind%2C+randomised%2C+placebo-controlled+phase+III+trial&doi=10.1016%2FS0140-6736%2808%2961039-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial</span></div><div class="casAuthors">Motzer, Robert J.; Escudier, Bernard; Oudard, Stephane; Hutson, Thomas E.; Porta, Camillo; Bracarda, Sergio; Gruenwald, Viktor; Thompson, John A.; Figlin, Robert A.; Hollaender, Norbert; Urbanowitz, Gladys; Berg, William J.; Kay, Andrea; Lebwohl, David; Ravaud, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">9637</span>),
    <span class="NLM_cas:pages">449-456</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma.  We did a phase III, randomized, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy.  Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both, were randomly assigned in a two to one ratio to receive everolimus 10 mg once daily (n=272) or placebo (n=138), in conjunction with best supportive care.  Randomisation was done centrally via an interactive voice response system using a validated computer system, and was stratified by Memorial Sloan-Kettering Cancer Center prognostic score and previous anticancer therapy, with a permuted block size of six.  The primary endpoint was progression-free survival, assessed via a blinded, independent central review.  The study was designed to be terminated after 290 events of progression.  Anal. was by intention to treat.  This study is registered with, no.  All randomized patients were included in efficacy analyses.  The results of the second interim anal. indicated a significant difference in efficacy between arms and the trial was thus halted early after 191 progression events had been obsd. (101 [37%] events in the everolimus group, 90 [65%] in the placebo group; hazard ratio 0.30, 95% CI 0.22-0.40, p<0.0001; median progression-free survival 4.0 [95% CI 3.7-5.5] vs 1.9 [1.8-1.9] months).  Stomatitis (107 [40%] patients in the everolimus group vs 11 [8%] in the placebo group), rash (66 [25%] vs six [4%]), and fatigue (53 [20%] vs 22 [16%]) were the most commonly reported adverse events, but were mostly mild or moderate in severity.  Pneumonitis (any grade) was detected in 22 (8%) patients in the everolimus group, of whom eight had pneumonitis of grade 3 severity.  Treatment with everolimus prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma that had progressed on other targeted therapies.  Novartis Oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyYj10av0L97Vg90H21EOLACvtfcHk0ljZ1qLWN9YUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1GmsLY%253D&md5=cbfa5d207cfab693b3bccd24963380f0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961039-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961039-9%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBracarda%26aufirst%3DS.%26aulast%3DGr%25C3%25BCnwald%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DHollaender%26aufirst%3DN.%26aulast%3DUrbanowitz%26aufirst%3DG.%26aulast%3DBerg%26aufirst%3DW.%2BJ.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DRavaud%26aufirst%3DA.%26atitle%3DEfficacy%2520of%2520everolimus%2520in%2520advanced%2520renal%2520cell%2520carcinoma%253A%2520a%2520double-blind%252C%2520randomised%252C%2520placebo-controlled%2520phase%2520III%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26issue%3D9637%26spage%3D449%26epage%3D456%26doi%3D10.1016%2FS0140-6736%2808%2961039-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorive, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collignon, J.</span></span> <span> </span><span class="NLM_article-title">Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes</span>. <i>Breast Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.2147/BCTT.S38679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.2147%2FBCTT.S38679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=43-57&author=G.+Jerusalemauthor=A.+Roriveauthor=J.+Collignon&title=Use+of+mTOR+inhibitors+in+the+treatment+of+breast+cancer%3A+an+evaluation+of+factors+that+influence+patient+outcomes&doi=10.2147%2FBCTT.S38679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes</span></div><div class="casAuthors">Jerusalem, Guy; Rorive, Andree; Collignon, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-57, 15</span>CODEN:
                <span class="NLM_cas:coden">BCTTA9</span>;
        ISSN:<span class="NLM_cas:issn">1179-1314</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents.  Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an aromatase inhibitor, has been approved in Europe and the USA for patients suffering from estrogen receptor-pos., HER2-neg. advanced breast cancer previously treated by a nonsteroidal aromatase inhibitor, based on the results of BOLERO-2 (Breast cancer trials of OraL EveROlimus).  This study showed a statistically significant and clin. meaningful improvement in median progression-free survival.  Results concerning the impact on overall survival are expected in the near future.  This clin. oriented review focuses on the use of mTOR inhibitors in breast cancer.  Results reported with first-generation mTOR inhibitors (ridaforolimus, temsirolimus, everolimus) are discussed.  The current and potential role of mTOR inhibitors is reported according to breast cancer subtype (estrogen receptor-pos. HER2-neg., triple-neg., and HER2-pos. ER-pos./neg. disease).  Everolimus is currently being evaluated in the adjuvant setting in high-risk estrogen receptor-pos., HER2-neg. early breast cancer.  Continuing mTOR inhibition or alternatively administering other drugs targeting the phosphatidylinositol-3-kinase/protein kinase B-mTOR pathway after progression on treatments including an mTOR inhibitor is under evaluation.  Potential biomarkers to select patients showing a more pronounced benefit are reviewed, but we are not currently using these biomarkers in routine practice.  Subgroup anal. of BOLERO 2 has shown that the benefit is consistent in all subgroups and that it is impossible to select patients not benefiting from addn. of everolimus to exemestane.  Side effects and impact on quality of life are other important issues discussed in this review.  Second-generation mTOR inhibitors and dual mTOR-phosphatidylinositol-3-kinase inhibitors are currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXjFYIcn4ct7Vg90H21EOLACvtfcHk0ljZ1qLWN9YUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gsrjE&md5=9a12c70c7c917baa41d282bc135b12af</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2147%2FBCTT.S38679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBCTT.S38679%26sid%3Dliteratum%253Aachs%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DRorive%26aufirst%3DA.%26aulast%3DCollignon%26aufirst%3DJ.%26atitle%3DUse%2520of%2520mTOR%2520inhibitors%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%253A%2520an%2520evaluation%2520of%2520factors%2520that%2520influence%2520patient%2520outcomes%26jtitle%3DBreast%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D43%26epage%3D57%26doi%3D10.2147%2FBCTT.S38679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Regan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozguroglu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerzo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, L.</span></span> <span> </span><span class="NLM_article-title">Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(14)70138-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2FS1470-2045%2814%2970138-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=24742739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlWnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=580-591&issue=6&author=F.+Andr%C3%A9author=R.+O%E2%80%99Reganauthor=M.+Ozgurogluauthor=M.+Toiauthor=B.+Xuauthor=G.+Jerusalemauthor=N.+Masudaauthor=S.+Wilksauthor=F.+Arenaauthor=C.+Isaacsauthor=Y.-S.+Yapauthor=Z.+Papaiauthor=I.+Langauthor=A.+Armstrongauthor=G.+Lerzoauthor=M.+Whiteauthor=K.+Shenauthor=J.+Littonauthor=D.+Chenauthor=Y.+Zhangauthor=S.+Aliauthor=T.+Taranauthor=L.+Gianni&title=Everolimus+for+women+with+trastuzumab-resistant%2C+HER2-positive%2C+advanced+breast+cancer+%28BOLERO-3%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+phase+3+trial&doi=10.1016%2FS1470-2045%2814%2970138-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial</span></div><div class="casAuthors">Andre, Fabrice; O'Regan, Ruth; Ozguroglu, Mustafa; Toi, Masakazu; Xu, Binghe; Jerusalem, Guy; Masuda, Norikazu; Wilks, Sharon; Arena, Francis; Isaacs, Claudine; Yap, Yoon-Sim; Papai, Zsuzsanna; Lang, Istvan; Armstrong, Anne; Lerzo, Guillermo; White, Michelle; Shen, Kunwei; Litton, Jennifer; Chen, David; Zhang, Yufen; Ali, Shyanne; Taran, Tetiana; Gianni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">580-591</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Disease progression in patients with HER2-pos. breast cancer receiving trastuzumab might be assocd. with activation of the PI3K/Akt/mTOR intracellular signalling pathway.  We aimed to assess whether the addn. of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.  In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited women with HER2-pos., trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy.  Eligible patients were randomly assigned (1:1) using a central patient screening and randomization system to daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m2) or to placebo plus trastuzumab plus vinorelbine, in 3-wk cycles, stratified by previous lapatinib use.  The primary endpoint was progression-free survival (PFS) by local assessment in the intention-to-treat population.  We report the final anal. for PFS; overall survival follow-up is still in progress.  This trial is registered with ClinicalTrials.gov, no. NCT01007942.Between Oct 26, 2009, and May 23, 2012, 569 patients were randomly assigned to everolimus (n=284) or placebo (n=285).  Median follow-up at the time of anal. was 20·2 mo (IQR 15·0-27·1).  Median PFS was 7·00 mo (95% CI 6·74-8·18) with everolimus and 5·78 mo (5·49-6·90) with placebo (hazard ratio 0·78 [95% CI 0·65-0·95]; p=0·0067).  The most common grade 3-4 adverse events were neutropenia (204 [73%] of 280 patients in the everolimus group vs 175 [62%] of 282 patients in the placebo group), leucopenia (106 [38%] vs 82 [29%]), anemia (53 [19%] vs 17 [6%]), febrile neutropenia (44 [16%] vs ten [4%]), stomatitis (37 [13%] vs four [1%]), and fatigue (34 [12%] vs 11 [4%]).  Serious adverse events were reported in 117 (42%) patients in the everolimus group and 55 (20%) in the placebo group; two on-treatment deaths due to adverse events occurred in each group.  The addn. of everolimus to trastuzumab plus vinorelbine significantly prolongs PFS in patients with trastuzumab-resistant and taxane-pretreated, HER2-pos., advanced breast cancer.  The clin. benefit should be considered in the context of the adverse event profile in this population.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Bm76N8uISbVg90H21EOLACvtfcHk0lhtKCt6FFhUqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlWnsr4%253D&md5=cfbb16368227cc80463ef26c2593b69d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970138-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970138-X%26sid%3Dliteratum%253Aachs%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DR.%26aulast%3DOzguroglu%26aufirst%3DM.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DWilks%26aufirst%3DS.%26aulast%3DArena%26aufirst%3DF.%26aulast%3DIsaacs%26aufirst%3DC.%26aulast%3DYap%26aufirst%3DY.-S.%26aulast%3DPapai%26aufirst%3DZ.%26aulast%3DLang%26aufirst%3DI.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DLerzo%26aufirst%3DG.%26aulast%3DWhite%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DTaran%26aufirst%3DT.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DEverolimus%2520for%2520women%2520with%2520trastuzumab-resistant%252C%2520HER2-positive%252C%2520advanced%2520breast%2520cancer%2520%2528BOLERO-3%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26issue%3D6%26spage%3D580%26epage%3D591%26doi%3D10.1016%2FS1470-2045%2814%2970138-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. E.</span></span> <span> </span><span class="NLM_article-title">Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial</span>. <i>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2341</span>– <span class="NLM_lpage">2349</span>, <span class="refDoi"> DOI: 10.1007/s00520-013-1826-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1007%2Fs00520-013-1826-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=23686401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A280%3ADC%252BC3snkvVKksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2341-2349&issue=8&author=M.+E.+Peterson&title=Management+of+adverse+events+in+patients+with+hormone+receptor-positive+breast+cancer+treated+with+everolimus%3A+observations+from+a+phase+III+clinical+trial&doi=10.1007%2Fs00520-013-1826-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial</span></div><div class="casAuthors">Peterson Mary E</div><div class="citationInfo"><span class="NLM_cas:title">Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2341-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive HER2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole.  Results from the phase III BOLERO-2 trial demonstrated that everolimus in combination with exemestane provided significant clinical benefit to patients with advanced hormone receptor-positive breast cancer.  Although everolimus is generally well tolerated, as with most therapies administered in an advanced cancer setting, drug-related adverse events (AEs) inevitably occur.  Most common AEs observed in the everolimus studies include stomatitis, rash, infection, noninfectious pneumonitis, and hyperglycemia.  Clinical awareness and early identification of such AEs by oncology nurses are essential to dosing (interruptions, reduction, and treatment discontinuation); quality of life; and, ultimately, patient outcomes.  Because everolimus has already been shown to significantly improve clinical efficacy in patients with advanced breast cancer, a proactive approach to the practical management of AEs associated with this mTOR inhibitor as well as other most common AEs observed in this patient population has been reviewed and outlined here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWnMo5wnFbuA5nADWVYHg1fW6udTcc2eY4y0Gwa2AH3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snkvVKksw%253D%253D&md5=21bfc1094be58365540d6fe494138198</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00520-013-1826-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00520-013-1826-3%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DM.%2BE.%26atitle%3DManagement%2520of%2520adverse%2520events%2520in%2520patients%2520with%2520hormone%2520receptor-positive%2520breast%2520cancer%2520treated%2520with%2520everolimus%253A%2520observations%2520from%2520a%2520phase%2520III%2520clinical%2520trial%26jtitle%3DSupportive%2520care%2520in%2520cancer%253A%2520official%2520journal%2520of%2520the%2520Multinational%2520Association%2520of%2520Supportive%2520Care%2520in%2520Cancer%26date%3D2013%26volume%3D21%26issue%3D8%26spage%3D2341%26epage%3D2349%26doi%3D10.1007%2Fs00520-013-1826-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totary-Jain, H.</span></span> <span> </span><span class="NLM_article-title">Tailoring mTOR-based therapy: molecular evidence and clinical challenges</span>. <i>Pharmacogenomics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1517</span>– <span class="NLM_lpage">1526</span>, <span class="refDoi"> DOI: 10.2217/pgs.13.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.2217%2Fpgs.13.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=24024901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWrurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1517-1526&issue=12&author=G.+Santulliauthor=H.+Totary-Jain&title=Tailoring+mTOR-based+therapy%3A+molecular+evidence+and+clinical+challenges&doi=10.2217%2Fpgs.13.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tailoring mTOR-based therapy: molecular evidence and clinical challenges</span></div><div class="casAuthors">Santulli, Gaetano; Totary-Jain, Hana</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1517-1526</span>CODEN:
                <span class="NLM_cas:coden">PARMFL</span>;
        ISSN:<span class="NLM_cas:issn">1462-2416</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The mTOR signaling pathway integrates inputs from a variety of upstream stimuli to regulate diverse cellular processes including proliferation, growth, survival, motility, autophagy, protein synthesis and metab.  The mTOR pathway is dysregulated in a no. of human pathologies including cancer, diabetes, obesity, autoimmune disorders, neurol. disease and aging.  Ongoing clin. trials testing mTOR-targeted treatments no. in the hundreds and underscore its therapeutic potential.  To date mTOR inhibitors are clin. approved to prevent organ rejection, to inhibit restenosis after angioplasty, and to treat several advanced cancers.  In this review we discuss the continuously evolving field of mTOR pharmacogenomics, as well as highlight the emerging efforts in identifying diagnostic and prognostic markers, including miRNAs, in order to assess successful therapeutic responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqrLZCgBBxXrVg90H21EOLACvtfcHk0lj0oJsMrLS8DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWrurrN&md5=0a3798fb659843d231910151b2f148ed</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2217%2Fpgs.13.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fpgs.13.143%26sid%3Dliteratum%253Aachs%26aulast%3DSantulli%26aufirst%3DG.%26aulast%3DTotary-Jain%26aufirst%3DH.%26atitle%3DTailoring%2520mTOR-based%2520therapy%253A%2520molecular%2520evidence%2520and%2520clinical%2520challenges%26jtitle%3DPharmacogenomics%26date%3D2013%26volume%3D14%26issue%3D12%26spage%3D1517%26epage%3D1526%26doi%3D10.2217%2Fpgs.13.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. F.</span></span> <span> </span><span class="NLM_article-title">Toward rapamycin analog (rapalog)-based precision cancer therapy</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1169</span>, <span class="refDoi"> DOI: 10.1038/aps.2015.68</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Faps.2015.68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=26299952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wls7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1163-1169&issue=10&author=L.+H.+Mengauthor=X.+F.+Zheng&title=Toward+rapamycin+analog+%28rapalog%29-based+precision+cancer+therapy&doi=10.1038%2Faps.2015.68"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Toward rapamycin analog (rapalog)-based precision cancer therapy</span></div><div class="casAuthors">Meng, Ling-hua; Zheng, X. F. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1163-1169</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Rapamycin and its analogs (rapalogs) are the first generation of mTOR inhibitors, which have the same mol. scaffold, but different physiochem. properties.  Rapalogs are being tested in a wide spectrum of human tumors as both monotherapy and a component of combination therapy.  Among them, temsirolimus and everolimus have been approved for the treatment of breast and renal cancer.  However, objective response rates with rapalogs in clin. trials are modest and variable.  Identification of biomarkers predicting response to rapalogs, and discovery of drug combinations with improved efficacy and tolerated toxicity are crit. to moving this class of targeted therapeutics forward.  This review focuses on the aberrations in the PI3K/mTOR pathway in human tumor cells or tissues as predictive biomarkers for rapalog efficacy.  Recent results of combinational therapy using rapalogs and other anticancer drugs are documented.  With the rapid development of next-generation genomic sequencing and precision medicine, rapalogs will provide greater benefits to cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMIearchWtebVg90H21EOLACvtfcHk0lj0oJsMrLS8DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wls7jP&md5=af1357a49b132c2264ca74577ae2ae48</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Faps.2015.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2015.68%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DZheng%26aufirst%3DX.%2BF.%26atitle%3DToward%2520rapamycin%2520analog%2520%2528rapalog%2529-based%2520precision%2520cancer%2520therapy%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2015%26volume%3D36%26issue%3D10%26spage%3D1163%26epage%3D1169%26doi%3D10.1038%2Faps.2015.68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apsel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uotila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e1000038</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1000038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1371%2Fjournal.pbio.1000038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=e1000038&issue=2&author=M.+E.+Feldmanauthor=B.+Apselauthor=A.+Uotilaauthor=R.+Loewithauthor=Z.+A.+Knightauthor=D.+Ruggeroauthor=K.+M.+Shokat&title=Active-site+inhibitors+of+mTOR+target+rapamycin-resistant+outputs+of+mTORC1+and+mTORC2&doi=10.1371%2Fjournal.pbio.1000038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1000038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1000038%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DUotila%26aufirst%3DA.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DActive-site%2520inhibitors%2520of%2520mTOR%2520target%2520rapamycin-resistant%2520outputs%2520of%2520mTORC1%2520and%2520mTORC2%26jtitle%3DPLoS%2520Biol.%26date%3D2009%26volume%3D7%26issue%3D2%26spage%3De1000038%26doi%3D10.1371%2Fjournal.pbio.1000038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>341</i></span> (<span class="NLM_issue">6144</span>),  <span class="NLM_fpage">1236566</span>, <span class="refDoi"> DOI: 10.1126/science.1236566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1126%2Fscience.1236566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=23888043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A280%3ADC%252BC3sfktVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2013&pages=1236566&issue=6144&author=S.+A.+Kangauthor=M.+E.+Pacoldauthor=C.+L.+Cervantesauthor=D.+Limauthor=H.+J.+Louauthor=K.+Ottinaauthor=N.+S.+Grayauthor=B.+E.+Turkauthor=M.+B.+Yaffeauthor=D.+M.+Sabatini&title=mTORC1+phosphorylation+sites+encode+their+sensitivity+to+starvation+and+rapamycin&doi=10.1126%2Fscience.1236566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin</span></div><div class="casAuthors">Kang Seong A; Pacold Michael E; Cervantes Christopher L; Lim Daniel; Lou Hua Jane; Ottina Kathleen; Gray Nathanael S; Turk Benjamin E; Yaffe Michael B; Sabatini David M</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6144</span>),
    <span class="NLM_cas:pages">1236566</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) protein kinase promotes growth and is the target of rapamycin, a clinically useful drug that also prolongs life span in model organisms.  A persistent mystery is why the phosphorylation of many bona fide mTORC1 substrates is resistant to rapamycin.  We find that the in vitro kinase activity of mTORC1 toward peptides encompassing established phosphorylation sites varies widely and correlates strongly with the resistance of the sites to rapamycin, as well as to nutrient and growth factor starvation within cells.  Slight modifications of the sites were sufficient to alter mTORC1 activity toward them in vitro and to cause concomitant changes within cells in their sensitivity to rapamycin and starvation.  Thus, the intrinsic capacity of a phosphorylation site to serve as an mTORC1 substrate, a property we call substrate quality, is a major determinant of its sensitivity to modulators of the pathway.  Our results reveal a mechanism through which mTORC1 effectors can respond differentially to the same signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVUX1crROrkZPlX7E30qdzfW6udTcc2eY1MpKVcgm6drntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfktVWmsw%253D%253D&md5=904daf44e853714de3fb540a359e2546</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscience.1236566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1236566%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DCervantes%26aufirst%3DC.%2BL.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DLou%26aufirst%3DH.%2BJ.%26aulast%3DOttina%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DTurk%26aufirst%3DB.%2BE.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTORC1%2520phosphorylation%2520sites%2520encode%2520their%2520sensitivity%2520to%2520starvation%2520and%2520rapamycin%26jtitle%3DScience%26date%3D2013%26volume%3D341%26issue%3D6144%26spage%3D1236566%26doi%3D10.1126%2Fscience.1236566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacinto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruegg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. N.</span></span> <span> </span><span class="NLM_article-title">Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1038/ncb1183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fncb1183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15467718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFentL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1122-8&issue=11&author=E.+Jacintoauthor=R.+Loewithauthor=A.+Schmidtauthor=S.+Linauthor=M.+A.+Rueggauthor=A.+Hallauthor=M.+N.+Hall&title=Mammalian+TOR+complex+2+controls+the+actin+cytoskeleton+and+is+rapamycin+insensitive&doi=10.1038%2Fncb1183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive</span></div><div class="casAuthors">Jacinto, Estela; Loewith, Robbie; Schmidt, Anja; Lin, Shuo; Rueegg, Markus A.; Hall, Alan; Hall, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1122-1128</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The target of rapamycin (TOR) is a highly conserved protein kinase and a central controller of cell growth.  In budding yeast, TOR is found in structurally and functionally distinct protein complexes: TORC1 and TORC2.  A mammalian counterpart of TORC1 (mTORC1) has been described, but it is not known whether TORC2 is conserved in mammals.  Here, the authors report that a mammalian counterpart of TORC2 (mTORC2) also exists.  The mTORC2 contains mTOR, mLST8 and mAVO3, but not raptor.  Like yeast TORC2, mTORC2 is rapamycin insensitive and seems to function upstream of Rho GTPases to regulate the actin cytoskeleton.  The mTORC2 is not upstream of the mTORC1 effector S6K.  Thus, two distinct TOR complexes constitute a primordial signaling network conserved in eukaryotic evolution to control the fundamental process of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnbO542vXw7Vg90H21EOLACvtfcHk0ljXnepyBtJ5jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFentL8%253D&md5=42d53ee5d9dfc24287cf05fd29f41aa8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fncb1183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1183%26sid%3Dliteratum%253Aachs%26aulast%3DJacinto%26aufirst%3DE.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DRuegg%26aufirst%3DM.%2BA.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DHall%26aufirst%3DM.%2BN.%26atitle%3DMammalian%2520TOR%2520complex%25202%2520controls%2520the%2520actin%2520cytoskeleton%2520and%2520is%2520rapamycin%2520insensitive%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2004%26volume%3D6%26issue%3D11%26spage%3D1122%26epage%3D8%26doi%3D10.1038%2Fncb1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Q. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1500</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&issue=3&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0ljXnepyBtJ5jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D3%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1194</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F2159-8290.CD-15-0460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=26293922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=1194-1209&issue=11&author=P.+Liuauthor=W.+Ganauthor=Y.+R.+Chinauthor=K.+Oguraauthor=J.+Guoauthor=J.+Zhangauthor=B.+Wangauthor=J.+Blenisauthor=L.+C.+Cantleyauthor=A.+Tokerauthor=B.+Suauthor=W.+Wei&title=PtdIns%283%2C4%2C5%29P3-dependent+activation+of+the+mTORC2+kinase+complex&doi=10.1158%2F2159-8290.CD-15-0460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">PtdIns(3,4,5)P3-dependent activation of the mtorc2 kinase complex</span></div><div class="casAuthors">Liu, Pengda; Gan, Wenjian; Chin, Y. Rebecca; Ogura, Kohei; Guo, Jianping; Zhang, Jinfang; Wang, Bin; Blenis, John; Cantley, Lewis C.; Toker, Alex; Su, Bing; Wei, Wenyi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1194-1209</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MTOR serves as a central regulator of cell growth and metab. by forming two distinct complexes, mTORC1 and mTORC2.  Although mechanisms of mTORC1 activation by growth factors and amino acids have been extensively studied, the upstream regulatory mechanisms leading to mTORC2 activation remain largely elusive.  Here, we report that the pleckstrin homol. (PH) domain of SIN1, an essential and unique component of mTORC2, interacts with the mTOR kinase domain to suppress mTOR activity.  More importantly, PtdIns(3,4,5)P3, but not other PtdInsPn species, interacts with SIN1-PH to release its inhibition on the mTOR kinase domain, thereby triggering mTORC2 activation.  Mutating crit. SIN1 residues that mediate PtdIns(3,4,5)P3 interaction inactivates mTORC2, whereas mTORC2 activity is pathol. increased by patient-derived mutations in the SIN1-PH domain, promoting cell growth and tumor formation.  Together, our study unravels a PI3K-dependent mechanism for mTORC2 activation, allowing mTORC2 to activate AKT in a manner that is regulated temporally and spatially by PtdIns(3,4,5)P3.  Significance: The SIN1-PH domain interacts with the mTOR kinase domain to suppress mTOR activity, and PtdIns(3,4,5)P3 binds the SIN1-PH domain to release its inhibition on the mTOR kinase domain, leading to mTORC2 activation.  Cancer patient-derived SIN1-PH domain mutations gain oncogenicity by loss of suppressing mTOR activity as a means to facilitate tumorigenesis.  Cancer Discov; 5(11); 1194-209. ©2015 AACR.  See related commentary by Yuan and Guan, p. 1127.  This article is highlighted in the In This Issue feature, p.1111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotBvVUrg3Jo7Vg90H21EOLACvtfcHk0ljXnepyBtJ5jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsr3E&md5=a218e7e37d78aaa532a8ff44db230447</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0460%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DGan%26aufirst%3DW.%26aulast%3DChin%26aufirst%3DY.%2BR.%26aulast%3DOgura%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DBlenis%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DToker%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DPtdIns%25283%252C4%252C5%2529P3-dependent%2520activation%2520of%2520the%2520mTORC2%2520kinase%2520complex%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D11%26spage%3D1194%26epage%3D1209%26doi%3D10.1158%2F2159-8290.CD-15-0460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursavich, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingboe, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malwitz, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toral-Barza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">7081</span>– <span class="NLM_lpage">7089</span>, <span class="refDoi"> DOI: 10.1021/jm9012642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9012642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Oku7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7081-7089&issue=22&author=P.+Nowakauthor=D.+C.+Coleauthor=N.+Brooijmansauthor=M.+G.+Bursavichauthor=K.+J.+Curranauthor=J.+W.+Ellingboeauthor=J.+J.+Gibbonsauthor=I.+Hollanderauthor=Y.+Huauthor=J.+Kaplanauthor=D.+J.+Malwitzauthor=L.+Toral-Barzaauthor=J.+C.+Verheijenauthor=A.+Zaskauthor=W.+G.+Zhangauthor=K.+Yu&title=Discovery+of+potent+and+selective+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29+kinase&doi=10.1021%2Fjm9012642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase</span></div><div class="casAuthors">Nowak, Pawel; Cole, Derek C.; Brooijmans, Natasja; Curran, Kevin J.; Ellingboe, John W.; Gibbons, James J.; Hollander, Irwin; Hu, Yong Bo; Kaplan, Joshua; Malwitz, David J.; Toral-Barza, Lourdes; Verheijen, Jeroen C.; Zask, Arie; Zhang, Wei-Guo; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7081-7089</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a central regulator of cell growth, metab., and angiogenesis and an emerging target in cancer research.  High throughput screening (HTS) of our compd. collection led to the identification of 3-(4-morpholin-4-yl-1-piperidin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenol (5a), a modestly potent and nonselective inhibitor of mTOR and phosphoinositide 3-kinase (PI3K).  Optimization of compd. 5a, employing an mTOR homol. model based on an X-ray crystal structure of closely related PI3Kγ led to the discovery of 6-(1H-indol-5-yl)-4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidine (5u), a potent and selective mTOR inhibitor (mTOR IC50 = 9 nM; PI3Kα IC50 = 1962 nM).  Compd. 5u selectively inhibited cellular biomarker of mTORC1 (P-S6K, P-4EBP1) and mTORC2 (P-AKT S473) over the biomarker of PI3K/PDK1 (P-AKT T308) and did not inhibit PI3K-related kinases (PIKKs) in cellular assays.  These pyrazolopyrimidines represent an exciting new series of mTOR-selective inhibitors with potential for development for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8sFoF2rplwrVg90H21EOLACvtfcHk0lgEvPlPCZX6lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Oku7zL&md5=5a60157598d9eb85e4fff6dc07f01cc2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm9012642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9012642%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DD.%2BC.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBursavich%26aufirst%3DM.%2BG.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DEllingboe%26aufirst%3DJ.%2BW.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.%2BG.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D22%26spage%3D7081%26epage%3D7089%26doi%3D10.1021%2Fjm9012642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">58469</span>– <span class="NLM_lpage">58479</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.18632%2Foncotarget.17753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=28938571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=58469-58479&issue=35&author=Z.+Jinauthor=H.+Niuauthor=X.+Wangauthor=L.+Zhangauthor=Q.+Wangauthor=A.+Yang&title=Preclinical+study+of+CC223+as+a+potential+anti-ovarian+cancer+agent&doi=10.18632%2Foncotarget.17753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span></div><div class="casAuthors">Jin Zhenzhen; Niu Huanfu; Wang Xuenan; Wang Qin; Yang Aijun; Zhang Lei</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">58469-58479</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aberrant activation of mTOR contributes to ovarian cancer progression.  CC223 is a novel and potent mTOR kinase inhibitor.  The current study tested its activity against human ovarian cancer cells.  We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary human ovarian cancer cells.  Further, significant apoptosis activation was observed in CC223-treated ovarian cancer cells.  CC223 disrupted assembly of mTOR complex 1 (mTORC1) and mTORC2 in SKOV3 cells.  Meanwhile, activation of mTORC1 and mTORC2 was almost completely blocked by CC223.  Intriguingly, restoring mTOR activation by introduction of a constitutively-active Akt1 only partially inhibited CC223-induced cytotoxicity in SKOV3 cells.  Further studies showed that CC223 inhibited sphingosine kinase 1 (SphK1) activity and induced reactive oxygen species (ROS) production in SKOV3 cells.  At last, oral administration of CC223 potently inhibited SKOV3 xenografted tumor growth in nude mice.  The results of this study imply that CC223 could be further studied as a potential anti-ovarian cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcU4AE24nN2t1QT_1O5WBYfW6udTcc2eZGPMcPOiJkgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D&md5=091fdb75cec2ddb9018ba74c124041e8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17753%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DA.%26atitle%3DPreclinical%2520study%2520of%2520CC223%2520as%2520a%2520potential%2520anti-ovarian%2520cancer%2520agent%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D35%26spage%3D58469%26epage%3D58479%26doi%3D10.18632%2Foncotarget.17753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slotkin, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudeva, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F1535-7163.MCT-14-0711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=25519700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=395-406&issue=2&author=E.+K.+Slotkinauthor=P.+P.+Patwardhanauthor=S.+D.+Vasudevaauthor=E.+de+Stanchinaauthor=W.+D.+Tapauthor=G.+K.+Schwartz&title=MLN0128%2C+an+ATP-competitive+mTOR+kinase+inhibitor+with+potent+in+vitro+and+in+vivo+antitumor+activity%2C+as+potential+therapy+for+bone+and+soft-tissue+sarcoma&doi=10.1158%2F1535-7163.MCT-14-0711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma</span></div><div class="casAuthors">Slotkin, Emily K.; Patwardhan, Parag P.; Vasudeva, Shyamprasad D.; de Stanchina, Elisa; Tap, William D.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-406</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular and intracellular signals to act as a master regulator of cell growth, survival, and metab.  The PI3K/AKT/mTOR prosurvival pathway is often dysregulated in multiple sarcoma subtypes.  First-generation allosteric inhibitors of mTORC1 (rapalogues) have been extensively tested with great preclin. promise, but have had limited clin. utility.  Here, we report that MLN0128, a second-generation, ATP-competitive, pan-mTOR kinase inhibitor, acts on both mTORC1 and mTORC2 and has potent in vitro and in vivo antitumor activity in multiple sarcoma subtypes.  In vitro, MLN0128 inhibits mTORC1/2 targets in a concn.-dependent fashion and shows striking antiproliferative effect in rhabdomyosarcoma (RMS), Ewing sarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma, osteosarcoma, and liposarcoma.  Unlike rapamycin, MLN0128 inhibits phosphorylation of 4EBP1 and NDRG1 as well as prevents the reactivation of pAKT that occurs via neg. feedback release with mTORC1 inhibition alone.  In xenograft models, MLN0128 treatment results in suppression of tumor growth with two dosing schedules (1 mg/kg daily and 3 mg/kg b.i.d. t.i.w.).  At the 3 mg/kg dosing schedule, MLN0128 treatment results in significantly better tumor growth suppression than rapamycin in RMS and Ewing sarcoma models.  In addn., MLN0128 induces apoptosis in models of RMS both in vitro and in vivo.  Results from our study strongly suggest that MLN0128 treatment should be explored further as potential therapy for sarcoma.  Mol Cancer Ther; 14(2); 395-406. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2RbwSW4yjmLVg90H21EOLACvtfcHk0lhcp-GpI9aOzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D&md5=7c1d867aae6e5ca99c63b554295a539a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0711%26sid%3Dliteratum%253Aachs%26aulast%3DSlotkin%26aufirst%3DE.%2BK.%26aulast%3DPatwardhan%26aufirst%3DP.%2BP.%26aulast%3DVasudeva%26aufirst%3DS.%2BD.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DMLN0128%252C%2520an%2520ATP-competitive%2520mTOR%2520kinase%2520inhibitor%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%252C%2520as%2520potential%2520therapy%2520for%2520bone%2520and%2520soft-tissue%2520sarcoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D2%26spage%3D395%26epage%3D406%26doi%3D10.1158%2F1535-7163.MCT-14-0711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malagu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummersone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.bmcl.2013.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=23375793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1212-1216&issue=5&author=K.+G.+Pikeauthor=K.+Malaguauthor=M.+G.+Hummersoneauthor=K.+A.+Menearauthor=H.+M.+Dugganauthor=S.+Gomezauthor=N.+M.+Martinauthor=L.+Rustonauthor=S.+L.+Passauthor=M.+Pass&title=Optimization+of+potent+and+selective+dual+mTORC1+and+mTORC2+inhibitors%3A+the+discovery+of+AZD8055+and+AZD2014&doi=10.1016%2Fj.bmcl.2013.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014</span></div><div class="casAuthors">Pike, Kurt G.; Malagu, Karine; Hummersone, Marc G.; Menear, Keith A.; Duggan, Heather M. E.; Gomez, Sylvie; Martin, Niall M. B.; Ruston, Linette; Pass, Sarah L.; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1212-1216</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described.  An initial focus on improving cellular potency while maintaining or improving other key parameters, such as aq. soly. and margins over hERG IC50, led to the discovery of the clin. candidate AZD8055.  Further optimization, particularly aimed at reducing the rate of metab. in human hepatocyte incubations, resulted in the discovery of the clin. candidate AZD2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo07emMEKp9mrVg90H21EOLACvtfcHk0lhcp-GpI9aOzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D&md5=325cb45f84bb4357005315ab3b27c0aa</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DHummersone%26aufirst%3DM.%2BG.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DDuggan%26aufirst%3DH.%2BM.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DS.%2BL.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520potent%2520and%2520selective%2520dual%2520mTORC1%2520and%2520mTORC2%2520inhibitors%253A%2520the%2520discovery%2520of%2520AZD8055%2520and%2520AZD2014%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D5%26spage%3D1212%26epage%3D1216%26doi%3D10.1016%2Fj.bmcl.2013.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vo, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span> <span> </span><span class="NLM_article-title">Targeting mTOR for the treatment of B cell malignancies</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1213</span>– <span class="NLM_lpage">1228</span>, <span class="refDoi"> DOI: 10.1111/bcp.12888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1111%2Fbcp.12888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=26805380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Gqsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2016&pages=1213-1228&issue=5&author=J.+S.+Leeauthor=T.+T.+Voauthor=D.+A.+Fruman&title=Targeting+mTOR+for+the+treatment+of+B+cell+malignancies&doi=10.1111%2Fbcp.12888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mTOR for the treatment of B cell malignancies</span></div><div class="casAuthors">Lee, Jong-Hoon Scott; Vo, Thanh-Trang; Fruman, David A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1213-1228</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, division and survival.  Many haematol. malignancies exhibit elevated or aberrant mTOR activation, supporting the launch of numerous clin. trials aimed at evaluating the potential of single agent mTOR-targeted therapies.  While promising early clin. data using allosteric mTOR inhibitors (rapamycin and its derivs., rapalogs) have suggested activity in a subset of haematol. malignancies, these agents have shown limited efficacy in most contexts.  Whether the efficacy of these partial mTOR inhibitors might be enhanced by more complete target inhibition is being actively addressed with second generation ATP-competitive mTOR kinase inhibitors (TOR-KIs), which have only recently entered clin. trials.  However, emerging preclin. data suggest that despite their biochem. advantage over rapalogs, TOR-KIs may retain a primarily cytostatic response.  Rather, combinations of mTOR inhibition with other targeted therapies have demonstrated promising efficacy in several preclin. models.  This review investigates the current status of rapalogs and TOR-KIs in B cell malignancies, with an emphasis on emerging preclin. evidence of synergistic combinations involving mTOR inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7dt4KJJSA7LVg90H21EOLACvtfcHk0lhcp-GpI9aOzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Gqsr7L&md5=0ae355bfde2b1b275eb2bdfd55b4cbab</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12888%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DVo%26aufirst%3DT.%2BT.%26aulast%3DFruman%26aufirst%3DD.%2BA.%26atitle%3DTargeting%2520mTOR%2520for%2520the%2520treatment%2520of%2520B%2520cell%2520malignancies%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D82%26issue%3D5%26spage%3D1213%26epage%3D1228%26doi%3D10.1111%2Fbcp.12888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoro methyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1/2 inhibitor for cancer and neurological disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10105</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01262</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01262" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10084-10105&issue=22&author=D.+Rageotauthor=T.+Bohnackerauthor=A.+Meloneauthor=J.+B.+Langloisauthor=C.+Borsariauthor=P.+Hillmannauthor=A.+M.+Seleauthor=F.+Beaufilsauthor=M.+Zvelebilauthor=P.+Hebeisenauthor=W.+Loscherauthor=J.+Burkeauthor=D.+Fabbroauthor=M.+P.+Wymann&title=Discovery+and+preclinical+characterization+of+5-%5B4%2C6-Bis%28%7B3-oxa-8-azabicyclo%5B3.2.1%5Doctan-8-yl%7D%29-1%2C3%2C5-triazin-2-yl%5D-4-%28difluoro+methyl%29pyridin-2-amine+%28PQR620%29%2C+a+highly+potent+and+selective+mTORC1%2F2+inhibitor+for+cancer+and+neurological+disorders&doi=10.1021%2Facs.jmedchem.8b01262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders</span></div><div class="casAuthors">Rageot, Denise; Bohnacker, Thomas; Melone, Anna; Langlois, Jean-Baptiste; Borsari, Chiara; Hillmann, Petra; Sele, Alexander M.; Beaufils, Florent; Zvelebil, Marketa; Hebeisen, Paul; Loscher, Wolfgang; Burke, John; Fabbro, Doriano; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10105</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders.  I is a novel, potent, selective, and brain penetrable inhibitor of mTORC1/2 kinase.  I showed excellent selectivity for mTOR over PI3K and protein kinases and efficiently prevented cancer cell growth in a 66 cancer cell line panel.  In C57BL/6J and Sprague-Dawley mice, max. concn. (Cmax) in plasma and brain was reached after 30 min, with a half-life (t1/2) > 5 h.  In an ovarian carcinoma mouse xenograft model (OVCAR-3), daily dosing of I inhibited tumor growth significantly.  Moreover, I attenuated epileptic seizures in a tuberous sclerosis complex (TSC) mouse model.  In conclusion, I inhibits mTOR kinase potently and selectively, shows antitumor effects in vitro and in vivo, and promises advantages in CNS indications due to its brain/plasma distribution ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTlRg0fJo97Vg90H21EOLACvtfcHk0ljdw_B85X0AUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLjO&md5=e6ebf8147d6ba041285eb6538ade46ab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01262%26sid%3Dliteratum%253Aachs%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DJ.%2BB.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DLoscher%26aufirst%3DW.%26aulast%3DBurke%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%25205-%255B4%252C6-Bis%2528%257B3-oxa-8-azabicyclo%255B3.2.1%255Doctan-8-yl%257D%2529-1%252C3%252C5-triazin-2-yl%255D-4-%2528difluoro%2520methyl%2529pyridin-2-amine%2520%2528PQR620%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520mTORC1%252F2%2520inhibitor%2520for%2520cancer%2520and%2520neurological%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D10084%26epage%3D10105%26doi%3D10.1021%2Facs.jmedchem.8b01262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+Diazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2ebXcE1N52FH07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7524</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00930</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00930" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7524-7538&issue=17&author=F.+Beaufilsauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=T.+Bohnackerauthor=A.+Meloneauthor=R.+Maroneauthor=E.+Jacksonauthor=X.+Zhangauthor=A.+Seleauthor=C.+Borsariauthor=J.+Mestanauthor=P.+Hebeisenauthor=P.+Hillmannauthor=B.+Gieseauthor=M.+Zvelebilauthor=D.+Fabbroauthor=R.+L.+Williamsauthor=D.+Rageotauthor=M.+P.+Wymann&title=5-%284%2C6-Dimorpholino-1%2C3%2C5-triazin-2-yl%29-4-%28trifluoromethyl%29pyridin-2-amine+%28PQR309%29%2C+a+potent%2C+brain-penetrant%2C+orally+bioavailable%2C+pan-class+I+PI3K%2FmTOR+inhibitor+as+clinical+candidate+in+oncology&doi=10.1021%2Facs.jmedchem.7b00930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></div><div class="casAuthors">Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jurgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7524-7538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).  Here we describe the preclin. characterization of compd. 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concns.  No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays.  Moreover, 1 did not bind tubulin, which was obsd. for the structurally related 4 (BKM120, buparlisib).  Compd. 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.  Compd. 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model.  This, together with the compd.'s safety profile, identifies 1 as a clin. candidate with a broad application range in oncol., including treatment of brain tumors or CNS metastasis.  Compd. 1 is currently in phase II clin. trials for advanced solid tumors and refractory lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtvYAarVqsarVg90H21EOLACvtfcHk0ljfEhj5l-_rqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP&md5=54d4db75f6a8bda3f12eaf1d196352fd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D5-%25284%252C6-Dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2520%2528PQR309%2529%252C%2520a%2520potent%252C%2520brain-penetrant%252C%2520orally%2520bioavailable%252C%2520pan-class%2520I%2520PI3K%252FmTOR%2520inhibitor%2520as%2520clinical%2520candidate%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D17%26spage%3D7524%26epage%3D7538%26doi%3D10.1021%2Facs.jmedchem.7b00930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarantelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arribas, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittau, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritschard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dossena, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taborelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gattei, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stussi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, F.</span></span> <span> </span><span class="NLM_article-title">PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F1078-0432.CCR-17-1041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=29066507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=120-129&issue=1&author=C.+Tarantelliauthor=E.+Gaudioauthor=A.+J.+Arribasauthor=I.+Kweeauthor=P.+Hillmannauthor=A.+Rinaldiauthor=L.+Cascioneauthor=F.+Sprianoauthor=E.+Bernasconiauthor=F.+Guidettiauthor=L.+Carrassaauthor=R.+B.+Pittauauthor=F.+Beaufilsauthor=R.+Ritschardauthor=D.+Rageotauthor=A.+Seleauthor=B.+Dossenaauthor=F.+M.+Rossiauthor=A.+Zucchettoauthor=M.+Taborelliauthor=V.+Gatteiauthor=D.+Rossiauthor=A.+Stathisauthor=G.+Stussiauthor=M.+Brogginiauthor=M.+P.+Wymannauthor=A.+Wickiauthor=E.+Zuccaauthor=V.+Cmiljanovicauthor=D.+Fabbroauthor=F.+Bertoni&title=PQR309+is+a+novel+dual+PI3K%2FmTOR+inhibitor+with+preclinical+antitumor+activity+in+lymphomas+as+a+single+agent+and+in+combination+therapy&doi=10.1158%2F1078-0432.CCR-17-1041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy</span></div><div class="casAuthors">Tarantelli, Chiara; Gaudio, Eugenio; Arribas, Alberto J.; Kwee, Ivo; Hillmann, Petra; Rinaldi, Andrea; Cascione, Luciano; Spriano, Filippo; Bernasconi, Elena; Guidetti, Francesca; Carrassa, Laura; Pittau, Roberta Bordone; Beaufils, Florent; Ritschard, Reto; Rageot, Denise; Sele, Alexander; Dossena, Barbara; Rossi, Francesca Maria; Zucchetto, Antonella; Taborelli, Monica; Gattei, Valter; Rossi, Davide; Stathis, Anastasios; Stussi, Georg; Broggini, Massimo; Wymann, Matthias P.; Wicki, Andreas; Zucca, Emanuele; Cmiljanovic, Vladimir; Fabbro, Doriano; Bertoni, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-129</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacol. inhibition of the PI3K/mTOR pathway has shown activity in lymphoma patients.  Here, we extensively characterized the in vitro and in vivo activity and the mechanism of action of PQR309 (bimiralisib), a novel oral selective dual PI3K/mTOR inhibitor under clin. evaluation, in preclin. lymphoma models.  Exptl. Design: This study included preclin. in vitro activity screening on a large panel of cell lines, both as single agent and in combination, validation expts. on in vivo models and primary cells, proteomics and gene-expression profiling, and comparison with other signaling inhibitors.  Results: PQR309 had in vitro antilymphoma activity as single agent and in combination with venetoclax, panobinostat, ibrutinib, lenalidomide, ARV-825, marizomib, and rituximab.  Sensitivity to PQR309 was assocd. with specific baseline gene-expression features, such as high expression of transcripts coding for the BCR pathway.  Combining proteomics and RNA profiling, we identified the different contribution of PQR309-induced protein phosphorylation and gene expression changes to the drug mechanism of action.  Gene-expression signatures induced by PQR309 and by other signaling inhibitors largely overlapped.  PQR309 showed activity in cells with primary or secondary resistance to idelalisib.  Conclusions: On the basis of these results, PQR309 appeared as a novel and promising compd. that is worth developing in the lymphoma setting.  Clin Cancer Res; 24(1); 120-9. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEmEWXHaG3ObVg90H21EOLACvtfcHk0ljfEhj5l-_rqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWktw%253D%253D&md5=730305c33b7f669b0eedd0614edd886c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1041%26sid%3Dliteratum%253Aachs%26aulast%3DTarantelli%26aufirst%3DC.%26aulast%3DGaudio%26aufirst%3DE.%26aulast%3DArribas%26aufirst%3DA.%2BJ.%26aulast%3DKwee%26aufirst%3DI.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DRinaldi%26aufirst%3DA.%26aulast%3DCascione%26aufirst%3DL.%26aulast%3DSpriano%26aufirst%3DF.%26aulast%3DBernasconi%26aufirst%3DE.%26aulast%3DGuidetti%26aufirst%3DF.%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DPittau%26aufirst%3DR.%2BB.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DRitschard%26aufirst%3DR.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DDossena%26aufirst%3DB.%26aulast%3DRossi%26aufirst%3DF.%2BM.%26aulast%3DZucchetto%26aufirst%3DA.%26aulast%3DTaborelli%26aufirst%3DM.%26aulast%3DGattei%26aufirst%3DV.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DStussi%26aufirst%3DG.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBertoni%26aufirst%3DF.%26atitle%3DPQR309%2520is%2520a%2520novel%2520dual%2520PI3K%252FmTOR%2520inhibitor%2520with%2520preclinical%2520antitumor%2520activity%2520in%2520lymphomas%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D1%26spage%3D120%26epage%3D129%26doi%3D10.1158%2F1078-0432.CCR-17-1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xyrafas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bize, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretre, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritschard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzankov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hierro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Moos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span> <span> </span><span class="NLM_article-title">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2018.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.ejca.2018.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=29660598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1Snu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2018&pages=6-16&author=A.+Wickiauthor=N.+Brownauthor=A.+Xyrafasauthor=V.+Bizeauthor=H.+Hawleauthor=S.+Berardiauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=M.+Stummauthor=S.+Dimitrijevicauthor=R.+Herrmannauthor=V.+Pretreauthor=R.+Ritschardauthor=A.+Tzankovauthor=V.+Hessauthor=A.+Childsauthor=C.+Hierroauthor=J.+Rodonauthor=D.+Hessauthor=M.+Joergerauthor=R.+von+Moosauthor=C.+Sessaauthor=R.+Kristeleit&title=First-in+human%2C+phase+1%2C+dose-escalation+pharmacokinetic+and+pharmacodynamic+study+of+the+oral+dual+PI3K+and+mTORC1%2F2+inhibitor+PQR309+in+patients+with+advanced+solid+tumors+%28SAKK+67%2F13%29&doi=10.1016%2Fj.ejca.2018.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)</span></div><div class="casAuthors">Wicki, Andreas; Brown, Nicholas; Xyrafas, Alexandros; Bize, Vincent; Hawle, Hanne; Berardi, Simona; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Stumm, Michael; Dimitrijevic, Sasa; Herrmann, Richard; Pretre, Vincent; Ritschard, Reto; Tzankov, Alexandar; Hess, Viviane; Childs, Alexa; Hierro, Cinta; Rodon, Jordi; Hess, Dagmar; Joerger, Markus; von Moos, Roger; Sessa, Cristiana; Kristeleit, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6-16</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">PQR309 is an orally bioavailable, balanced pan-phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhibitor.  This is an accelerated titrn., 3 D 3 dose-escalation, open-label phase Itrial of continuous once-daily (OD) PQR309 administration to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics in patients with advanced solid tumors.  Primary objectives were to det. the max. tolerated dose (MTD) and recommended phase 2 dose (RP2D).Twenty-eight patients were included in six dosing cohorts and treated at a daily PQR309 dose ranging from 10 to 150 mg.  Common adverse events (AEs; ≥30% patients) included fatigue, hyperglycemia, nausea, diarrhea, constipation, rash, anorexia and vomiting.  Grade (G) 3 or 4 drug-related AEs were seen in 13 (46%) and three (11%) patients, resp.  Dose-limiting toxicity (DLT) was obsd. in two patients at 100 mg OD (>14-d interruption in PQR309 due to G3 rash, G2 hyperbilirubinemia, G4 suicide attempt; dose redn. due to G3 fatigue, G2 diarrhoea, G4 transaminitis) and one patient at 80 mg (G3 hyperglycemia >7 d).  PK shows fast absorption (Tmax 1-2 h) and dose proportionality for Cmax and area under the curve.  A partial response in a patient with metastatic thymus cancer, 24% disease vol. redn. in a patient with sinonasal cancer and stable disease for more than 16 wk in a patient with clear cell Bartholin's gland cancer were obsd.The MTD and RP2D of PQR309 is 80 mg of orally OD.  PK is dose-proportional.  PD shows PI3K pathway phosphoprotein downregulation in paired tumor biopsies.  Clin. activity was obsd. in patients with and without PI3K pathway dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVIhZzSTJb7Vg90H21EOLACvtfcHk0ljhZncMbMjYRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1Snu70%253D&md5=acbdfdb59498f5543ba7f02ed9709d0e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2018.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2018.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DXyrafas%26aufirst%3DA.%26aulast%3DBize%26aufirst%3DV.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DBerardi%26aufirst%3DS.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DPretre%26aufirst%3DV.%26aulast%3DRitschard%26aufirst%3DR.%26aulast%3DTzankov%26aufirst%3DA.%26aulast%3DHess%26aufirst%3DV.%26aulast%3DChilds%26aufirst%3DA.%26aulast%3DHierro%26aufirst%3DC.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DJoerger%26aufirst%3DM.%26aulast%3Dvon%2BMoos%26aufirst%3DR.%26aulast%3DSessa%26aufirst%3DC.%26aulast%3DKristeleit%26aufirst%3DR.%26atitle%3DFirst-in%2520human%252C%2520phase%25201%252C%2520dose-escalation%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520the%2520oral%2520dual%2520PI3K%2520and%2520mTORC1%252F2%2520inhibitor%2520PQR309%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520%2528SAKK%252067%252F13%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2018%26volume%3D96%26spage%3D6%26epage%3D16%26doi%3D10.1016%2Fj.ejca.2018.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Conformational restriction: an effective tactic in “follow-on”-based drug discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.4155%2Ffmc.14.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=24962281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=885-901&issue=8&author=Z.+Fangauthor=Y.+Songauthor=P.+Zhanauthor=Q.+Zhangauthor=X.+Liu&title=Conformational+restriction%3A+an+effective+tactic+in+%E2%80%9Cfollow-on%E2%80%9D-based+drug+discovery&doi=10.4155%2Ffmc.14.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction: an effective tactic in 'follow-on'-based drug discovery</span></div><div class="casAuthors">Fang, Zengjun; Song, Yu'ning; Zhan, Peng; Zhang, Qingzhu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-901</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss assocd. with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiol. target, improved selectivity for isoforms and reduced the possibility of drug metab.  Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally.  The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupMomfg9J_bVg90H21EOLACvtfcHk0ljhZncMbMjYRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE&md5=dcf5fa6cead84c77b3603c7e0800f49b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.50%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DConformational%2520restriction%253A%2520an%2520effective%2520tactic%2520in%2520%25E2%2580%259Cfollow-on%25E2%2580%259D-based%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26issue%3D8%26spage%3D885%26epage%3D901%26doi%3D10.4155%2Ffmc.14.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span>; <span class="NLM_string-name">Hebeisen, P.</span>; <span class="NLM_string-name">Jackson, E.</span>; <span class="NLM_string-name">Beaufils, F.</span>; <span class="NLM_string-name">Bohnacker, T.</span>; <span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Conformationally Restricted PI3K and mTOR Inhibitors</span>. Patent <span class="NLM_patent">WO2015049369</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=V.+Cmiljanovic&author=P.+Hebeisen&author=E.+Jackson&author=F.+Beaufils&author=T.+Bohnacker&author=M.+P.+Wymann&title=Conformationally+Restricted+PI3K+and+mTOR+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCmiljanovic%26aufirst%3DV.%26atitle%3DConformationally%2520Restricted%2520PI3K%2520and%2520mTOR%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, F. R.</span>; <span class="NLM_string-name">Manteau, B.</span>; <span class="NLM_string-name">Vors, J. P.</span>; <span class="NLM_string-name">Pazenok, S.</span></span> <span> </span><span class="NLM_article-title">Trifluoromethyl ethers--synthesis and properties of an unusual substituent</span>.  <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume">4</span> (<span class="NLM_issue">13</span>), <span class="refDoi"> DOI: 10.3762/bjoc.4.13</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.3762%2Fbjoc.4.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18941485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&issue=13&author=F.+R.+Leroux&author=B.+Manteau&author=J.+P.+Vors&author=S.+Pazenok&title=Trifluoromethyl+ethers%2D%2Dsynthesis+and+properties+of+an+unusual+substituent&doi=10.3762%2Fbjoc.4.13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.4.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.4.13%26sid%3Dliteratum%253Aachs%26aulast%3DLeroux%26aufirst%3DF.%2BR.%26atitle%3DTrifluoromethyl%2520ethers--synthesis%2520and%2520properties%2520of%2520an%2520unusual%2520substituent%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2008%26volume%3D4%26issue%3D13%26doi%3D10.3762%2Fbjoc.4.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M.
T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 Kinase inhibitor for treating cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&issue=10&author=M.%0AT.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.+J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.+M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+Kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0ljVGDKIVVHVcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.%2BJ.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520Kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D10%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chekroun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrosse, J. R.</span></span> <span> </span><span class="NLM_article-title">Concise preparation of a stable cyclic sulfamidate intermediate in the synthesis of a enantiopure chiral active diamine derivative</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1021/op500264v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op500264v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=506-513&issue=4&author=J.+F.+Rousseauauthor=I.+Chekrounauthor=V.+Fereyauthor=J.+R.+Labrosse&title=Concise+preparation+of+a+stable+cyclic+sulfamidate+intermediate+in+the+synthesis+of+a+enantiopure+chiral+active+diamine+derivative&doi=10.1021%2Fop500264v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Concise Preparation of a Stable Cyclic Sulfamidate Intermediate in the Synthesis of a Enantiopure Chiral Active Diamine Derivative</span></div><div class="casAuthors">Rousseau, Jean-Francois; Chekroun, Isaac; Ferey, Vincent; Labrosse, Jean Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">506-513</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A potentially scalable route to the nonracemic antipsychotic candidate SSR 504374 I was developed using the stereoselective substitution reaction of nonracemic sulfamidate II with 2-chloro-3-trifluoromethylbenzamide as the key step.  II was prepd. in seven steps from 2-benzoylpyridine by chemo- and diastereoselective hydrogenation, sepn. of the desired racemic erythro diastereomer, resoln. with di-p-toluoyl-(+)-tartaric acid, formation of a sulfamidite, and oxidn. at sulfur with RuCl3 and sodium hypochlorite; a workup for the sulfamidite oxidn. using isopropanol was developed to avoid darkening of the intermediate due to oxidn. by RuO2 and RuO4 left in the sulfamidate product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsX3_hyMn6JrVg90H21EOLACvtfcHk0ljVGDKIVVHVcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOrurk%253D&md5=72c5ea832b893e2bccf01a80c9ea1734</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fop500264v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop500264v%26sid%3Dliteratum%253Aachs%26aulast%3DRousseau%26aufirst%3DJ.%2BF.%26aulast%3DChekroun%26aufirst%3DI.%26aulast%3DFerey%26aufirst%3DV.%26aulast%3DLabrosse%26aufirst%3DJ.%2BR.%26atitle%3DConcise%2520preparation%2520of%2520a%2520stable%2520cyclic%2520sulfamidate%2520intermediate%2520in%2520the%2520synthesis%2520of%2520a%2520enantiopure%2520chiral%2520active%2520diamine%2520derivative%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26issue%3D4%26spage%3D506%26epage%3D513%26doi%3D10.1021%2Fop500264v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foubister, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, B.</span></span> <span> </span><span class="NLM_article-title">Chiral synthesis of 3-substituted morpholines via serine enantiomers and reductions of 5-oxomorpholine-3-carboxylates</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">2577</span>– <span class="NLM_lpage">2580</span>, <span class="refDoi"> DOI: 10.1039/p19850002577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1039%2Fp19850002577" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1985&pages=2577-2580&author=G.+R.+Brownauthor=A.+J.+Foubisterauthor=B.+Wright&title=Chiral+synthesis+of+3-substituted+morpholines+via+serine+enantiomers+and+reductions+of+5-oxomorpholine-3-carboxylates&doi=10.1039%2Fp19850002577"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2Fp19850002577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp19850002577%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DG.%2BR.%26aulast%3DFoubister%26aufirst%3DA.%2BJ.%26aulast%3DWright%26aufirst%3DB.%26atitle%3DChiral%2520synthesis%2520of%25203-substituted%2520morpholines%2520via%2520serine%2520enantiomers%2520and%2520reductions%2520of%25205-oxomorpholine-3-carboxylates%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1985%26volume%3D1%26spage%3D2577%26epage%3D2580%26doi%3D10.1039%2Fp19850002577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buerkler, M.</span></span> <span> </span><span class="NLM_article-title">Iterative one pot reactions of a chiral sulfamidate with 2,4,6-trichloropyridine: regiocontrolled synthesis of linear and angular chiral dipyrrolidino pyridines</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.3987/COM-11-12360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.3987%2FCOM-11-12360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2012&pages=65-72&issue=1&author=P.+Hebeisenauthor=A.+Alkerauthor=M.+Buerkler&title=Iterative+one+pot+reactions+of+a+chiral+sulfamidate+with+2%2C4%2C6-trichloropyridine%3A+regiocontrolled+synthesis+of+linear+and+angular+chiral+dipyrrolidino+pyridines&doi=10.3987%2FCOM-11-12360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Iterative one pot reactions of a chiral sulfamidate with 2,4,6-trichloropyridine: Regiocontrolled synthesis of linear and angular chiral dipyrrolidino pyridines</span></div><div class="casAuthors">Hebeisen, Paul; Alker, Andre; Buerkler, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Heterocycles</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">HTCYAM</span>;
        ISSN:<span class="NLM_cas:issn">0385-5414</span>.
    
            (<span class="NLM_cas:orgname">Japan Institute of Heterocyclic Chemistry</span>)
        </div><div class="casAbstract">The product of the ring opening of a chiral sulfamidate with the 3-lithiopyridine species obtained by deprotonation of 2,4,6-trichloropyridine with BuLi was deprotonated again in situ with BuLi and reacted with a 2nd equiv. of the sulfamidate furnishing a bis(β-aminoethyl)pyridine deriv., which could be cyclized regioselectively to linear or angular chiral dipyrrolidinopyridines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTe-kbbFHcgbVg90H21EOLACvtfcHk0li6j95gh7wpTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslWnug%253D%253D&md5=07450591f843628878b047a25205e5bf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3987%2FCOM-11-12360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-11-12360%26sid%3Dliteratum%253Aachs%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DAlker%26aufirst%3DA.%26aulast%3DBuerkler%26aufirst%3DM.%26atitle%3DIterative%2520one%2520pot%2520reactions%2520of%2520a%2520chiral%2520sulfamidate%2520with%25202%252C4%252C6-trichloropyridine%253A%2520regiocontrolled%2520synthesis%2520of%2520linear%2520and%2520angular%2520chiral%2520dipyrrolidino%2520pyridines%26jtitle%3DHeterocycles%26date%3D2012%26volume%3D85%26issue%3D1%26spage%3D65%26epage%3D72%26doi%3D10.3987%2FCOM-11-12360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toral-Barza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7942</span>– <span class="NLM_lpage">7945</span>, <span class="refDoi"> DOI: 10.1021/jm901415x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901415x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7942-7945&issue=24&author=A.+Zaskauthor=J.+Kaplanauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=K.+Curranauthor=N.+Brooijmansauthor=E.+M.+Bennettauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=Morpholine+derivatives+greatly+enhance+the+selectivity+of+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors&doi=10.1021%2Fjm901415x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors</span></div><div class="casAuthors">Zask, Arie; Kaplan, Joshua; Verheijen, Jeroen C.; Richard, David J.; Curran, Kevin; Brooijmans, Natasja; Bennett, Eric M.; Toral-Barza, Lourdes; Hollander, Irwin; Ayral-Kaloustian, Semiramis; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7942-7945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dramatic improvements in mTOR-targeting selectivity were achieved by replacing morpholine in pyrazolopyrimidine inhibitors with bridged morpholines.  Analogs I [R1 = (R)- or (S)-3-methyl-4-morpholinyl, 2-methyl-4-morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, etc.; R2 = Me, Et, cyclopropyl, FCH2CH2, 3-pyridyl, 4-pyridyl; R3 = F3CCH2, 1-methoxycarbonyl-4-piperidinyl, 1-ethoxycarbonyl-4-piperidinyl, 3-pyridylmethyl] with subnanomolar mTOR IC50 values and up to 26000-fold selectivity vs. PI3Kα were prepd.  Chiral morpholines gave inhibitors whose enantiomers had different selectivity and potency profiles.  Mol. modeling suggests that a single amino acid difference between PI3K and mTOR (Phe961Leu) accounts for the profound selectivity seen by creating a deeper pocket in mTOR that can accommodate bridged morpholines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2HnMHqTHqbVg90H21EOLACvtfcHk0li6j95gh7wpTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J&md5=5ef1eee5aa79531970049d3d26b46eb2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm901415x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901415x%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DMorpholine%2520derivatives%2520greatly%2520enhance%2520the%2520selectivity%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D24%26spage%3D7942%26epage%3D7945%26doi%3D10.1021%2Fjm901415x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattachar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchingham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocharski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surendran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span> <span> </span><span class="NLM_article-title">The road map to oral bioavailability: an industrial perspective</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1517/17425255.2.4.591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1517%2F17425255.2.4.591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=16859407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=591-608&issue=4&author=V.+H.+Thomasauthor=S.+Bhattacharauthor=L.+Hitchinghamauthor=P.+Zocharskiauthor=M.+Naathauthor=N.+Surendranauthor=C.+L.+Stonerauthor=A.+El-Kattan&title=The+road+map+to+oral+bioavailability%3A+an+industrial+perspective&doi=10.1517%2F17425255.2.4.591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The road map to oral bioavailability: an industrial perspective</span></div><div class="casAuthors">Thomas, V. Hayden; Bhattachar, Shobha; Hitchingham, Linda; Zocharski, Philip; Naath, Maryanne; Surendran, Narayanan; Stoner, Chad L.; El-Kattan, Ayman</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-608</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Optimization of oral bioavailability is a continuing challenge for the pharmaceutical and biotechnol. industries.  The no. of potential drug candidates requiring in vivo evaluation has significantly increased with the advent of combinatorial chem.  In addn., drug discovery programs are increasingly forced into more lipophilic and lower soly. chem. space.  To aid in the use of in vitro and in silico tools as well as reduce the no. of in vivo studies required, a team-based discussion tool is proposed that provides a road map' to guide the selection of profiling assays that should be considered when optimizing oral bioavailability.  This road map divides the factors that contribute to poor oral bioavailability into two interrelated categories: absorption and metab.  This road map provides an interface for cross discipline discussions and a systematic approach to the experimentation that drives the drug discovery process towards a common goal - acceptable oral bioavailability using minimal resources in an acceptable time frame.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7_zZKacXE7Vg90H21EOLACvtfcHk0li6j95gh7wpTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D&md5=79cf4cea1b89914bd3a8826b5d7360f9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.4.591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.4.591%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DV.%2BH.%26aulast%3DBhattachar%26aufirst%3DS.%26aulast%3DHitchingham%26aufirst%3DL.%26aulast%3DZocharski%26aufirst%3DP.%26aulast%3DNaath%26aufirst%3DM.%26aulast%3DSurendran%26aufirst%3DN.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DEl-Kattan%26aufirst%3DA.%26atitle%3DThe%2520road%2520map%2520to%2520oral%2520bioavailability%253A%2520an%2520industrial%2520perspective%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26issue%3D4%26spage%3D591%26epage%3D608%26doi%3D10.1517%2F17425255.2.4.591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span> <span> </span><span class="NLM_article-title">CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F1535-7163.MCT-14-1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=25855786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1295-1305&issue=6&author=D.+S.+Mortensenauthor=K.+E.+Fultzauthor=S.+Xuauthor=W.+Xuauthor=G.+Packardauthor=G.+Khambattaauthor=J.+C.+Gamezauthor=J.+Leistenauthor=J.+Zhaoauthor=J.+Apuyauthor=K.+Ghoreishiauthor=M.+Hickmanauthor=R.+K.+Narlaauthor=R.+Bissonetteauthor=S.+Richardsonauthor=S.+X.+Pengauthor=S.+Perrin-Ninkovicauthor=T.+Tranauthor=T.+Shiauthor=W.+Q.+Yangauthor=Z.+Tongauthor=B.+E.+Cathersauthor=M.+F.+Moghaddamauthor=S.+S.+Cananauthor=P.+Worlandauthor=S.+Sankarauthor=H.+K.+Raymon&title=CC-223%2C+a+potent+and+selective+inhibitor+of+mTOR+kinase%3A+in+vitro+and+in+vivo+characterization&doi=10.1158%2F1535-7163.MCT-14-1052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization</span></div><div class="casAuthors">Mortensen, Deborah S.; Fultz, Kimberly E.; Xu, Shuichan; Xu, Weiming; Packard, Garrick; Khambatta, Godrej; Gamez, James C.; Leisten, Jim; Zhao, Jingjing; Apuy, Julius; Ghoreishi, Kamran; Hickman, Matt; Narla, Rama Krishna; Bissonette, Rene; Richardson, Samantha; Peng, Sophie X.; Perrin-Ninkovic, Sophie; Tran, Tam; Shi, Tao; Yang, Wen Qing; Tong, Zeen; Cathers, Brian E.; Moghaddam, Mehran F.; Canan, Stacie S.; Worland, Peter; Sankar, Sabita; Raymon, Heather K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1295-1305</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MTOR is a serine/threonine kinase that regulates cell growth, metab., proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) are crit. mediators of the PI3K-AKT pathway, which is frequently mutated in many cancers, leading to hyperactivation of mTOR signaling.  Although rapamycin analogs, allosteric inhibitors that target only the mTORC1 complex, have shown some clin. activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.  Here, we describe the preclin. characterization of CC-223.  CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems.  Growth inhibitory activity was demonstrated in hematol. and solid tumor cell lines. mTOR kinase inhibition in cells, by CC-223, resulted in more complete inhibition of the mTOR pathway biomarkers and improved antiproliferative activity as compared with rapamycin.  Growth inhibitory activity and apoptosis was demonstrated in a panel of hematol. cancer cell lines.  Correlative anal. revealed that IRF4 expression level assocs. with resistance, whereas mTOR pathway activation seems to assoc. with sensitivity.  Treatment with CC-223 afforded in vivo tumor biomarker inhibition in tumor-bearing mice, after a single oral dose.  CC-223 exhibited dose-dependent tumor growth inhibition in multiple solid tumor xenografts.  Significant inhibition of mTOR pathway markers pS6RP and pAKT in CC-223-treated tumors suggests that the obsd. antitumor activity of CC-223 was mediated through inhibition of both mTORC1 and mTORC2.  CC-223 is currently in phase I clin. trials.  Mol Cancer Ther; 14(6); 1295-305. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDt9130-L0z7Vg90H21EOLACvtfcHk0lgMH4CE3EQ03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D&md5=f33b21dc89dedaf14fab54a819afb917</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1052%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DGamez%26aufirst%3DJ.%2BC.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DApuy%26aufirst%3DJ.%26aulast%3DGhoreishi%26aufirst%3DK.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DBissonette%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.%2BX.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DW.%2BQ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26aulast%3DCanan%26aufirst%3DS.%2BS.%26aulast%3DWorland%26aufirst%3DP.%26aulast%3DSankar%26aufirst%3DS.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26atitle%3DCC-223%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520mTOR%2520kinase%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D6%26spage%3D1295%26epage%3D1305%26doi%3D10.1158%2F1535-7163.MCT-14-1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nosik, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabukhin, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artamonov, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grygorenko, O. O.</span></span> <span> </span><span class="NLM_article-title">Synthesis of trans-disubstituted pyrazolylcyclopropane building blocks</span>. <i>Monatsh. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>147</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1629</span>– <span class="NLM_lpage">1636</span>, <span class="refDoi"> DOI: 10.1007/s00706-016-1726-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1007%2Fs00706-016-1726-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFyksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2016&pages=1629-1636&issue=9&author=P.+S.+Nosikauthor=S.+V.+Ryabukhinauthor=O.+S.+Artamonovauthor=O.+O.+Grygorenko&title=Synthesis+of+trans-disubstituted+pyrazolylcyclopropane+building+blocks&doi=10.1007%2Fs00706-016-1726-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of trans-disubstituted pyrazolylcyclopropane building blocks</span></div><div class="casAuthors">Nosik, Pavel S.; Ryabukhin, Sergey V.; Artamonov, Oleksiy S.; Grygorenko, Oleksandr O.</div><div class="citationInfo"><span class="NLM_cas:title">Monatshefte fuer Chemie</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1629-1636</span>CODEN:
                <span class="NLM_cas:coden">MOCMB7</span>;
        ISSN:<span class="NLM_cas:issn">0026-9247</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">Diastereoselective synthesis of trans-disubstituted pyrazolylcyclopropane building blocks (i.e. carboxylic acids and amines) is described starting from easily available pyrazolecarbaldehydes.  The key step of the synthesis was Corey-Chaikowsky cyclopropanation of the corresponding α,β-unsatd. Weinreb amides.  The title compds. were prepd. in four or six steps and 32-60 and 17-40 % overall yields, resp., on up to 50 g scale.  The building blocks obtained are good starting points for the design of lead-like libraries of peptidomimetic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5JO82cKC1R7Vg90H21EOLACvtfcHk0lgMH4CE3EQ03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFyksbg%253D&md5=1b4cd76fed0aa27fc3134d8bbe4a301f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs00706-016-1726-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00706-016-1726-6%26sid%3Dliteratum%253Aachs%26aulast%3DNosik%26aufirst%3DP.%2BS.%26aulast%3DRyabukhin%26aufirst%3DS.%2BV.%26aulast%3DArtamonov%26aufirst%3DO.%2BS.%26aulast%3DGrygorenko%26aufirst%3DO.%2BO.%26atitle%3DSynthesis%2520of%2520trans-disubstituted%2520pyrazolylcyclopropane%2520building%2520blocks%26jtitle%3DMonatsh.%2520Chem.%26date%3D2016%26volume%3D147%26issue%3D9%26spage%3D1629%26epage%3D1636%26doi%3D10.1007%2Fs00706-016-1726-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. P.</span></span> <span> </span><span class="NLM_article-title">Combinatorial synthesis of functionalized chiral and doubly chiral ionic liquids and their applications as asymmetric covalent/non-covalent bifunctional organocatalysts</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1039/B713843A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1039%2FB713843A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18219429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=567-576&issue=3&author=L.+Zhangauthor=S.+Luoauthor=X.+Miauthor=S.+Liuauthor=Y.+Qiaoauthor=H.+Xuauthor=J.+P.+Cheng&title=Combinatorial+synthesis+of+functionalized+chiral+and+doubly+chiral+ionic+liquids+and+their+applications+as+asymmetric+covalent%2Fnon-covalent+bifunctional+organocatalysts&doi=10.1039%2FB713843A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial synthesis of functionalized chiral and doubly chiral ionic liquids and their applications as asymmetric covalent/non-covalent bifunctional organocatalysts</span></div><div class="casAuthors">Zhang, Long; Luo, Sanzhong; Mi, Xueling; Liu, Song; Qiao, Yupu; Xu, Hui; Cheng, Jin-Pei</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-576</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A facile combinatorial strategy was developed for the construction of libraries of functionalized chiral ionic liqs. (FCILs) including doubly chiral ionic liqs. and bis-functional chiral ionic liqs.  These FCIL libraries have the potential to be used as asym. catalysts or chiral ligands.  As an example, novel asym. bifunctional catalysts were developed by simultaneously incorporating functional groups onto the cation and anion.  The resultant bis-functionalized CILs showed significantly improved stereoselectivity over the mono-functionalized parent CILs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hq6lB5tNW7Vg90H21EOLACvtfcHk0lgMH4CE3EQ03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWhs7o%253D&md5=4cec4a7bff2e3b65c7aac57156230d27</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2FB713843A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB713843A%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DMi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DJ.%2BP.%26atitle%3DCombinatorial%2520synthesis%2520of%2520functionalized%2520chiral%2520and%2520doubly%2520chiral%2520ionic%2520liquids%2520and%2520their%2520applications%2520as%2520asymmetric%2520covalent%252Fnon-covalent%2520bifunctional%2520organocatalysts%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2008%26volume%3D6%26issue%3D3%26spage%3D567%26epage%3D576%26doi%3D10.1039%2FB713843A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.%0AA.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgozdmUYY-4ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgozdmUYY-4ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, Anna Melone, Rohitha Sriramaratnam, Florent Beaufils, Matthias Hamburger, Paul Hebeisen, Wolfgang Löscher, Doriano Fabbro, Petra Hillmann, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13595-13617. <a href="https://doi.org/10.1021/acs.jmedchem.0c00620" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00620</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00620%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-%252528Difluoromethyl%252529-5-%2525284-%252528%2525283R%25252C5S%252529-3%25252C5-dimethylmorpholino%252529-6-%252528%252528R%252529-3-methylmorpholino%252529-1%25252C3%25252C5-triazin-2-yl%252529pyridin-2-amine%252B%252528PQR626%252529%25252C%252Ba%252BPotent%25252C%252BOrally%252BAvailable%25252C%252Band%252BBrain-Penetrant%252BmTOR%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BNeurological%252BDisorders%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15042020%26date%3D09112020%26volume%3D63%26issue%3D22%26spage%3D13595%26epage%3D13617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Simone Bonazzi, Carleton P. Goold, Audrey Gray, Noel M. Thomsen, Jill Nunez, Rajeshri G. Karki, Aakruti Gorde, Jonathan D. Biag, Hasnain A. Malik, Yingchuan Sun, Guiqing Liang, Danuta Lubicka, Sarah Salas, Nancy Labbe-Giguere, Erin P. Keaney, Stephanie McTighe, Shanming Liu, Lin Deng, Grazia Piizzi, Franco Lombardo, Doug Burdette, Jean-Cosme Dodart, Christopher J. Wilson, Stefan Peukert, Daniel Curtis, Lawrence G. Hamann, <span class="NLM_string-name hlFld-ContribAuthor">Leon O. Murphy</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 1068-1083. <a href="https://doi.org/10.1021/acs.jmedchem.9b01398" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01398</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01398%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BBrain-Penetrant%252BATP-Competitive%252BInhibitor%252Bof%252Bthe%252BMechanistic%252BTarget%252Bof%252BRapamycin%252B%252528mTOR%252529%252Bfor%252BCNS%252BDisorders%26aulast%3DBonazzi%26aufirst%3DSimone%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D23082019%26date%3D31012020%26date%3D20012020%26volume%3D63%26issue%3D3%26spage%3D1068%26epage%3D1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Denise Rageot, Florent Beaufils, Chiara Borsari, Alix Dall’Asen, Markus Neuburger, Paul Hebeisen, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (11)
                                     , 2416-2424. <a href="https://doi.org/10.1021/acs.oprd.9b00312" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00312%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DScalable%25252C%252BEconomical%25252C%252Band%252BPractical%252BSynthesis%252Bof%252B4-%252528Difluoromethyl%252529pyridin-2-amine%25252C%252Ba%252BKey%252BIntermediate%252Bfor%252BLipid%252BKinase%252BInhibitors%26aulast%3DRageot%26aufirst%3DDenise%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D09072019%26date%3D10102019%26date%3D25092019%26volume%3D23%26issue%3D11%26spage%3D2416%26epage%3D2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chiara Borsari, Denise Rageot, Florent Beaufils, Thomas Bohnacker, Erhan Keles, Ivan Buslov, Anna Melone, Alexander M. Sele, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1473-1479. <a href="https://doi.org/10.1021/acsmedchemlett.9b00333" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00333</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00333%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPreclinical%252BDevelopment%252Bof%252BPQR514%25252C%252Ba%252BHighly%252BPotent%252BPI3K%252BInhibitor%252BBearing%252Ba%252BDifluoromethyl%2525E2%252580%252593Pyrimidine%252BMoiety%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22072019%26date%3D03092019%26date%3D11092019%26date%3D03092019%26volume%3D10%26issue%3D10%26spage%3D1473%26epage%3D1479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Xing-Han  Yun</span>, <span class="hlFld-ContribAuthor ">Tian-Hui  Hao</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-component cascade reaction of 3-formylchromones: highly selective synthesis of 4,5-dihydro-[4,5′-bipyrimidin]-6(1
              H
              )-one derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (62)
                                     , 7657-7660. <a href="https://doi.org/10.1039/D1CC02437J" title="DOI URL">https://doi.org/10.1039/D1CC02437J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CC02437J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CC02437J%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DMulti-component%252Bcascade%252Breaction%252Bof%252B3-formylchromones%25253A%252Bhighly%252Bselective%252Bsynthesis%252Bof%252B4%25252C5-dihydro-%25255B4%25252C5%2525E2%252580%2525B2-bipyrimidin%25255D-6%2525281%252BH%252B%252529-one%252Bderivatives%26aulast%3DChen%26aufirst%3DLi%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D62%26spage%3D7657%26epage%3D7660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical and Structural Strategies to Selectively Target mTOR Kinase. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1002/cmdc.202100332" title="DOI URL">https://doi.org/10.1002/cmdc.202100332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100332%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DChemical%252Band%252BStructural%252BStrategies%252Bto%252BSelectively%252BTarget%252BmTOR%252BKinase%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Erhan  Keles</span>, <span class="hlFld-ContribAuthor ">Andrea  Treyer</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Paul  Hebeisen</span>, <span class="hlFld-ContribAuthor ">Matthias  Hamburger</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 579-583. <a href="https://doi.org/10.1039/D0MD00408A" title="DOI URL">https://doi.org/10.1039/D0MD00408A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00408A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00408A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSecond-generation%252Btricyclic%252Bpyrimido-pyrrolo-oxazine%252BmTOR%252Binhibitor%252Bwith%252Bpredicted%252Bblood%2525E2%252580%252593brain%252Bbarrier%252Bpermeability%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D579%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajkumar Lalji  Sahani</span>, <span class="hlFld-ContribAuthor ">Raquel  Diana-Rivero</span>, <span class="hlFld-ContribAuthor ">Sanjeev Kumar V.  Vernekar</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Haijuan  Du</span>, <span class="hlFld-ContribAuthor ">Huanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Andres Emanuelli  Castaner</span>, <span class="hlFld-ContribAuthor ">Mary C.  Casey</span>, <span class="hlFld-ContribAuthor ">Karen A.  Kirby</span>, <span class="hlFld-ContribAuthor ">Philip R.  Tedbury</span>, <span class="hlFld-ContribAuthor ">Jiashu  Xie</span>, <span class="hlFld-ContribAuthor ">Stefan G.  Sarafianos</span>, <span class="hlFld-ContribAuthor ">Zhengqiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Characterization of HIV-1 CA-Targeting Small Molecules: Conformational Restriction of PF74. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (3)
                                     , 479. <a href="https://doi.org/10.3390/v13030479" title="DOI URL">https://doi.org/10.3390/v13030479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13030479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13030479%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BCharacterization%252Bof%252BHIV-1%252BCA-Targeting%252BSmall%252BMolecules%25253A%252BConformational%252BRestriction%252Bof%252BPF74%26aulast%3DSahani%26aufirst%3DRajkumar%2BLalji%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D3%26spage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. V.  Fedoseev</span>, <span class="hlFld-ContribAuthor ">O. E.  Ershov</span>. </span><span class="cited-content_cbyCitation_article-title">Reaction of 4-Halo-3-hydroxyfuro[3,4-c]pyridin-1(3H)-ones with Morpholine and Thiomorpholine. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>57 </em>
                                    (3)
                                     , 483-485. <a href="https://doi.org/10.1134/S1070428021030234" title="DOI URL">https://doi.org/10.1134/S1070428021030234</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428021030234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428021030234%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DReaction%252Bof%252B4-Halo-3-hydroxyfuro%25255B3%25252C4-c%25255Dpyridin-1%2525283H%252529-ones%252Bwith%252BMorpholine%252Band%252BThiomorpholine%26aulast%3DFedoseev%26aufirst%3DS.%2BV.%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D3%26spage%3D483%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruoyu  He</span>, <span class="hlFld-ContribAuthor ">Bingyong  Xu</span>, <span class="hlFld-ContribAuthor ">Li  Ping</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113249. <a href="https://doi.org/10.1016/j.ejmech.2021.113249" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113249%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Btowards%252Bpromising%252B%2525CE%2525B2-methyl-4-acrylamido%252Bquinoline%252Bderivatives%252Bas%252BPI3K%25252FmTOR%252Bdual%252Binhibitors%252Bfor%252Banti-cancer%252Btherapy%25253A%252BThe%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bbiological%252Bevaluation%26aulast%3DHe%26aufirst%3DRuoyu%26date%3D2021%26volume%3D214%26spage%3D113249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajibul  Islam</span>, <span class="hlFld-ContribAuthor ">Kok Wai  Lam</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112812. <a href="https://doi.org/10.1016/j.ejmech.2020.112812" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112812%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bsmall%252Bmolecule%252Bagents%252Bfor%252Bthe%252Btargeted%252Btherapy%252Bof%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DIslam%26aufirst%3DRajibul%26date%3D2020%26volume%3D207%26spage%3D112812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting-Ting  Wu</span>, <span class="hlFld-ContribAuthor ">Qing-Qing  Guo</span>, <span class="hlFld-ContribAuthor ">Zi-Li  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Li  Wang</span>, <span class="hlFld-ContribAuthor ">Yao  Du</span>, <span class="hlFld-ContribAuthor ">Rui  Chen</span>, <span class="hlFld-ContribAuthor ">Yuan-Hu  Mao</span>, <span class="hlFld-ContribAuthor ">Sheng-Gang  Yang</span>, <span class="hlFld-ContribAuthor ">Jing  Huang</span>, <span class="hlFld-ContribAuthor ">Jian-Ta  Wang</span>, <span class="hlFld-ContribAuthor ">Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Tang</span>, <span class="hlFld-ContribAuthor ">Ji-Quan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112637. <a href="https://doi.org/10.1016/j.ejmech.2020.112637" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112637%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbioevaluation%252Bof%252Bnovel%252Bsubstituted%252Btriazines%252Bas%252Bpotential%252Bdual%252BPI3K%25252FmTOR%252Binhibitors%26aulast%3DWu%26aufirst%3DTing-Ting%26date%3D2020%26volume%3D204%26spage%3D112637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cedric  Magaway</span>, <span class="hlFld-ContribAuthor ">Eugene  Kim</span>, <span class="hlFld-ContribAuthor ">Estela  Jacinto</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting mTOR and Metabolism in Cancer: Lessons and Innovations. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (12)
                                     , 1584. <a href="https://doi.org/10.3390/cells8121584" title="DOI URL">https://doi.org/10.3390/cells8121584</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8121584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8121584%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DTargeting%252BmTOR%252Band%252BMetabolism%252Bin%252BCancer%25253A%252BLessons%252Band%252BInnovations%26aulast%3DMagaway%26aufirst%3DCedric%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D12%26spage%3D1584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of rapamycin and rapalogs and a selection of ATP-competitive mTOR kinase inhibitor (TORKi) compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Strategy for the development of mTOR selective inhibitors starting from PQR309 (<b>1</b>): rigidification strategy (red dotted lines) and removal of trifluoromethyl group from the 2-aminopyridine moiety (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Docking of compound <b>3a</b> (plum) into PI3Kγ (gray) starting from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB">5JHB</a> (see ref <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>). Structural water molecules are shown in red, and water-mediated H-bonds are depicted as dashed black lines. (B) Docking of compound <b>2a</b> (gold) and (C) compound <b>2b</b> (green) into mTOR (turquoise) starting from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>. The important features for mTOR selectivity are depicted in a ball and stick representation. (D) Docking of compound <b>2a</b> (gold) and (E) compound <b>2b</b> (green) into PI3Kα (gray) starting from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZIM">3ZIM</a>. The exit vector from the restricted morpholine oxygen is shown as a black arrow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>c</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Prepared according to ref  <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>.</p><p><span class="fn-label"><sup>b</sup></span>Prepared according to procedure vii. After the reaction, the two regioisomers (<b>26</b> and <b>32</b>) were separated by column chromatography.</p><p class="last"><span class="fn-label"><sup>c</sup></span>(A) Reagents and conditions: (i) (1) benzaldehyde, 2 M NaOH, rt, 30 min; (2) NaBH<sub>4</sub>, 5 °C → rt, 1 h; (ii) (1) chloroacetyl chloride, K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 0 °C, 1 h; (2) NaOH, 5 °C, 2 h; (iii) borane–dimethyl sulfide complex, Et<sub>3</sub>N, THF, 0 °C → 65 °C, 5 h; (iv) Pd/C, H<sub>2</sub>, 2.8 bar, 48 h; (v) thionyl chloride, imidazole, DCM, −5 °C → rt → 0 °C, 2 h; (vi) ruthenium(IV) oxide hydrate, NaIO<sub>4</sub>, rt, o/n. (B) Reagents and conditions: (vii) morpholine derivative (M<sub>n</sub>–H), DIPEA, DCM, 0 °C → rt, o/n; (viii) (1) <i>n</i>-BuLi, CuI, −78 °C → rt, o/n; (2) HCl conc, MeOH, 45 °C, 4–6 h; (3) NaOH, H<sub>2</sub>O, rt, 1–16 h; (ix) (1) boronic ester <b>38</b> or <b>41</b>, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2–16 h; (2) HCl, dioxane/H<sub>2</sub>O, 60 °C, 3–16 h (for <b>2a</b>, <b>2b</b>, <b>2c</b>, <b>2d</b>, <b>6a</b>, <b>6b</b>, <b>7a</b>, <b>7b</b>, <b>8a</b>, <b>8b</b>, <b>9a</b>, <b>9b</b>, <b>10a</b>, <b>10b</b>, and <b>14b</b>); (x) 2-aminopyridine-5-boronic acid pinacol ester, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C (for <b>11b</b>), o/n; (xi) boronic ester <b>39</b>, Pd(dppf)Cl<sub>2</sub> (cat.), CsCO<sub>3</sub>, THF, Δ, o/n (for <b>12b</b>); (xii) (1) boronic ester generated in situ, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 3–3.5 h; (2) HCl, 80 °C, o/n (for <b>13b</b> and <b>15b</b>); (xiii) (1) boronic ester generated in situ, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2–16 h (isolated intermediates <b>18b</b> and <b>19b</b>); (2) <b>18b</b> or <b>19b</b>, TFA, DCM, 0 °C → rt, 1–3 h (for <b>16b</b> and <b>17b</b>).</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma and brain concentration of (A) compound <b>7b</b> and (B) compound <b>12b</b> after po dosing at 5 mg/kg in male Sprague Dawley rats. Stability of compound <b>11b</b> (5 μM) with primary hepatocytes from (C) mice (green) and rats (turquoise) and (D) dogs (red) and humans (black) (<i>n</i> = 2). All values are the mean ± SEM. Error bars are not shown when smaller than the symbols.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/medium/jm9b00972_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pie chart showing the percentage of compound <b>11b</b> and its metabolites after 60 min of incubation with human recombinant (A) CYP1A1 and (B) CYP1A2. (C) Major metabolites observed upon incubation of <b>11b</b> with CYP1A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00972/20190920/images/large/jm9b00972_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00972&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63743" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63743" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneiter, R.</span></span> <span> </span><span class="NLM_article-title">Lipid signalling in disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nrm2335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnrm2335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18216772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=162-176&issue=2&author=M.+P.+Wymannauthor=R.+Schneiter&title=Lipid+signalling+in+disease&doi=10.1038%2Fnrm2335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid signalling in disease</span></div><div class="casAuthors">Wymann, Matthias P.; Schneiter, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-176</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling lipids such as eicosanoids, phosphoinositides, sphingolipids and fatty acids control important cellular processes, including cell proliferation, apoptosis, metab. and migration.  Extracellular signals from cytokines, growth factors and nutrients control the activity of a key set of lipid-modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase.  These enzymes and their downstream targets constitute a complex lipid signaling network with multiple nodes of interaction and cross-regulation.  Imbalances in this network contribute to the pathogenesis of human disease.  Although the function of a particular signaling lipid is traditionally studied in isolation, this review attempts a more integrated overview of the key role of these signaling lipids in inflammation, cancer and metabolic disease, and discusses emerging strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYZ1NX2T9QbVg90H21EOLACvtfcHk0lhdx6w0lPqHHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D&md5=c96aabfdfa8e93c9e98386f1a407de85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2335%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DSchneiter%26aufirst%3DR.%26atitle%3DLipid%2520signalling%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26issue%3D2%26spage%3D162%26epage%3D176%26doi%3D10.1038%2Fnrm2335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidialingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">mTOR kinase structure, mechanism and regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>497</i></span> (<span class="NLM_issue">7448</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nature12122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnature12122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=23636326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=2013&pages=217-223&issue=7448&author=H.+Yangauthor=D.+G.+Rudgeauthor=J.+D.+Koosauthor=B.+Vaidialingamauthor=H.+J.+Yangauthor=N.+P.+Pavletich&title=mTOR+kinase+structure%2C+mechanism+and+regulation&doi=10.1038%2Fnature12122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR kinase structure, mechanism and regulation</span></div><div class="casAuthors">Yang, Haijuan; Rudge, Derek G.; Koos, Joseph D.; Vaidialingam, Bhamini; Yang, Hyo J.; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">7448</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.  Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic (MgF3-) and with ATP-site inhibitors (Torin2, PP242, and PI-103).  The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases.  The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft.  MTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access.  In vitro biochem. shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site.  Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access.  The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjvPQtdm6yCbVg90H21EOLACvtfcHk0lhdx6w0lPqHHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D&md5=07809555fbdf2004819a7f2da5727baf</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature12122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12122%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRudge%26aufirst%3DD.%2BG.%26aulast%3DKoos%26aufirst%3DJ.%2BD.%26aulast%3DVaidialingam%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DmTOR%2520kinase%2520structure%252C%2520mechanism%2520and%2520regulation%26jtitle%3DNature%26date%3D2013%26volume%3D497%26issue%3D7448%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fnature12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span> (<span class="NLM_issue">5712</span>),  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&issue=5712&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lhdx6w0lPqHHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26issue%3D5712%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">41189</span>– <span class="NLM_lpage">41196</span>, <span class="refDoi"> DOI: 10.1074/jbc.M406731200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1074%2Fjbc.M406731200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15262962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnslWms70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=41189-41196&issue=39&author=J.+Fengauthor=J.+Parkauthor=P.+Cronauthor=D.+Hessauthor=B.+A.+Hemmings&title=Identification+of+a+PKB%2FAkt+hydrophobic+motif+Ser-473+kinase+as+DNA-dependent+protein+kinase&doi=10.1074%2Fjbc.M406731200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase</span></div><div class="casAuthors">Feng, Jianhua; Park, Jongsun; Cron, Peter; Hess, Daniel; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">41189-41196</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Full activation of protein kinase B (PKB)/Akt requires phosphorylation on Thr-308 and Ser-473 by 3-phosphoinositide-dependent kinase-1 (PDK1) and Ser-473 kinase (S473K), resp.  Although PDK1 has been well characterized, the identification of the S473K remains controversial.  A major PKB Ser-473 kinase activity was purified from the membrane fraction of HEK293 cells and found to be DNA-dependent protein kinase (DNA-PK).  DNA-PK co-localized and assocd. with PKB at the plasma membrane.  In vitro, DNA-PK phosphorylated PKB on Ser-473, resulting in a ∼10-fold enhancement of PKB activity.  Knockdown of DNA-PK by small interfering RNA inhibited Ser-473 phosphorylation induced by insulin and pervanadate.  DNA-PK-deficient glioblastoma cells did not respond to insulin at the level of Ser-473 phosphorylation; this effect was restored by complementation with the human PRKDC gene.  We conclude that DNA-PK is a long sought after kinase responsible for the Ser-473 phosphorylation step in the activation of PKB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoem_keSTepy7Vg90H21EOLACvtfcHk0ljMwfFMZQngEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnslWms70%253D&md5=b6bad6828d91d47e2b36f537ca6d5f85</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M406731200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M406731200%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DCron%26aufirst%3DP.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DIdentification%2520of%2520a%2520PKB%252FAkt%2520hydrophobic%2520motif%2520Ser-473%2520kinase%2520as%2520DNA-dependent%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D39%26spage%3D41189%26epage%3D41196%26doi%3D10.1074%2Fjbc.M406731200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase in disease: timing, location, and scaffolding</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2005.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.ceb.2005.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15780590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVCqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=141-149&issue=2&author=M.+P.+Wymannauthor=R.+Marone&title=Phosphoinositide+3-kinase+in+disease%3A+timing%2C+location%2C+and+scaffolding&doi=10.1016%2Fj.ceb.2005.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase in disease: timing, location, and scaffolding</span></div><div class="casAuthors">Wymann, Matthias P.; Marone, Romina</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  When PI3Ks are deregulated by aberrant surface receptors or modulators, accumulation of PtdIns(3,4,5)P3 leads to increased cell growth, proliferation and contact-independent survival.  The PI3K/PKB/TOR axis controls protein synthesis and growth, while PtdIns(3,4,5)P3-mediated activation of Rho GTPases directs cell motility.  PI3K activity has been linked to the formation of tumors, metastasis, chronic inflammation, allergy and cardiovascular disease.  Although increased PtdIns(3,4,5)P3 is a well-established cause of disease, it is seldom known which PI3K isoform is implied.  Recent work has demonstrated that PI3Kγ contributes to the control of cAMP levels in the cardiac system, where the protein acts as a scaffold, but not as a lipid kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhcm4IPHLzd7Vg90H21EOLACvtfcHk0ljMwfFMZQngEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVCqtb4%253D&md5=d126dfae131b86e73e8842ec9149fd01</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2005.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2005.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DMarone%26aufirst%3DR.%26atitle%3DPhosphoinositide%25203-kinase%2520in%2520disease%253A%2520timing%252C%2520location%252C%2520and%2520scaffolding%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2005%26volume%3D17%26issue%3D2%26spage%3D141%26epage%3D149%26doi%3D10.1016%2Fj.ceb.2005.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bozulic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">PIKKing on PKB: regulation of PKB activity by phosphorylation</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2009.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.ceb.2009.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=19303758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVClu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=256-261&issue=2&author=L.+Bozulicauthor=B.+A.+Hemmings&title=PIKKing+on+PKB%3A+regulation+of+PKB+activity+by+phosphorylation&doi=10.1016%2Fj.ceb.2009.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">PIKKing on PKB: regulation of PKB activity by phosphorylation</span></div><div class="casAuthors">Bozulic, Lana; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-261</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinase B (PKB)/Akt kinase is a key regulator of a wide range of cellular processes including growth, proliferation and survival.  PKB is clearly a crucial signaling mol. and extensive research efforts aim to understand its regulation and action.  Recent studies of the regulation of PKB activity by hydrophobic motif phosphorylation have yielded several exciting findings about members of the phosphatidylinositol 3-kinase (PI3K)-like family of kinases (PIKKs) acting as PKB regulators.  Mammalian target of rapamycin complex 2 (mTORC2) and DNA-dependent protein kinase (DNA-PK) can both phosphorylate Ser-473 and activate PKB.  This review concerns PKB regulation by mTORC2 and DNA-PK in a stimulus-dependent and context-dependent manner and the possible implications of this for PKB activity, substrate specificity, and therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgDTdYbqJWtLVg90H21EOLACvtfcHk0ljMwfFMZQngEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVClu7Y%253D&md5=0b7a3e6ea561f8479701a01133b5d30c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DBozulic%26aufirst%3DL.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DPIKKing%2520on%2520PKB%253A%2520regulation%2520of%2520PKB%2520activity%2520by%2520phosphorylation%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26issue%3D2%26spage%3D256%26epage%3D261%26doi%3D10.1016%2Fj.ceb.2009.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingar, D. C.</span></span> <span> </span><span class="NLM_article-title">Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>441</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1042/BJ20110892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1042%2FBJ20110892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=22168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2012&pages=1-21&issue=1&author=B.+Magnusonauthor=B.+Ekimauthor=D.+C.+Fingar&title=Regulation+and+function+of+ribosomal+protein+S6+kinase+%28S6K%29+within+mTOR+signalling+networks&doi=10.1042%2FBJ20110892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks</span></div><div class="casAuthors">Magnuson, Brian; Ekim, Bilgen; Fingar, Diane C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">441</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The ribosomal protein S6K (S6 kinase) represents an extensively studied effector of the TORC1 [TOR (target of rapamycin) complex 1], which possesses important yet incompletely defined roles in cellular and organismal physiol.  TORC1 functions as an environmental sensor by integrating signals derived from diverse environmental cues to promote anabolic and inhibit catabolic cellular functions. mTORC1 (mammalian TORC1) phosphorylates and activates S6K1 and S6K2, whose first identified substrate was rpS6 (ribosomal protein S6), a component of the 40S ribosome.  Studies over the past decade have uncovered a no. of addnl. S6K1 substrates, revealing multiple levels at which the mTORC1-S6K1 axis regulates cell physiol.  The results thus far indicate that the mTORC1-S6K1 axis controls fundamental cellular processes, including transcription, translation, protein and lipid synthesis, cell growth/size and cell metab.  In the present review we summarize the regulation of S6Ks, their cellular substrates and functions, and their integration within rapidly expanding mTOR (mammalian TOR) signalling networks.  Although our understanding of the role of mTORC1-S6K1 signalling in physiol. remains in its infancy, evidence indicates that this signalling axis controls, at least in part, glucose homeostasis, insulin sensitivity, adipocyte metab., body mass and energy balance, tissue and organ size, learning, memory and aging.  As dysregulation of this signalling axis contributes to diverse disease states, improved understanding of S6K regulation and function within mTOR signalling networks may enable the development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAHhGhhxqDTbVg90H21EOLACvtfcHk0lh1T4v2khV_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7jK&md5=5d69e3be00deef02d3fce1ed2716873d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1042%2FBJ20110892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110892%26sid%3Dliteratum%253Aachs%26aulast%3DMagnuson%26aufirst%3DB.%26aulast%3DEkim%26aufirst%3DB.%26aulast%3DFingar%26aufirst%3DD.%2BC.%26atitle%3DRegulation%2520and%2520function%2520of%2520ribosomal%2520protein%2520S6%2520kinase%2520%2528S6K%2529%2520within%2520mTOR%2520signalling%2520networks%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D441%26issue%3D1%26spage%3D1%26epage%3D21%26doi%3D10.1042%2FBJ20110892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth control and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.cell.2012.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=22500797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=274-293&issue=2&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth+control+and+disease&doi=10.1016%2Fj.cell.2012.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth control and disease</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-293</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis.  The pathway regulates many major cellular processes and is implicated in an increasing no. of pathol. conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.  Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging.  We further discuss pharmacol. approaches to treat human pathologies linked to mTOR deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjbKBX-sScfrVg90H21EOLACvtfcHk0lh1T4v2khV_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D&md5=d1adac8ec64da63358e0af26a17ceb4e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%2520control%2520and%2520disease%26jtitle%3DCell%26date%3D2012%26volume%3D149%26issue%3D2%26spage%3D274%26epage%3D293%26doi%3D10.1016%2Fj.cell.2012.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth, metabolism, and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.cell.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=28283069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=960-976&issue=6&author=R.+A.+Saxtonauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth%2C+metabolism%2C+and+disease&doi=10.1016%2Fj.cell.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth, metabolism, and disease</span></div><div class="casAuthors">Saxton, Robert A.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">960-976</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) coordinates eukaryotic cell growth and metab. with environmental inputs, including nutrients and growth factors.  Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated in the progression of cancer and diabetes, as well as the aging process.  Here, we review recent advances in our understanding of mTOR function, regulation, and importance in mammalian physiol.  We also highlight how the mTOR signaling network contributes to human disease and discuss the current and future prospects for therapeutically targeting mTOR in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvk5jg6e_MrVg90H21EOLACvtfcHk0lh1T4v2khV_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D&md5=3fdee3d04bf88d3aafc532d4e2f1e2dc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DSaxton%26aufirst%3DR.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%252C%2520metabolism%252C%2520and%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D168%26issue%3D6%26spage%3D960%26epage%3D976%26doi%3D10.1016%2Fj.cell.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivanco, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">The phosphatidylinositol 3-kinase AKT pathway in human cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1038/nrc839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&issue=7&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+phosphatidylinositol+3-kinase+AKT+pathway+in+human+cancer&doi=10.1038%2Fnrc839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lh1T4v2khV_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520phosphatidylinositol%25203-kinase%2520AKT%2520pathway%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26issue%3D7%26spage%3D489%26epage%3D501%26doi%3D10.1038%2Fnrc839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Targeting phosphoinositide 3-kinase: moving towards therapy</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1784</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2007.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.bbapap.2007.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=17997386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1784&publication_year=2008&pages=159-185&issue=1&author=R.+Maroneauthor=V.+Cmiljanovicauthor=B.+Gieseauthor=M.+P.+Wymann&title=Targeting+phosphoinositide+3-kinase%3A+moving+towards+therapy&doi=10.1016%2Fj.bbapap.2007.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase-Moving towards therapy</span></div><div class="casAuthors">Marone, Romina; Cmiljanovic, Vladimir; Giese, Bernd; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1784</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">159-185</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3K) orchestrate cell responses including mitogenic signaling, cell survival and growth, metabolic control, vesicular trafficking, degranulation, cytoskeletal rearrangement and migration.  Deregulation of the PI3K pathway occurs by activating mutations in growth factor receptors or the PIK3CA locus coding for PI3Kα, by loss of function of the lipid phosphatase and tensin homolog deleted in chromosome ten (PTEN/MMAC/TEP1), by the up-regulation of protein kinase B (PKB/Akt), or the impairment of the tuberous sclerosis complex (TSC1/2).  All these events are linked to growth and proliferation, and have thus prompted a significant interest in the pharmaceutical targeting of the PI3K pathway in cancer.  Genetic targeting of PI3Kγ (p110γ) and PI3Kδ (p110δ) in mice has underlined a central role of these PI3K isoforms in inflammation and allergy, as they modulate chemotaxis of leukocytes and degranulation in mast cells.  Proof-of-concept mols. selective for PI3Kγ have already successfully alleviated disease progress in murine models of rheumatoid arthritis and lupus erythematosus.  As targeting PI3K moves forward to therapy of chronic, non-fatal disease, safety concerns for PI3K inhibitors increase.  Many of the present inhibitor series interfere with target of rapamycin (TOR), DNA-dependent protein kinase (DNA-PKcs) and activity of the ataxia telangiectasia mutated gene product (ATM).  Here we review the current disease-relevant knowledge for isoform-specific PI3K function in the above mentioned diseases, and review the progress of > 400 recent patents covering pharmaceutical targeting of PI3K.  Currently, several drugs targeting the PI3K pathway have entered clin. trials (phase I) for solid tumors and suppression of tissue damage after myocardial infarction (phases I,II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwrI_aSA632bVg90H21EOLACvtfcHk0ljRprDbwwp2fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D&md5=bf9f259b3da61067631823656658e0f7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2007.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2007.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520phosphoinositide%25203-kinase%253A%2520moving%2520towards%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2008%26volume%3D1784%26issue%3D1%26spage%3D159%26epage%3D185%26doi%3D10.1016%2Fj.bbapap.2007.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M.</span></span> <span> </span><span class="NLM_article-title">PI3Ks—Drug Targets in Inflammation and Cancer</span>. In  <i>Phosphoinositides I: Enzymes of Synthesis and Degradation</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, T.</span>, <span class="NLM_string-name">Wymann, M.</span>, <span class="NLM_string-name">York, J.
D.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Dordrecht, The Netherlands</span>, <span class="NLM_year">2012</span>; pp  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">181</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1007%2F978-94-007-3012-0_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=111-181&author=M.+Wymannauthor=T.+Balla&author=M.+Wymann&author=J.%0AD.+York&title=Phosphoinositides+I%3A+Enzymes+of+Synthesis+and+Degradation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2F978-94-007-3012-0_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-94-007-3012-0_5%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%26atitle%3DPI3Ks%25E2%2580%2594Drug%2520Targets%2520in%2520Inflammation%2520and%2520Cancer%26btitle%3DPhosphoinositides%2520I%253A%2520Enzymes%2520of%2520Synthesis%2520and%2520Degradation%26aulast%3DBalla%26aufirst%3DT.%26pub%3DSpringer%26date%3D2012%26spage%3D111%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the FKBP1 2-rapamycin complex interacting with the binding domain of human FRAP</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span> (<span class="NLM_issue">5272</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1126/science.273.5272.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&issue=5272&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP1+2-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP&doi=10.1126%2Fscience.273.5272.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0ljRprDbwwp2fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP1%25202-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26issue%3D5272%26spage%3D239%26epage%3D242%26doi%3D10.1126%2Fscience.273.5272.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutcher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staroslawska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodrogi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacevic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesovoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Wolf, I. G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbarash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokmen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Toole, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustgarten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span> <span> </span><span class="NLM_article-title">Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2271</span>– <span class="NLM_lpage">2281</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa066838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1056%2FNEJMoa066838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=17538086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVKkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2271-2281&issue=22&author=G.+Hudesauthor=M.+Carducciauthor=P.+Tomczakauthor=J.+Dutcherauthor=R.+Figlinauthor=A.+Kapoorauthor=E.+Staroslawskaauthor=J.+Sosmanauthor=D.+McDermottauthor=I.+Bodrogiauthor=Z.+Kovacevicauthor=V.+Lesovoyauthor=I.+G.+H.+Schmidt-Wolfauthor=O.+Barbarashauthor=E.+Gokmenauthor=T.+O%E2%80%99Tooleauthor=S.+Lustgartenauthor=L.+Mooreauthor=R.+J.+Motzer&title=Temsirolimus%2C+interferon+alfa%2C+or+both+for+advanced+renal-cell+carcinoma&doi=10.1056%2FNEJMoa066838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma</span></div><div class="casAuthors">Hudes, Gary; Carducci, Michael; Tomczak, Piotr; Dutcher, Janice; Figlin, Robert; Kapoor, Anil; Staroslawska, Elzbieta; Sosman, Jeffrey; McDermott, David; Bodrogi, Istvan; Kovacevic, Zoran; Lesovoy, Vladimir; Schmidt-Wolf, Ingo G. H.; Barbarash, Olga; Gokmen, Erhan; O'Toole, Timothy; Lustgarten, Stephanie; Moore, Laurence; Motzer, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2271-2281</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability.  Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.  In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of i.v. temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) s.c. three times weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa three times weekly.  The primary end point was overall survival in comparisons of the temsirolimus group and the combination-therapy group with the interferon group.  RESULTS Patients who received temsirolimus alone had longer overall survival (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P = 0.008) and progression-free survival (P < 0.001) than did patients who received interferon alone.  Overall survival in the combination-therapy group did not differ significantly from that in the interferon group (hazard ratio, 0.96; 95% CI, 0.76 to 1.20; P = 0.70).  Median overall survival times in the interferon group, the temsirolimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 mo, resp.  Rash, peripheral edema, hyperglycemia, and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in the interferon group.  There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P = 0.02).  As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis.  The addn. of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov no., NCT00065468.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkvpThNoniLVg90H21EOLACvtfcHk0lgYS1EWnVEkfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVKkurs%253D&md5=2fc7685df067fd6ea813483610e89dc8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa066838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa066838%26sid%3Dliteratum%253Aachs%26aulast%3DHudes%26aufirst%3DG.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DTomczak%26aufirst%3DP.%26aulast%3DDutcher%26aufirst%3DJ.%26aulast%3DFiglin%26aufirst%3DR.%26aulast%3DKapoor%26aufirst%3DA.%26aulast%3DStaroslawska%26aufirst%3DE.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DMcDermott%26aufirst%3DD.%26aulast%3DBodrogi%26aufirst%3DI.%26aulast%3DKovacevic%26aufirst%3DZ.%26aulast%3DLesovoy%26aufirst%3DV.%26aulast%3DSchmidt-Wolf%26aufirst%3DI.%2BG.%2BH.%26aulast%3DBarbarash%26aufirst%3DO.%26aulast%3DGokmen%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DT.%26aulast%3DLustgarten%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DL.%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26atitle%3DTemsirolimus%252C%2520interferon%2520alfa%252C%2520or%2520both%2520for%2520advanced%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26issue%3D22%26spage%3D2271%26epage%3D2281%26doi%3D10.1056%2FNEJMoa066838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünwald, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollaender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanowitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravaud, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">9637</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)61039-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2FS0140-6736%2808%2961039-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18653228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1GmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=449-456&issue=9637&author=R.+J.+Motzerauthor=B.+Escudierauthor=S.+Oudardauthor=T.+E.+Hutsonauthor=C.+Portaauthor=S.+Bracardaauthor=V.+Gr%C3%BCnwaldauthor=J.+A.+Thompsonauthor=R.+A.+Figlinauthor=N.+Hollaenderauthor=G.+Urbanowitzauthor=W.+J.+Bergauthor=A.+Kayauthor=D.+Lebwohlauthor=A.+Ravaud&title=Efficacy+of+everolimus+in+advanced+renal+cell+carcinoma%3A+a+double-blind%2C+randomised%2C+placebo-controlled+phase+III+trial&doi=10.1016%2FS0140-6736%2808%2961039-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial</span></div><div class="casAuthors">Motzer, Robert J.; Escudier, Bernard; Oudard, Stephane; Hutson, Thomas E.; Porta, Camillo; Bracarda, Sergio; Gruenwald, Viktor; Thompson, John A.; Figlin, Robert A.; Hollaender, Norbert; Urbanowitz, Gladys; Berg, William J.; Kay, Andrea; Lebwohl, David; Ravaud, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">9637</span>),
    <span class="NLM_cas:pages">449-456</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma.  We did a phase III, randomized, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy.  Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both, were randomly assigned in a two to one ratio to receive everolimus 10 mg once daily (n=272) or placebo (n=138), in conjunction with best supportive care.  Randomisation was done centrally via an interactive voice response system using a validated computer system, and was stratified by Memorial Sloan-Kettering Cancer Center prognostic score and previous anticancer therapy, with a permuted block size of six.  The primary endpoint was progression-free survival, assessed via a blinded, independent central review.  The study was designed to be terminated after 290 events of progression.  Anal. was by intention to treat.  This study is registered with, no.  All randomized patients were included in efficacy analyses.  The results of the second interim anal. indicated a significant difference in efficacy between arms and the trial was thus halted early after 191 progression events had been obsd. (101 [37%] events in the everolimus group, 90 [65%] in the placebo group; hazard ratio 0.30, 95% CI 0.22-0.40, p<0.0001; median progression-free survival 4.0 [95% CI 3.7-5.5] vs 1.9 [1.8-1.9] months).  Stomatitis (107 [40%] patients in the everolimus group vs 11 [8%] in the placebo group), rash (66 [25%] vs six [4%]), and fatigue (53 [20%] vs 22 [16%]) were the most commonly reported adverse events, but were mostly mild or moderate in severity.  Pneumonitis (any grade) was detected in 22 (8%) patients in the everolimus group, of whom eight had pneumonitis of grade 3 severity.  Treatment with everolimus prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma that had progressed on other targeted therapies.  Novartis Oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyYj10av0L97Vg90H21EOLACvtfcHk0lgYS1EWnVEkfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1GmsLY%253D&md5=cbfa5d207cfab693b3bccd24963380f0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961039-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961039-9%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBracarda%26aufirst%3DS.%26aulast%3DGr%25C3%25BCnwald%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DHollaender%26aufirst%3DN.%26aulast%3DUrbanowitz%26aufirst%3DG.%26aulast%3DBerg%26aufirst%3DW.%2BJ.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DRavaud%26aufirst%3DA.%26atitle%3DEfficacy%2520of%2520everolimus%2520in%2520advanced%2520renal%2520cell%2520carcinoma%253A%2520a%2520double-blind%252C%2520randomised%252C%2520placebo-controlled%2520phase%2520III%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26issue%3D9637%26spage%3D449%26epage%3D456%26doi%3D10.1016%2FS0140-6736%2808%2961039-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorive, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collignon, J.</span></span> <span> </span><span class="NLM_article-title">Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes</span>. <i>Breast Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.2147/BCTT.S38679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.2147%2FBCTT.S38679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=43-57&author=G.+Jerusalemauthor=A.+Roriveauthor=J.+Collignon&title=Use+of+mTOR+inhibitors+in+the+treatment+of+breast+cancer%3A+an+evaluation+of+factors+that+influence+patient+outcomes&doi=10.2147%2FBCTT.S38679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes</span></div><div class="casAuthors">Jerusalem, Guy; Rorive, Andree; Collignon, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-57, 15</span>CODEN:
                <span class="NLM_cas:coden">BCTTA9</span>;
        ISSN:<span class="NLM_cas:issn">1179-1314</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents.  Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an aromatase inhibitor, has been approved in Europe and the USA for patients suffering from estrogen receptor-pos., HER2-neg. advanced breast cancer previously treated by a nonsteroidal aromatase inhibitor, based on the results of BOLERO-2 (Breast cancer trials of OraL EveROlimus).  This study showed a statistically significant and clin. meaningful improvement in median progression-free survival.  Results concerning the impact on overall survival are expected in the near future.  This clin. oriented review focuses on the use of mTOR inhibitors in breast cancer.  Results reported with first-generation mTOR inhibitors (ridaforolimus, temsirolimus, everolimus) are discussed.  The current and potential role of mTOR inhibitors is reported according to breast cancer subtype (estrogen receptor-pos. HER2-neg., triple-neg., and HER2-pos. ER-pos./neg. disease).  Everolimus is currently being evaluated in the adjuvant setting in high-risk estrogen receptor-pos., HER2-neg. early breast cancer.  Continuing mTOR inhibition or alternatively administering other drugs targeting the phosphatidylinositol-3-kinase/protein kinase B-mTOR pathway after progression on treatments including an mTOR inhibitor is under evaluation.  Potential biomarkers to select patients showing a more pronounced benefit are reviewed, but we are not currently using these biomarkers in routine practice.  Subgroup anal. of BOLERO 2 has shown that the benefit is consistent in all subgroups and that it is impossible to select patients not benefiting from addn. of everolimus to exemestane.  Side effects and impact on quality of life are other important issues discussed in this review.  Second-generation mTOR inhibitors and dual mTOR-phosphatidylinositol-3-kinase inhibitors are currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXjFYIcn4ct7Vg90H21EOLACvtfcHk0ljoAtwyTJbxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gsrjE&md5=9a12c70c7c917baa41d282bc135b12af</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2147%2FBCTT.S38679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBCTT.S38679%26sid%3Dliteratum%253Aachs%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DRorive%26aufirst%3DA.%26aulast%3DCollignon%26aufirst%3DJ.%26atitle%3DUse%2520of%2520mTOR%2520inhibitors%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%253A%2520an%2520evaluation%2520of%2520factors%2520that%2520influence%2520patient%2520outcomes%26jtitle%3DBreast%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D43%26epage%3D57%26doi%3D10.2147%2FBCTT.S38679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Regan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozguroglu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerzo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, L.</span></span> <span> </span><span class="NLM_article-title">Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(14)70138-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2FS1470-2045%2814%2970138-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=24742739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlWnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=580-591&issue=6&author=F.+Andr%C3%A9author=R.+O%E2%80%99Reganauthor=M.+Ozgurogluauthor=M.+Toiauthor=B.+Xuauthor=G.+Jerusalemauthor=N.+Masudaauthor=S.+Wilksauthor=F.+Arenaauthor=C.+Isaacsauthor=Y.-S.+Yapauthor=Z.+Papaiauthor=I.+Langauthor=A.+Armstrongauthor=G.+Lerzoauthor=M.+Whiteauthor=K.+Shenauthor=J.+Littonauthor=D.+Chenauthor=Y.+Zhangauthor=S.+Aliauthor=T.+Taranauthor=L.+Gianni&title=Everolimus+for+women+with+trastuzumab-resistant%2C+HER2-positive%2C+advanced+breast+cancer+%28BOLERO-3%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+phase+3+trial&doi=10.1016%2FS1470-2045%2814%2970138-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial</span></div><div class="casAuthors">Andre, Fabrice; O'Regan, Ruth; Ozguroglu, Mustafa; Toi, Masakazu; Xu, Binghe; Jerusalem, Guy; Masuda, Norikazu; Wilks, Sharon; Arena, Francis; Isaacs, Claudine; Yap, Yoon-Sim; Papai, Zsuzsanna; Lang, Istvan; Armstrong, Anne; Lerzo, Guillermo; White, Michelle; Shen, Kunwei; Litton, Jennifer; Chen, David; Zhang, Yufen; Ali, Shyanne; Taran, Tetiana; Gianni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">580-591</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Disease progression in patients with HER2-pos. breast cancer receiving trastuzumab might be assocd. with activation of the PI3K/Akt/mTOR intracellular signalling pathway.  We aimed to assess whether the addn. of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.  In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited women with HER2-pos., trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy.  Eligible patients were randomly assigned (1:1) using a central patient screening and randomization system to daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m2) or to placebo plus trastuzumab plus vinorelbine, in 3-wk cycles, stratified by previous lapatinib use.  The primary endpoint was progression-free survival (PFS) by local assessment in the intention-to-treat population.  We report the final anal. for PFS; overall survival follow-up is still in progress.  This trial is registered with ClinicalTrials.gov, no. NCT01007942.Between Oct 26, 2009, and May 23, 2012, 569 patients were randomly assigned to everolimus (n=284) or placebo (n=285).  Median follow-up at the time of anal. was 20·2 mo (IQR 15·0-27·1).  Median PFS was 7·00 mo (95% CI 6·74-8·18) with everolimus and 5·78 mo (5·49-6·90) with placebo (hazard ratio 0·78 [95% CI 0·65-0·95]; p=0·0067).  The most common grade 3-4 adverse events were neutropenia (204 [73%] of 280 patients in the everolimus group vs 175 [62%] of 282 patients in the placebo group), leucopenia (106 [38%] vs 82 [29%]), anemia (53 [19%] vs 17 [6%]), febrile neutropenia (44 [16%] vs ten [4%]), stomatitis (37 [13%] vs four [1%]), and fatigue (34 [12%] vs 11 [4%]).  Serious adverse events were reported in 117 (42%) patients in the everolimus group and 55 (20%) in the placebo group; two on-treatment deaths due to adverse events occurred in each group.  The addn. of everolimus to trastuzumab plus vinorelbine significantly prolongs PFS in patients with trastuzumab-resistant and taxane-pretreated, HER2-pos., advanced breast cancer.  The clin. benefit should be considered in the context of the adverse event profile in this population.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Bm76N8uISbVg90H21EOLACvtfcHk0ljoAtwyTJbxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlWnsr4%253D&md5=cfbb16368227cc80463ef26c2593b69d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970138-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970138-X%26sid%3Dliteratum%253Aachs%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DR.%26aulast%3DOzguroglu%26aufirst%3DM.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DWilks%26aufirst%3DS.%26aulast%3DArena%26aufirst%3DF.%26aulast%3DIsaacs%26aufirst%3DC.%26aulast%3DYap%26aufirst%3DY.-S.%26aulast%3DPapai%26aufirst%3DZ.%26aulast%3DLang%26aufirst%3DI.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DLerzo%26aufirst%3DG.%26aulast%3DWhite%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DTaran%26aufirst%3DT.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DEverolimus%2520for%2520women%2520with%2520trastuzumab-resistant%252C%2520HER2-positive%252C%2520advanced%2520breast%2520cancer%2520%2528BOLERO-3%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26issue%3D6%26spage%3D580%26epage%3D591%26doi%3D10.1016%2FS1470-2045%2814%2970138-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. E.</span></span> <span> </span><span class="NLM_article-title">Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial</span>. <i>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2341</span>– <span class="NLM_lpage">2349</span>, <span class="refDoi"> DOI: 10.1007/s00520-013-1826-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1007%2Fs00520-013-1826-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=23686401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A280%3ADC%252BC3snkvVKksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2341-2349&issue=8&author=M.+E.+Peterson&title=Management+of+adverse+events+in+patients+with+hormone+receptor-positive+breast+cancer+treated+with+everolimus%3A+observations+from+a+phase+III+clinical+trial&doi=10.1007%2Fs00520-013-1826-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial</span></div><div class="casAuthors">Peterson Mary E</div><div class="citationInfo"><span class="NLM_cas:title">Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2341-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive HER2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole.  Results from the phase III BOLERO-2 trial demonstrated that everolimus in combination with exemestane provided significant clinical benefit to patients with advanced hormone receptor-positive breast cancer.  Although everolimus is generally well tolerated, as with most therapies administered in an advanced cancer setting, drug-related adverse events (AEs) inevitably occur.  Most common AEs observed in the everolimus studies include stomatitis, rash, infection, noninfectious pneumonitis, and hyperglycemia.  Clinical awareness and early identification of such AEs by oncology nurses are essential to dosing (interruptions, reduction, and treatment discontinuation); quality of life; and, ultimately, patient outcomes.  Because everolimus has already been shown to significantly improve clinical efficacy in patients with advanced breast cancer, a proactive approach to the practical management of AEs associated with this mTOR inhibitor as well as other most common AEs observed in this patient population has been reviewed and outlined here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWnMo5wnFbuA5nADWVYHg1fW6udTcc2eaZPugNy-W5Yrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snkvVKksw%253D%253D&md5=21bfc1094be58365540d6fe494138198</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00520-013-1826-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00520-013-1826-3%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DM.%2BE.%26atitle%3DManagement%2520of%2520adverse%2520events%2520in%2520patients%2520with%2520hormone%2520receptor-positive%2520breast%2520cancer%2520treated%2520with%2520everolimus%253A%2520observations%2520from%2520a%2520phase%2520III%2520clinical%2520trial%26jtitle%3DSupportive%2520care%2520in%2520cancer%253A%2520official%2520journal%2520of%2520the%2520Multinational%2520Association%2520of%2520Supportive%2520Care%2520in%2520Cancer%26date%3D2013%26volume%3D21%26issue%3D8%26spage%3D2341%26epage%3D2349%26doi%3D10.1007%2Fs00520-013-1826-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totary-Jain, H.</span></span> <span> </span><span class="NLM_article-title">Tailoring mTOR-based therapy: molecular evidence and clinical challenges</span>. <i>Pharmacogenomics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1517</span>– <span class="NLM_lpage">1526</span>, <span class="refDoi"> DOI: 10.2217/pgs.13.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.2217%2Fpgs.13.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=24024901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWrurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1517-1526&issue=12&author=G.+Santulliauthor=H.+Totary-Jain&title=Tailoring+mTOR-based+therapy%3A+molecular+evidence+and+clinical+challenges&doi=10.2217%2Fpgs.13.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tailoring mTOR-based therapy: molecular evidence and clinical challenges</span></div><div class="casAuthors">Santulli, Gaetano; Totary-Jain, Hana</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1517-1526</span>CODEN:
                <span class="NLM_cas:coden">PARMFL</span>;
        ISSN:<span class="NLM_cas:issn">1462-2416</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The mTOR signaling pathway integrates inputs from a variety of upstream stimuli to regulate diverse cellular processes including proliferation, growth, survival, motility, autophagy, protein synthesis and metab.  The mTOR pathway is dysregulated in a no. of human pathologies including cancer, diabetes, obesity, autoimmune disorders, neurol. disease and aging.  Ongoing clin. trials testing mTOR-targeted treatments no. in the hundreds and underscore its therapeutic potential.  To date mTOR inhibitors are clin. approved to prevent organ rejection, to inhibit restenosis after angioplasty, and to treat several advanced cancers.  In this review we discuss the continuously evolving field of mTOR pharmacogenomics, as well as highlight the emerging efforts in identifying diagnostic and prognostic markers, including miRNAs, in order to assess successful therapeutic responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqrLZCgBBxXrVg90H21EOLACvtfcHk0lgRHMpksemJ9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWrurrN&md5=0a3798fb659843d231910151b2f148ed</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2217%2Fpgs.13.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fpgs.13.143%26sid%3Dliteratum%253Aachs%26aulast%3DSantulli%26aufirst%3DG.%26aulast%3DTotary-Jain%26aufirst%3DH.%26atitle%3DTailoring%2520mTOR-based%2520therapy%253A%2520molecular%2520evidence%2520and%2520clinical%2520challenges%26jtitle%3DPharmacogenomics%26date%3D2013%26volume%3D14%26issue%3D12%26spage%3D1517%26epage%3D1526%26doi%3D10.2217%2Fpgs.13.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. F.</span></span> <span> </span><span class="NLM_article-title">Toward rapamycin analog (rapalog)-based precision cancer therapy</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1169</span>, <span class="refDoi"> DOI: 10.1038/aps.2015.68</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Faps.2015.68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=26299952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wls7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1163-1169&issue=10&author=L.+H.+Mengauthor=X.+F.+Zheng&title=Toward+rapamycin+analog+%28rapalog%29-based+precision+cancer+therapy&doi=10.1038%2Faps.2015.68"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Toward rapamycin analog (rapalog)-based precision cancer therapy</span></div><div class="casAuthors">Meng, Ling-hua; Zheng, X. F. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1163-1169</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Rapamycin and its analogs (rapalogs) are the first generation of mTOR inhibitors, which have the same mol. scaffold, but different physiochem. properties.  Rapalogs are being tested in a wide spectrum of human tumors as both monotherapy and a component of combination therapy.  Among them, temsirolimus and everolimus have been approved for the treatment of breast and renal cancer.  However, objective response rates with rapalogs in clin. trials are modest and variable.  Identification of biomarkers predicting response to rapalogs, and discovery of drug combinations with improved efficacy and tolerated toxicity are crit. to moving this class of targeted therapeutics forward.  This review focuses on the aberrations in the PI3K/mTOR pathway in human tumor cells or tissues as predictive biomarkers for rapalog efficacy.  Recent results of combinational therapy using rapalogs and other anticancer drugs are documented.  With the rapid development of next-generation genomic sequencing and precision medicine, rapalogs will provide greater benefits to cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMIearchWtebVg90H21EOLACvtfcHk0lgRHMpksemJ9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wls7jP&md5=af1357a49b132c2264ca74577ae2ae48</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Faps.2015.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2015.68%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DZheng%26aufirst%3DX.%2BF.%26atitle%3DToward%2520rapamycin%2520analog%2520%2528rapalog%2529-based%2520precision%2520cancer%2520therapy%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2015%26volume%3D36%26issue%3D10%26spage%3D1163%26epage%3D1169%26doi%3D10.1038%2Faps.2015.68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apsel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uotila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e1000038</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1000038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1371%2Fjournal.pbio.1000038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=e1000038&issue=2&author=M.+E.+Feldmanauthor=B.+Apselauthor=A.+Uotilaauthor=R.+Loewithauthor=Z.+A.+Knightauthor=D.+Ruggeroauthor=K.+M.+Shokat&title=Active-site+inhibitors+of+mTOR+target+rapamycin-resistant+outputs+of+mTORC1+and+mTORC2&doi=10.1371%2Fjournal.pbio.1000038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1000038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1000038%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DUotila%26aufirst%3DA.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DActive-site%2520inhibitors%2520of%2520mTOR%2520target%2520rapamycin-resistant%2520outputs%2520of%2520mTORC1%2520and%2520mTORC2%26jtitle%3DPLoS%2520Biol.%26date%3D2009%26volume%3D7%26issue%3D2%26spage%3De1000038%26doi%3D10.1371%2Fjournal.pbio.1000038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>341</i></span> (<span class="NLM_issue">6144</span>),  <span class="NLM_fpage">1236566</span>, <span class="refDoi"> DOI: 10.1126/science.1236566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1126%2Fscience.1236566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=23888043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A280%3ADC%252BC3sfktVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2013&pages=1236566&issue=6144&author=S.+A.+Kangauthor=M.+E.+Pacoldauthor=C.+L.+Cervantesauthor=D.+Limauthor=H.+J.+Louauthor=K.+Ottinaauthor=N.+S.+Grayauthor=B.+E.+Turkauthor=M.+B.+Yaffeauthor=D.+M.+Sabatini&title=mTORC1+phosphorylation+sites+encode+their+sensitivity+to+starvation+and+rapamycin&doi=10.1126%2Fscience.1236566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin</span></div><div class="casAuthors">Kang Seong A; Pacold Michael E; Cervantes Christopher L; Lim Daniel; Lou Hua Jane; Ottina Kathleen; Gray Nathanael S; Turk Benjamin E; Yaffe Michael B; Sabatini David M</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6144</span>),
    <span class="NLM_cas:pages">1236566</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) protein kinase promotes growth and is the target of rapamycin, a clinically useful drug that also prolongs life span in model organisms.  A persistent mystery is why the phosphorylation of many bona fide mTORC1 substrates is resistant to rapamycin.  We find that the in vitro kinase activity of mTORC1 toward peptides encompassing established phosphorylation sites varies widely and correlates strongly with the resistance of the sites to rapamycin, as well as to nutrient and growth factor starvation within cells.  Slight modifications of the sites were sufficient to alter mTORC1 activity toward them in vitro and to cause concomitant changes within cells in their sensitivity to rapamycin and starvation.  Thus, the intrinsic capacity of a phosphorylation site to serve as an mTORC1 substrate, a property we call substrate quality, is a major determinant of its sensitivity to modulators of the pathway.  Our results reveal a mechanism through which mTORC1 effectors can respond differentially to the same signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVUX1crROrkZPlX7E30qdzfW6udTcc2eZzc0LiBzykf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfktVWmsw%253D%253D&md5=904daf44e853714de3fb540a359e2546</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscience.1236566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1236566%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DCervantes%26aufirst%3DC.%2BL.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DLou%26aufirst%3DH.%2BJ.%26aulast%3DOttina%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DTurk%26aufirst%3DB.%2BE.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTORC1%2520phosphorylation%2520sites%2520encode%2520their%2520sensitivity%2520to%2520starvation%2520and%2520rapamycin%26jtitle%3DScience%26date%3D2013%26volume%3D341%26issue%3D6144%26spage%3D1236566%26doi%3D10.1126%2Fscience.1236566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacinto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruegg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. N.</span></span> <span> </span><span class="NLM_article-title">Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1038/ncb1183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fncb1183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15467718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFentL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1122-8&issue=11&author=E.+Jacintoauthor=R.+Loewithauthor=A.+Schmidtauthor=S.+Linauthor=M.+A.+Rueggauthor=A.+Hallauthor=M.+N.+Hall&title=Mammalian+TOR+complex+2+controls+the+actin+cytoskeleton+and+is+rapamycin+insensitive&doi=10.1038%2Fncb1183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive</span></div><div class="casAuthors">Jacinto, Estela; Loewith, Robbie; Schmidt, Anja; Lin, Shuo; Rueegg, Markus A.; Hall, Alan; Hall, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1122-1128</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The target of rapamycin (TOR) is a highly conserved protein kinase and a central controller of cell growth.  In budding yeast, TOR is found in structurally and functionally distinct protein complexes: TORC1 and TORC2.  A mammalian counterpart of TORC1 (mTORC1) has been described, but it is not known whether TORC2 is conserved in mammals.  Here, the authors report that a mammalian counterpart of TORC2 (mTORC2) also exists.  The mTORC2 contains mTOR, mLST8 and mAVO3, but not raptor.  Like yeast TORC2, mTORC2 is rapamycin insensitive and seems to function upstream of Rho GTPases to regulate the actin cytoskeleton.  The mTORC2 is not upstream of the mTORC1 effector S6K.  Thus, two distinct TOR complexes constitute a primordial signaling network conserved in eukaryotic evolution to control the fundamental process of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnbO542vXw7Vg90H21EOLACvtfcHk0lhy-NQ_ve4urA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFentL8%253D&md5=42d53ee5d9dfc24287cf05fd29f41aa8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fncb1183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1183%26sid%3Dliteratum%253Aachs%26aulast%3DJacinto%26aufirst%3DE.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DRuegg%26aufirst%3DM.%2BA.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DHall%26aufirst%3DM.%2BN.%26atitle%3DMammalian%2520TOR%2520complex%25202%2520controls%2520the%2520actin%2520cytoskeleton%2520and%2520is%2520rapamycin%2520insensitive%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2004%26volume%3D6%26issue%3D11%26spage%3D1122%26epage%3D8%26doi%3D10.1038%2Fncb1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Q. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1500</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&issue=3&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0lhy-NQ_ve4urA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D3%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1194</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F2159-8290.CD-15-0460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=26293922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=1194-1209&issue=11&author=P.+Liuauthor=W.+Ganauthor=Y.+R.+Chinauthor=K.+Oguraauthor=J.+Guoauthor=J.+Zhangauthor=B.+Wangauthor=J.+Blenisauthor=L.+C.+Cantleyauthor=A.+Tokerauthor=B.+Suauthor=W.+Wei&title=PtdIns%283%2C4%2C5%29P3-dependent+activation+of+the+mTORC2+kinase+complex&doi=10.1158%2F2159-8290.CD-15-0460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">PtdIns(3,4,5)P3-dependent activation of the mtorc2 kinase complex</span></div><div class="casAuthors">Liu, Pengda; Gan, Wenjian; Chin, Y. Rebecca; Ogura, Kohei; Guo, Jianping; Zhang, Jinfang; Wang, Bin; Blenis, John; Cantley, Lewis C.; Toker, Alex; Su, Bing; Wei, Wenyi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1194-1209</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MTOR serves as a central regulator of cell growth and metab. by forming two distinct complexes, mTORC1 and mTORC2.  Although mechanisms of mTORC1 activation by growth factors and amino acids have been extensively studied, the upstream regulatory mechanisms leading to mTORC2 activation remain largely elusive.  Here, we report that the pleckstrin homol. (PH) domain of SIN1, an essential and unique component of mTORC2, interacts with the mTOR kinase domain to suppress mTOR activity.  More importantly, PtdIns(3,4,5)P3, but not other PtdInsPn species, interacts with SIN1-PH to release its inhibition on the mTOR kinase domain, thereby triggering mTORC2 activation.  Mutating crit. SIN1 residues that mediate PtdIns(3,4,5)P3 interaction inactivates mTORC2, whereas mTORC2 activity is pathol. increased by patient-derived mutations in the SIN1-PH domain, promoting cell growth and tumor formation.  Together, our study unravels a PI3K-dependent mechanism for mTORC2 activation, allowing mTORC2 to activate AKT in a manner that is regulated temporally and spatially by PtdIns(3,4,5)P3.  Significance: The SIN1-PH domain interacts with the mTOR kinase domain to suppress mTOR activity, and PtdIns(3,4,5)P3 binds the SIN1-PH domain to release its inhibition on the mTOR kinase domain, leading to mTORC2 activation.  Cancer patient-derived SIN1-PH domain mutations gain oncogenicity by loss of suppressing mTOR activity as a means to facilitate tumorigenesis.  Cancer Discov; 5(11); 1194-209. ©2015 AACR.  See related commentary by Yuan and Guan, p. 1127.  This article is highlighted in the In This Issue feature, p.1111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotBvVUrg3Jo7Vg90H21EOLACvtfcHk0lhy-NQ_ve4urA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsr3E&md5=a218e7e37d78aaa532a8ff44db230447</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0460%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DGan%26aufirst%3DW.%26aulast%3DChin%26aufirst%3DY.%2BR.%26aulast%3DOgura%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DBlenis%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DToker%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DPtdIns%25283%252C4%252C5%2529P3-dependent%2520activation%2520of%2520the%2520mTORC2%2520kinase%2520complex%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D11%26spage%3D1194%26epage%3D1209%26doi%3D10.1158%2F2159-8290.CD-15-0460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursavich, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingboe, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malwitz, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toral-Barza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">7081</span>– <span class="NLM_lpage">7089</span>, <span class="refDoi"> DOI: 10.1021/jm9012642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9012642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Oku7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7081-7089&issue=22&author=P.+Nowakauthor=D.+C.+Coleauthor=N.+Brooijmansauthor=M.+G.+Bursavichauthor=K.+J.+Curranauthor=J.+W.+Ellingboeauthor=J.+J.+Gibbonsauthor=I.+Hollanderauthor=Y.+Huauthor=J.+Kaplanauthor=D.+J.+Malwitzauthor=L.+Toral-Barzaauthor=J.+C.+Verheijenauthor=A.+Zaskauthor=W.+G.+Zhangauthor=K.+Yu&title=Discovery+of+potent+and+selective+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29+kinase&doi=10.1021%2Fjm9012642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase</span></div><div class="casAuthors">Nowak, Pawel; Cole, Derek C.; Brooijmans, Natasja; Curran, Kevin J.; Ellingboe, John W.; Gibbons, James J.; Hollander, Irwin; Hu, Yong Bo; Kaplan, Joshua; Malwitz, David J.; Toral-Barza, Lourdes; Verheijen, Jeroen C.; Zask, Arie; Zhang, Wei-Guo; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7081-7089</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a central regulator of cell growth, metab., and angiogenesis and an emerging target in cancer research.  High throughput screening (HTS) of our compd. collection led to the identification of 3-(4-morpholin-4-yl-1-piperidin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenol (5a), a modestly potent and nonselective inhibitor of mTOR and phosphoinositide 3-kinase (PI3K).  Optimization of compd. 5a, employing an mTOR homol. model based on an X-ray crystal structure of closely related PI3Kγ led to the discovery of 6-(1H-indol-5-yl)-4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidine (5u), a potent and selective mTOR inhibitor (mTOR IC50 = 9 nM; PI3Kα IC50 = 1962 nM).  Compd. 5u selectively inhibited cellular biomarker of mTORC1 (P-S6K, P-4EBP1) and mTORC2 (P-AKT S473) over the biomarker of PI3K/PDK1 (P-AKT T308) and did not inhibit PI3K-related kinases (PIKKs) in cellular assays.  These pyrazolopyrimidines represent an exciting new series of mTOR-selective inhibitors with potential for development for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8sFoF2rplwrVg90H21EOLACvtfcHk0ljbjeC85rlt2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Oku7zL&md5=5a60157598d9eb85e4fff6dc07f01cc2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm9012642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9012642%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DD.%2BC.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBursavich%26aufirst%3DM.%2BG.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DEllingboe%26aufirst%3DJ.%2BW.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.%2BG.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D22%26spage%3D7081%26epage%3D7089%26doi%3D10.1021%2Fjm9012642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">58469</span>– <span class="NLM_lpage">58479</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.18632%2Foncotarget.17753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=28938571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=58469-58479&issue=35&author=Z.+Jinauthor=H.+Niuauthor=X.+Wangauthor=L.+Zhangauthor=Q.+Wangauthor=A.+Yang&title=Preclinical+study+of+CC223+as+a+potential+anti-ovarian+cancer+agent&doi=10.18632%2Foncotarget.17753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span></div><div class="casAuthors">Jin Zhenzhen; Niu Huanfu; Wang Xuenan; Wang Qin; Yang Aijun; Zhang Lei</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">58469-58479</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aberrant activation of mTOR contributes to ovarian cancer progression.  CC223 is a novel and potent mTOR kinase inhibitor.  The current study tested its activity against human ovarian cancer cells.  We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary human ovarian cancer cells.  Further, significant apoptosis activation was observed in CC223-treated ovarian cancer cells.  CC223 disrupted assembly of mTOR complex 1 (mTORC1) and mTORC2 in SKOV3 cells.  Meanwhile, activation of mTORC1 and mTORC2 was almost completely blocked by CC223.  Intriguingly, restoring mTOR activation by introduction of a constitutively-active Akt1 only partially inhibited CC223-induced cytotoxicity in SKOV3 cells.  Further studies showed that CC223 inhibited sphingosine kinase 1 (SphK1) activity and induced reactive oxygen species (ROS) production in SKOV3 cells.  At last, oral administration of CC223 potently inhibited SKOV3 xenografted tumor growth in nude mice.  The results of this study imply that CC223 could be further studied as a potential anti-ovarian cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcU4AE24nN2t1QT_1O5WBYfW6udTcc2eYTeSYAwLZ--7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D&md5=091fdb75cec2ddb9018ba74c124041e8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17753%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DA.%26atitle%3DPreclinical%2520study%2520of%2520CC223%2520as%2520a%2520potential%2520anti-ovarian%2520cancer%2520agent%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D35%26spage%3D58469%26epage%3D58479%26doi%3D10.18632%2Foncotarget.17753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slotkin, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudeva, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F1535-7163.MCT-14-0711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=25519700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=395-406&issue=2&author=E.+K.+Slotkinauthor=P.+P.+Patwardhanauthor=S.+D.+Vasudevaauthor=E.+de+Stanchinaauthor=W.+D.+Tapauthor=G.+K.+Schwartz&title=MLN0128%2C+an+ATP-competitive+mTOR+kinase+inhibitor+with+potent+in+vitro+and+in+vivo+antitumor+activity%2C+as+potential+therapy+for+bone+and+soft-tissue+sarcoma&doi=10.1158%2F1535-7163.MCT-14-0711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma</span></div><div class="casAuthors">Slotkin, Emily K.; Patwardhan, Parag P.; Vasudeva, Shyamprasad D.; de Stanchina, Elisa; Tap, William D.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-406</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular and intracellular signals to act as a master regulator of cell growth, survival, and metab.  The PI3K/AKT/mTOR prosurvival pathway is often dysregulated in multiple sarcoma subtypes.  First-generation allosteric inhibitors of mTORC1 (rapalogues) have been extensively tested with great preclin. promise, but have had limited clin. utility.  Here, we report that MLN0128, a second-generation, ATP-competitive, pan-mTOR kinase inhibitor, acts on both mTORC1 and mTORC2 and has potent in vitro and in vivo antitumor activity in multiple sarcoma subtypes.  In vitro, MLN0128 inhibits mTORC1/2 targets in a concn.-dependent fashion and shows striking antiproliferative effect in rhabdomyosarcoma (RMS), Ewing sarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma, osteosarcoma, and liposarcoma.  Unlike rapamycin, MLN0128 inhibits phosphorylation of 4EBP1 and NDRG1 as well as prevents the reactivation of pAKT that occurs via neg. feedback release with mTORC1 inhibition alone.  In xenograft models, MLN0128 treatment results in suppression of tumor growth with two dosing schedules (1 mg/kg daily and 3 mg/kg b.i.d. t.i.w.).  At the 3 mg/kg dosing schedule, MLN0128 treatment results in significantly better tumor growth suppression than rapamycin in RMS and Ewing sarcoma models.  In addn., MLN0128 induces apoptosis in models of RMS both in vitro and in vivo.  Results from our study strongly suggest that MLN0128 treatment should be explored further as potential therapy for sarcoma.  Mol Cancer Ther; 14(2); 395-406. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2RbwSW4yjmLVg90H21EOLACvtfcHk0lhFme52BuplGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D&md5=7c1d867aae6e5ca99c63b554295a539a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0711%26sid%3Dliteratum%253Aachs%26aulast%3DSlotkin%26aufirst%3DE.%2BK.%26aulast%3DPatwardhan%26aufirst%3DP.%2BP.%26aulast%3DVasudeva%26aufirst%3DS.%2BD.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DMLN0128%252C%2520an%2520ATP-competitive%2520mTOR%2520kinase%2520inhibitor%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%252C%2520as%2520potential%2520therapy%2520for%2520bone%2520and%2520soft-tissue%2520sarcoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D2%26spage%3D395%26epage%3D406%26doi%3D10.1158%2F1535-7163.MCT-14-0711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malagu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummersone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.bmcl.2013.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=23375793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1212-1216&issue=5&author=K.+G.+Pikeauthor=K.+Malaguauthor=M.+G.+Hummersoneauthor=K.+A.+Menearauthor=H.+M.+Dugganauthor=S.+Gomezauthor=N.+M.+Martinauthor=L.+Rustonauthor=S.+L.+Passauthor=M.+Pass&title=Optimization+of+potent+and+selective+dual+mTORC1+and+mTORC2+inhibitors%3A+the+discovery+of+AZD8055+and+AZD2014&doi=10.1016%2Fj.bmcl.2013.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014</span></div><div class="casAuthors">Pike, Kurt G.; Malagu, Karine; Hummersone, Marc G.; Menear, Keith A.; Duggan, Heather M. E.; Gomez, Sylvie; Martin, Niall M. B.; Ruston, Linette; Pass, Sarah L.; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1212-1216</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described.  An initial focus on improving cellular potency while maintaining or improving other key parameters, such as aq. soly. and margins over hERG IC50, led to the discovery of the clin. candidate AZD8055.  Further optimization, particularly aimed at reducing the rate of metab. in human hepatocyte incubations, resulted in the discovery of the clin. candidate AZD2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo07emMEKp9mrVg90H21EOLACvtfcHk0lhFme52BuplGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D&md5=325cb45f84bb4357005315ab3b27c0aa</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DHummersone%26aufirst%3DM.%2BG.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DDuggan%26aufirst%3DH.%2BM.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DS.%2BL.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520potent%2520and%2520selective%2520dual%2520mTORC1%2520and%2520mTORC2%2520inhibitors%253A%2520the%2520discovery%2520of%2520AZD8055%2520and%2520AZD2014%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D5%26spage%3D1212%26epage%3D1216%26doi%3D10.1016%2Fj.bmcl.2013.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vo, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span> <span> </span><span class="NLM_article-title">Targeting mTOR for the treatment of B cell malignancies</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1213</span>– <span class="NLM_lpage">1228</span>, <span class="refDoi"> DOI: 10.1111/bcp.12888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1111%2Fbcp.12888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=26805380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Gqsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2016&pages=1213-1228&issue=5&author=J.+S.+Leeauthor=T.+T.+Voauthor=D.+A.+Fruman&title=Targeting+mTOR+for+the+treatment+of+B+cell+malignancies&doi=10.1111%2Fbcp.12888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mTOR for the treatment of B cell malignancies</span></div><div class="casAuthors">Lee, Jong-Hoon Scott; Vo, Thanh-Trang; Fruman, David A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1213-1228</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, division and survival.  Many haematol. malignancies exhibit elevated or aberrant mTOR activation, supporting the launch of numerous clin. trials aimed at evaluating the potential of single agent mTOR-targeted therapies.  While promising early clin. data using allosteric mTOR inhibitors (rapamycin and its derivs., rapalogs) have suggested activity in a subset of haematol. malignancies, these agents have shown limited efficacy in most contexts.  Whether the efficacy of these partial mTOR inhibitors might be enhanced by more complete target inhibition is being actively addressed with second generation ATP-competitive mTOR kinase inhibitors (TOR-KIs), which have only recently entered clin. trials.  However, emerging preclin. data suggest that despite their biochem. advantage over rapalogs, TOR-KIs may retain a primarily cytostatic response.  Rather, combinations of mTOR inhibition with other targeted therapies have demonstrated promising efficacy in several preclin. models.  This review investigates the current status of rapalogs and TOR-KIs in B cell malignancies, with an emphasis on emerging preclin. evidence of synergistic combinations involving mTOR inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7dt4KJJSA7LVg90H21EOLACvtfcHk0lhFme52BuplGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Gqsr7L&md5=0ae355bfde2b1b275eb2bdfd55b4cbab</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12888%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DVo%26aufirst%3DT.%2BT.%26aulast%3DFruman%26aufirst%3DD.%2BA.%26atitle%3DTargeting%2520mTOR%2520for%2520the%2520treatment%2520of%2520B%2520cell%2520malignancies%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D82%26issue%3D5%26spage%3D1213%26epage%3D1228%26doi%3D10.1111%2Fbcp.12888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoro methyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1/2 inhibitor for cancer and neurological disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10105</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01262</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01262" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10084-10105&issue=22&author=D.+Rageotauthor=T.+Bohnackerauthor=A.+Meloneauthor=J.+B.+Langloisauthor=C.+Borsariauthor=P.+Hillmannauthor=A.+M.+Seleauthor=F.+Beaufilsauthor=M.+Zvelebilauthor=P.+Hebeisenauthor=W.+Loscherauthor=J.+Burkeauthor=D.+Fabbroauthor=M.+P.+Wymann&title=Discovery+and+preclinical+characterization+of+5-%5B4%2C6-Bis%28%7B3-oxa-8-azabicyclo%5B3.2.1%5Doctan-8-yl%7D%29-1%2C3%2C5-triazin-2-yl%5D-4-%28difluoro+methyl%29pyridin-2-amine+%28PQR620%29%2C+a+highly+potent+and+selective+mTORC1%2F2+inhibitor+for+cancer+and+neurological+disorders&doi=10.1021%2Facs.jmedchem.8b01262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders</span></div><div class="casAuthors">Rageot, Denise; Bohnacker, Thomas; Melone, Anna; Langlois, Jean-Baptiste; Borsari, Chiara; Hillmann, Petra; Sele, Alexander M.; Beaufils, Florent; Zvelebil, Marketa; Hebeisen, Paul; Loscher, Wolfgang; Burke, John; Fabbro, Doriano; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10105</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders.  I is a novel, potent, selective, and brain penetrable inhibitor of mTORC1/2 kinase.  I showed excellent selectivity for mTOR over PI3K and protein kinases and efficiently prevented cancer cell growth in a 66 cancer cell line panel.  In C57BL/6J and Sprague-Dawley mice, max. concn. (Cmax) in plasma and brain was reached after 30 min, with a half-life (t1/2) > 5 h.  In an ovarian carcinoma mouse xenograft model (OVCAR-3), daily dosing of I inhibited tumor growth significantly.  Moreover, I attenuated epileptic seizures in a tuberous sclerosis complex (TSC) mouse model.  In conclusion, I inhibits mTOR kinase potently and selectively, shows antitumor effects in vitro and in vivo, and promises advantages in CNS indications due to its brain/plasma distribution ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTlRg0fJo97Vg90H21EOLACvtfcHk0lhA7aq8O4GKUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLjO&md5=e6ebf8147d6ba041285eb6538ade46ab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01262%26sid%3Dliteratum%253Aachs%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DJ.%2BB.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DLoscher%26aufirst%3DW.%26aulast%3DBurke%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%25205-%255B4%252C6-Bis%2528%257B3-oxa-8-azabicyclo%255B3.2.1%255Doctan-8-yl%257D%2529-1%252C3%252C5-triazin-2-yl%255D-4-%2528difluoro%2520methyl%2529pyridin-2-amine%2520%2528PQR620%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520mTORC1%252F2%2520inhibitor%2520for%2520cancer%2520and%2520neurological%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D10084%26epage%3D10105%26doi%3D10.1021%2Facs.jmedchem.8b01262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+Diazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eaSvrVmjvZqwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7524</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00930</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00930" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7524-7538&issue=17&author=F.+Beaufilsauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=T.+Bohnackerauthor=A.+Meloneauthor=R.+Maroneauthor=E.+Jacksonauthor=X.+Zhangauthor=A.+Seleauthor=C.+Borsariauthor=J.+Mestanauthor=P.+Hebeisenauthor=P.+Hillmannauthor=B.+Gieseauthor=M.+Zvelebilauthor=D.+Fabbroauthor=R.+L.+Williamsauthor=D.+Rageotauthor=M.+P.+Wymann&title=5-%284%2C6-Dimorpholino-1%2C3%2C5-triazin-2-yl%29-4-%28trifluoromethyl%29pyridin-2-amine+%28PQR309%29%2C+a+potent%2C+brain-penetrant%2C+orally+bioavailable%2C+pan-class+I+PI3K%2FmTOR+inhibitor+as+clinical+candidate+in+oncology&doi=10.1021%2Facs.jmedchem.7b00930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></div><div class="casAuthors">Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jurgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7524-7538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).  Here we describe the preclin. characterization of compd. 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concns.  No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays.  Moreover, 1 did not bind tubulin, which was obsd. for the structurally related 4 (BKM120, buparlisib).  Compd. 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.  Compd. 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model.  This, together with the compd.'s safety profile, identifies 1 as a clin. candidate with a broad application range in oncol., including treatment of brain tumors or CNS metastasis.  Compd. 1 is currently in phase II clin. trials for advanced solid tumors and refractory lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtvYAarVqsarVg90H21EOLACvtfcHk0lirSBQs2fJP9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP&md5=54d4db75f6a8bda3f12eaf1d196352fd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D5-%25284%252C6-Dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2520%2528PQR309%2529%252C%2520a%2520potent%252C%2520brain-penetrant%252C%2520orally%2520bioavailable%252C%2520pan-class%2520I%2520PI3K%252FmTOR%2520inhibitor%2520as%2520clinical%2520candidate%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D17%26spage%3D7524%26epage%3D7538%26doi%3D10.1021%2Facs.jmedchem.7b00930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarantelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arribas, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittau, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritschard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dossena, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taborelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gattei, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stussi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, F.</span></span> <span> </span><span class="NLM_article-title">PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F1078-0432.CCR-17-1041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=29066507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=120-129&issue=1&author=C.+Tarantelliauthor=E.+Gaudioauthor=A.+J.+Arribasauthor=I.+Kweeauthor=P.+Hillmannauthor=A.+Rinaldiauthor=L.+Cascioneauthor=F.+Sprianoauthor=E.+Bernasconiauthor=F.+Guidettiauthor=L.+Carrassaauthor=R.+B.+Pittauauthor=F.+Beaufilsauthor=R.+Ritschardauthor=D.+Rageotauthor=A.+Seleauthor=B.+Dossenaauthor=F.+M.+Rossiauthor=A.+Zucchettoauthor=M.+Taborelliauthor=V.+Gatteiauthor=D.+Rossiauthor=A.+Stathisauthor=G.+Stussiauthor=M.+Brogginiauthor=M.+P.+Wymannauthor=A.+Wickiauthor=E.+Zuccaauthor=V.+Cmiljanovicauthor=D.+Fabbroauthor=F.+Bertoni&title=PQR309+is+a+novel+dual+PI3K%2FmTOR+inhibitor+with+preclinical+antitumor+activity+in+lymphomas+as+a+single+agent+and+in+combination+therapy&doi=10.1158%2F1078-0432.CCR-17-1041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy</span></div><div class="casAuthors">Tarantelli, Chiara; Gaudio, Eugenio; Arribas, Alberto J.; Kwee, Ivo; Hillmann, Petra; Rinaldi, Andrea; Cascione, Luciano; Spriano, Filippo; Bernasconi, Elena; Guidetti, Francesca; Carrassa, Laura; Pittau, Roberta Bordone; Beaufils, Florent; Ritschard, Reto; Rageot, Denise; Sele, Alexander; Dossena, Barbara; Rossi, Francesca Maria; Zucchetto, Antonella; Taborelli, Monica; Gattei, Valter; Rossi, Davide; Stathis, Anastasios; Stussi, Georg; Broggini, Massimo; Wymann, Matthias P.; Wicki, Andreas; Zucca, Emanuele; Cmiljanovic, Vladimir; Fabbro, Doriano; Bertoni, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-129</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacol. inhibition of the PI3K/mTOR pathway has shown activity in lymphoma patients.  Here, we extensively characterized the in vitro and in vivo activity and the mechanism of action of PQR309 (bimiralisib), a novel oral selective dual PI3K/mTOR inhibitor under clin. evaluation, in preclin. lymphoma models.  Exptl. Design: This study included preclin. in vitro activity screening on a large panel of cell lines, both as single agent and in combination, validation expts. on in vivo models and primary cells, proteomics and gene-expression profiling, and comparison with other signaling inhibitors.  Results: PQR309 had in vitro antilymphoma activity as single agent and in combination with venetoclax, panobinostat, ibrutinib, lenalidomide, ARV-825, marizomib, and rituximab.  Sensitivity to PQR309 was assocd. with specific baseline gene-expression features, such as high expression of transcripts coding for the BCR pathway.  Combining proteomics and RNA profiling, we identified the different contribution of PQR309-induced protein phosphorylation and gene expression changes to the drug mechanism of action.  Gene-expression signatures induced by PQR309 and by other signaling inhibitors largely overlapped.  PQR309 showed activity in cells with primary or secondary resistance to idelalisib.  Conclusions: On the basis of these results, PQR309 appeared as a novel and promising compd. that is worth developing in the lymphoma setting.  Clin Cancer Res; 24(1); 120-9. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEmEWXHaG3ObVg90H21EOLACvtfcHk0lirSBQs2fJP9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWktw%253D%253D&md5=730305c33b7f669b0eedd0614edd886c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1041%26sid%3Dliteratum%253Aachs%26aulast%3DTarantelli%26aufirst%3DC.%26aulast%3DGaudio%26aufirst%3DE.%26aulast%3DArribas%26aufirst%3DA.%2BJ.%26aulast%3DKwee%26aufirst%3DI.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DRinaldi%26aufirst%3DA.%26aulast%3DCascione%26aufirst%3DL.%26aulast%3DSpriano%26aufirst%3DF.%26aulast%3DBernasconi%26aufirst%3DE.%26aulast%3DGuidetti%26aufirst%3DF.%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DPittau%26aufirst%3DR.%2BB.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DRitschard%26aufirst%3DR.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DDossena%26aufirst%3DB.%26aulast%3DRossi%26aufirst%3DF.%2BM.%26aulast%3DZucchetto%26aufirst%3DA.%26aulast%3DTaborelli%26aufirst%3DM.%26aulast%3DGattei%26aufirst%3DV.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DStussi%26aufirst%3DG.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBertoni%26aufirst%3DF.%26atitle%3DPQR309%2520is%2520a%2520novel%2520dual%2520PI3K%252FmTOR%2520inhibitor%2520with%2520preclinical%2520antitumor%2520activity%2520in%2520lymphomas%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D1%26spage%3D120%26epage%3D129%26doi%3D10.1158%2F1078-0432.CCR-17-1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xyrafas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bize, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretre, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritschard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzankov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hierro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Moos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span> <span> </span><span class="NLM_article-title">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2018.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1016%2Fj.ejca.2018.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=29660598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1Snu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2018&pages=6-16&author=A.+Wickiauthor=N.+Brownauthor=A.+Xyrafasauthor=V.+Bizeauthor=H.+Hawleauthor=S.+Berardiauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=M.+Stummauthor=S.+Dimitrijevicauthor=R.+Herrmannauthor=V.+Pretreauthor=R.+Ritschardauthor=A.+Tzankovauthor=V.+Hessauthor=A.+Childsauthor=C.+Hierroauthor=J.+Rodonauthor=D.+Hessauthor=M.+Joergerauthor=R.+von+Moosauthor=C.+Sessaauthor=R.+Kristeleit&title=First-in+human%2C+phase+1%2C+dose-escalation+pharmacokinetic+and+pharmacodynamic+study+of+the+oral+dual+PI3K+and+mTORC1%2F2+inhibitor+PQR309+in+patients+with+advanced+solid+tumors+%28SAKK+67%2F13%29&doi=10.1016%2Fj.ejca.2018.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)</span></div><div class="casAuthors">Wicki, Andreas; Brown, Nicholas; Xyrafas, Alexandros; Bize, Vincent; Hawle, Hanne; Berardi, Simona; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Stumm, Michael; Dimitrijevic, Sasa; Herrmann, Richard; Pretre, Vincent; Ritschard, Reto; Tzankov, Alexandar; Hess, Viviane; Childs, Alexa; Hierro, Cinta; Rodon, Jordi; Hess, Dagmar; Joerger, Markus; von Moos, Roger; Sessa, Cristiana; Kristeleit, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6-16</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">PQR309 is an orally bioavailable, balanced pan-phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhibitor.  This is an accelerated titrn., 3 D 3 dose-escalation, open-label phase Itrial of continuous once-daily (OD) PQR309 administration to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics in patients with advanced solid tumors.  Primary objectives were to det. the max. tolerated dose (MTD) and recommended phase 2 dose (RP2D).Twenty-eight patients were included in six dosing cohorts and treated at a daily PQR309 dose ranging from 10 to 150 mg.  Common adverse events (AEs; ≥30% patients) included fatigue, hyperglycemia, nausea, diarrhea, constipation, rash, anorexia and vomiting.  Grade (G) 3 or 4 drug-related AEs were seen in 13 (46%) and three (11%) patients, resp.  Dose-limiting toxicity (DLT) was obsd. in two patients at 100 mg OD (>14-d interruption in PQR309 due to G3 rash, G2 hyperbilirubinemia, G4 suicide attempt; dose redn. due to G3 fatigue, G2 diarrhoea, G4 transaminitis) and one patient at 80 mg (G3 hyperglycemia >7 d).  PK shows fast absorption (Tmax 1-2 h) and dose proportionality for Cmax and area under the curve.  A partial response in a patient with metastatic thymus cancer, 24% disease vol. redn. in a patient with sinonasal cancer and stable disease for more than 16 wk in a patient with clear cell Bartholin's gland cancer were obsd.The MTD and RP2D of PQR309 is 80 mg of orally OD.  PK is dose-proportional.  PD shows PI3K pathway phosphoprotein downregulation in paired tumor biopsies.  Clin. activity was obsd. in patients with and without PI3K pathway dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVIhZzSTJb7Vg90H21EOLACvtfcHk0ljhhmFo_W7-Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1Snu70%253D&md5=acbdfdb59498f5543ba7f02ed9709d0e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2018.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2018.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DXyrafas%26aufirst%3DA.%26aulast%3DBize%26aufirst%3DV.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DBerardi%26aufirst%3DS.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DPretre%26aufirst%3DV.%26aulast%3DRitschard%26aufirst%3DR.%26aulast%3DTzankov%26aufirst%3DA.%26aulast%3DHess%26aufirst%3DV.%26aulast%3DChilds%26aufirst%3DA.%26aulast%3DHierro%26aufirst%3DC.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DJoerger%26aufirst%3DM.%26aulast%3Dvon%2BMoos%26aufirst%3DR.%26aulast%3DSessa%26aufirst%3DC.%26aulast%3DKristeleit%26aufirst%3DR.%26atitle%3DFirst-in%2520human%252C%2520phase%25201%252C%2520dose-escalation%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520the%2520oral%2520dual%2520PI3K%2520and%2520mTORC1%252F2%2520inhibitor%2520PQR309%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520%2528SAKK%252067%252F13%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2018%26volume%3D96%26spage%3D6%26epage%3D16%26doi%3D10.1016%2Fj.ejca.2018.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Conformational restriction: an effective tactic in “follow-on”-based drug discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.4155%2Ffmc.14.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=24962281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=885-901&issue=8&author=Z.+Fangauthor=Y.+Songauthor=P.+Zhanauthor=Q.+Zhangauthor=X.+Liu&title=Conformational+restriction%3A+an+effective+tactic+in+%E2%80%9Cfollow-on%E2%80%9D-based+drug+discovery&doi=10.4155%2Ffmc.14.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction: an effective tactic in 'follow-on'-based drug discovery</span></div><div class="casAuthors">Fang, Zengjun; Song, Yu'ning; Zhan, Peng; Zhang, Qingzhu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-901</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss assocd. with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiol. target, improved selectivity for isoforms and reduced the possibility of drug metab.  Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally.  The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupMomfg9J_bVg90H21EOLACvtfcHk0ljhhmFo_W7-Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE&md5=dcf5fa6cead84c77b3603c7e0800f49b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.50%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DConformational%2520restriction%253A%2520an%2520effective%2520tactic%2520in%2520%25E2%2580%259Cfollow-on%25E2%2580%259D-based%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26issue%3D8%26spage%3D885%26epage%3D901%26doi%3D10.4155%2Ffmc.14.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span>; <span class="NLM_string-name">Hebeisen, P.</span>; <span class="NLM_string-name">Jackson, E.</span>; <span class="NLM_string-name">Beaufils, F.</span>; <span class="NLM_string-name">Bohnacker, T.</span>; <span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Conformationally Restricted PI3K and mTOR Inhibitors</span>. Patent <span class="NLM_patent">WO2015049369</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=V.+Cmiljanovic&author=P.+Hebeisen&author=E.+Jackson&author=F.+Beaufils&author=T.+Bohnacker&author=M.+P.+Wymann&title=Conformationally+Restricted+PI3K+and+mTOR+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCmiljanovic%26aufirst%3DV.%26atitle%3DConformationally%2520Restricted%2520PI3K%2520and%2520mTOR%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, F. R.</span>; <span class="NLM_string-name">Manteau, B.</span>; <span class="NLM_string-name">Vors, J. P.</span>; <span class="NLM_string-name">Pazenok, S.</span></span> <span> </span><span class="NLM_article-title">Trifluoromethyl ethers--synthesis and properties of an unusual substituent</span>.  <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume">4</span> (<span class="NLM_issue">13</span>), <span class="refDoi"> DOI: 10.3762/bjoc.4.13</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.3762%2Fbjoc.4.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18941485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&issue=13&author=F.+R.+Leroux&author=B.+Manteau&author=J.+P.+Vors&author=S.+Pazenok&title=Trifluoromethyl+ethers%2D%2Dsynthesis+and+properties+of+an+unusual+substituent&doi=10.3762%2Fbjoc.4.13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.4.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.4.13%26sid%3Dliteratum%253Aachs%26aulast%3DLeroux%26aufirst%3DF.%2BR.%26atitle%3DTrifluoromethyl%2520ethers--synthesis%2520and%2520properties%2520of%2520an%2520unusual%2520substituent%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2008%26volume%3D4%26issue%3D13%26doi%3D10.3762%2Fbjoc.4.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M.
T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 Kinase inhibitor for treating cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&issue=10&author=M.%0AT.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.+J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.+M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+Kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0livGR0JbtxxRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.%2BJ.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520Kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D10%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chekroun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrosse, J. R.</span></span> <span> </span><span class="NLM_article-title">Concise preparation of a stable cyclic sulfamidate intermediate in the synthesis of a enantiopure chiral active diamine derivative</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1021/op500264v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op500264v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=506-513&issue=4&author=J.+F.+Rousseauauthor=I.+Chekrounauthor=V.+Fereyauthor=J.+R.+Labrosse&title=Concise+preparation+of+a+stable+cyclic+sulfamidate+intermediate+in+the+synthesis+of+a+enantiopure+chiral+active+diamine+derivative&doi=10.1021%2Fop500264v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Concise Preparation of a Stable Cyclic Sulfamidate Intermediate in the Synthesis of a Enantiopure Chiral Active Diamine Derivative</span></div><div class="casAuthors">Rousseau, Jean-Francois; Chekroun, Isaac; Ferey, Vincent; Labrosse, Jean Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">506-513</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A potentially scalable route to the nonracemic antipsychotic candidate SSR 504374 I was developed using the stereoselective substitution reaction of nonracemic sulfamidate II with 2-chloro-3-trifluoromethylbenzamide as the key step.  II was prepd. in seven steps from 2-benzoylpyridine by chemo- and diastereoselective hydrogenation, sepn. of the desired racemic erythro diastereomer, resoln. with di-p-toluoyl-(+)-tartaric acid, formation of a sulfamidite, and oxidn. at sulfur with RuCl3 and sodium hypochlorite; a workup for the sulfamidite oxidn. using isopropanol was developed to avoid darkening of the intermediate due to oxidn. by RuO2 and RuO4 left in the sulfamidate product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsX3_hyMn6JrVg90H21EOLACvtfcHk0livGR0JbtxxRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOrurk%253D&md5=72c5ea832b893e2bccf01a80c9ea1734</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fop500264v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop500264v%26sid%3Dliteratum%253Aachs%26aulast%3DRousseau%26aufirst%3DJ.%2BF.%26aulast%3DChekroun%26aufirst%3DI.%26aulast%3DFerey%26aufirst%3DV.%26aulast%3DLabrosse%26aufirst%3DJ.%2BR.%26atitle%3DConcise%2520preparation%2520of%2520a%2520stable%2520cyclic%2520sulfamidate%2520intermediate%2520in%2520the%2520synthesis%2520of%2520a%2520enantiopure%2520chiral%2520active%2520diamine%2520derivative%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26issue%3D4%26spage%3D506%26epage%3D513%26doi%3D10.1021%2Fop500264v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foubister, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, B.</span></span> <span> </span><span class="NLM_article-title">Chiral synthesis of 3-substituted morpholines via serine enantiomers and reductions of 5-oxomorpholine-3-carboxylates</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">2577</span>– <span class="NLM_lpage">2580</span>, <span class="refDoi"> DOI: 10.1039/p19850002577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1039%2Fp19850002577" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1985&pages=2577-2580&author=G.+R.+Brownauthor=A.+J.+Foubisterauthor=B.+Wright&title=Chiral+synthesis+of+3-substituted+morpholines+via+serine+enantiomers+and+reductions+of+5-oxomorpholine-3-carboxylates&doi=10.1039%2Fp19850002577"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2Fp19850002577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp19850002577%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DG.%2BR.%26aulast%3DFoubister%26aufirst%3DA.%2BJ.%26aulast%3DWright%26aufirst%3DB.%26atitle%3DChiral%2520synthesis%2520of%25203-substituted%2520morpholines%2520via%2520serine%2520enantiomers%2520and%2520reductions%2520of%25205-oxomorpholine-3-carboxylates%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1985%26volume%3D1%26spage%3D2577%26epage%3D2580%26doi%3D10.1039%2Fp19850002577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buerkler, M.</span></span> <span> </span><span class="NLM_article-title">Iterative one pot reactions of a chiral sulfamidate with 2,4,6-trichloropyridine: regiocontrolled synthesis of linear and angular chiral dipyrrolidino pyridines</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.3987/COM-11-12360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.3987%2FCOM-11-12360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2012&pages=65-72&issue=1&author=P.+Hebeisenauthor=A.+Alkerauthor=M.+Buerkler&title=Iterative+one+pot+reactions+of+a+chiral+sulfamidate+with+2%2C4%2C6-trichloropyridine%3A+regiocontrolled+synthesis+of+linear+and+angular+chiral+dipyrrolidino+pyridines&doi=10.3987%2FCOM-11-12360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Iterative one pot reactions of a chiral sulfamidate with 2,4,6-trichloropyridine: Regiocontrolled synthesis of linear and angular chiral dipyrrolidino pyridines</span></div><div class="casAuthors">Hebeisen, Paul; Alker, Andre; Buerkler, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Heterocycles</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">HTCYAM</span>;
        ISSN:<span class="NLM_cas:issn">0385-5414</span>.
    
            (<span class="NLM_cas:orgname">Japan Institute of Heterocyclic Chemistry</span>)
        </div><div class="casAbstract">The product of the ring opening of a chiral sulfamidate with the 3-lithiopyridine species obtained by deprotonation of 2,4,6-trichloropyridine with BuLi was deprotonated again in situ with BuLi and reacted with a 2nd equiv. of the sulfamidate furnishing a bis(β-aminoethyl)pyridine deriv., which could be cyclized regioselectively to linear or angular chiral dipyrrolidinopyridines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTe-kbbFHcgbVg90H21EOLACvtfcHk0liWqqLGL1SmHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslWnug%253D%253D&md5=07450591f843628878b047a25205e5bf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3987%2FCOM-11-12360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-11-12360%26sid%3Dliteratum%253Aachs%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DAlker%26aufirst%3DA.%26aulast%3DBuerkler%26aufirst%3DM.%26atitle%3DIterative%2520one%2520pot%2520reactions%2520of%2520a%2520chiral%2520sulfamidate%2520with%25202%252C4%252C6-trichloropyridine%253A%2520regiocontrolled%2520synthesis%2520of%2520linear%2520and%2520angular%2520chiral%2520dipyrrolidino%2520pyridines%26jtitle%3DHeterocycles%26date%3D2012%26volume%3D85%26issue%3D1%26spage%3D65%26epage%3D72%26doi%3D10.3987%2FCOM-11-12360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toral-Barza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7942</span>– <span class="NLM_lpage">7945</span>, <span class="refDoi"> DOI: 10.1021/jm901415x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901415x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7942-7945&issue=24&author=A.+Zaskauthor=J.+Kaplanauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=K.+Curranauthor=N.+Brooijmansauthor=E.+M.+Bennettauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=Morpholine+derivatives+greatly+enhance+the+selectivity+of+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors&doi=10.1021%2Fjm901415x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors</span></div><div class="casAuthors">Zask, Arie; Kaplan, Joshua; Verheijen, Jeroen C.; Richard, David J.; Curran, Kevin; Brooijmans, Natasja; Bennett, Eric M.; Toral-Barza, Lourdes; Hollander, Irwin; Ayral-Kaloustian, Semiramis; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7942-7945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dramatic improvements in mTOR-targeting selectivity were achieved by replacing morpholine in pyrazolopyrimidine inhibitors with bridged morpholines.  Analogs I [R1 = (R)- or (S)-3-methyl-4-morpholinyl, 2-methyl-4-morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, etc.; R2 = Me, Et, cyclopropyl, FCH2CH2, 3-pyridyl, 4-pyridyl; R3 = F3CCH2, 1-methoxycarbonyl-4-piperidinyl, 1-ethoxycarbonyl-4-piperidinyl, 3-pyridylmethyl] with subnanomolar mTOR IC50 values and up to 26000-fold selectivity vs. PI3Kα were prepd.  Chiral morpholines gave inhibitors whose enantiomers had different selectivity and potency profiles.  Mol. modeling suggests that a single amino acid difference between PI3K and mTOR (Phe961Leu) accounts for the profound selectivity seen by creating a deeper pocket in mTOR that can accommodate bridged morpholines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2HnMHqTHqbVg90H21EOLACvtfcHk0liWqqLGL1SmHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J&md5=5ef1eee5aa79531970049d3d26b46eb2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm901415x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901415x%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DMorpholine%2520derivatives%2520greatly%2520enhance%2520the%2520selectivity%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D24%26spage%3D7942%26epage%3D7945%26doi%3D10.1021%2Fjm901415x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattachar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchingham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocharski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surendran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span> <span> </span><span class="NLM_article-title">The road map to oral bioavailability: an industrial perspective</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1517/17425255.2.4.591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1517%2F17425255.2.4.591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=16859407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=591-608&issue=4&author=V.+H.+Thomasauthor=S.+Bhattacharauthor=L.+Hitchinghamauthor=P.+Zocharskiauthor=M.+Naathauthor=N.+Surendranauthor=C.+L.+Stonerauthor=A.+El-Kattan&title=The+road+map+to+oral+bioavailability%3A+an+industrial+perspective&doi=10.1517%2F17425255.2.4.591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The road map to oral bioavailability: an industrial perspective</span></div><div class="casAuthors">Thomas, V. Hayden; Bhattachar, Shobha; Hitchingham, Linda; Zocharski, Philip; Naath, Maryanne; Surendran, Narayanan; Stoner, Chad L.; El-Kattan, Ayman</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-608</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Optimization of oral bioavailability is a continuing challenge for the pharmaceutical and biotechnol. industries.  The no. of potential drug candidates requiring in vivo evaluation has significantly increased with the advent of combinatorial chem.  In addn., drug discovery programs are increasingly forced into more lipophilic and lower soly. chem. space.  To aid in the use of in vitro and in silico tools as well as reduce the no. of in vivo studies required, a team-based discussion tool is proposed that provides a road map' to guide the selection of profiling assays that should be considered when optimizing oral bioavailability.  This road map divides the factors that contribute to poor oral bioavailability into two interrelated categories: absorption and metab.  This road map provides an interface for cross discipline discussions and a systematic approach to the experimentation that drives the drug discovery process towards a common goal - acceptable oral bioavailability using minimal resources in an acceptable time frame.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7_zZKacXE7Vg90H21EOLACvtfcHk0lhKae_13zIjpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D&md5=79cf4cea1b89914bd3a8826b5d7360f9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.4.591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.4.591%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DV.%2BH.%26aulast%3DBhattachar%26aufirst%3DS.%26aulast%3DHitchingham%26aufirst%3DL.%26aulast%3DZocharski%26aufirst%3DP.%26aulast%3DNaath%26aufirst%3DM.%26aulast%3DSurendran%26aufirst%3DN.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DEl-Kattan%26aufirst%3DA.%26atitle%3DThe%2520road%2520map%2520to%2520oral%2520bioavailability%253A%2520an%2520industrial%2520perspective%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26issue%3D4%26spage%3D591%26epage%3D608%26doi%3D10.1517%2F17425255.2.4.591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span> <span> </span><span class="NLM_article-title">CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1158%2F1535-7163.MCT-14-1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=25855786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1295-1305&issue=6&author=D.+S.+Mortensenauthor=K.+E.+Fultzauthor=S.+Xuauthor=W.+Xuauthor=G.+Packardauthor=G.+Khambattaauthor=J.+C.+Gamezauthor=J.+Leistenauthor=J.+Zhaoauthor=J.+Apuyauthor=K.+Ghoreishiauthor=M.+Hickmanauthor=R.+K.+Narlaauthor=R.+Bissonetteauthor=S.+Richardsonauthor=S.+X.+Pengauthor=S.+Perrin-Ninkovicauthor=T.+Tranauthor=T.+Shiauthor=W.+Q.+Yangauthor=Z.+Tongauthor=B.+E.+Cathersauthor=M.+F.+Moghaddamauthor=S.+S.+Cananauthor=P.+Worlandauthor=S.+Sankarauthor=H.+K.+Raymon&title=CC-223%2C+a+potent+and+selective+inhibitor+of+mTOR+kinase%3A+in+vitro+and+in+vivo+characterization&doi=10.1158%2F1535-7163.MCT-14-1052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization</span></div><div class="casAuthors">Mortensen, Deborah S.; Fultz, Kimberly E.; Xu, Shuichan; Xu, Weiming; Packard, Garrick; Khambatta, Godrej; Gamez, James C.; Leisten, Jim; Zhao, Jingjing; Apuy, Julius; Ghoreishi, Kamran; Hickman, Matt; Narla, Rama Krishna; Bissonette, Rene; Richardson, Samantha; Peng, Sophie X.; Perrin-Ninkovic, Sophie; Tran, Tam; Shi, Tao; Yang, Wen Qing; Tong, Zeen; Cathers, Brian E.; Moghaddam, Mehran F.; Canan, Stacie S.; Worland, Peter; Sankar, Sabita; Raymon, Heather K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1295-1305</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MTOR is a serine/threonine kinase that regulates cell growth, metab., proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) are crit. mediators of the PI3K-AKT pathway, which is frequently mutated in many cancers, leading to hyperactivation of mTOR signaling.  Although rapamycin analogs, allosteric inhibitors that target only the mTORC1 complex, have shown some clin. activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.  Here, we describe the preclin. characterization of CC-223.  CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems.  Growth inhibitory activity was demonstrated in hematol. and solid tumor cell lines. mTOR kinase inhibition in cells, by CC-223, resulted in more complete inhibition of the mTOR pathway biomarkers and improved antiproliferative activity as compared with rapamycin.  Growth inhibitory activity and apoptosis was demonstrated in a panel of hematol. cancer cell lines.  Correlative anal. revealed that IRF4 expression level assocs. with resistance, whereas mTOR pathway activation seems to assoc. with sensitivity.  Treatment with CC-223 afforded in vivo tumor biomarker inhibition in tumor-bearing mice, after a single oral dose.  CC-223 exhibited dose-dependent tumor growth inhibition in multiple solid tumor xenografts.  Significant inhibition of mTOR pathway markers pS6RP and pAKT in CC-223-treated tumors suggests that the obsd. antitumor activity of CC-223 was mediated through inhibition of both mTORC1 and mTORC2.  CC-223 is currently in phase I clin. trials.  Mol Cancer Ther; 14(6); 1295-305. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDt9130-L0z7Vg90H21EOLACvtfcHk0liL4mxo3skyaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D&md5=f33b21dc89dedaf14fab54a819afb917</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1052%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DGamez%26aufirst%3DJ.%2BC.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DApuy%26aufirst%3DJ.%26aulast%3DGhoreishi%26aufirst%3DK.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DBissonette%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.%2BX.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DW.%2BQ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26aulast%3DCanan%26aufirst%3DS.%2BS.%26aulast%3DWorland%26aufirst%3DP.%26aulast%3DSankar%26aufirst%3DS.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26atitle%3DCC-223%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520mTOR%2520kinase%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D6%26spage%3D1295%26epage%3D1305%26doi%3D10.1158%2F1535-7163.MCT-14-1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nosik, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabukhin, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artamonov, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grygorenko, O. O.</span></span> <span> </span><span class="NLM_article-title">Synthesis of trans-disubstituted pyrazolylcyclopropane building blocks</span>. <i>Monatsh. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>147</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1629</span>– <span class="NLM_lpage">1636</span>, <span class="refDoi"> DOI: 10.1007/s00706-016-1726-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1007%2Fs00706-016-1726-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFyksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2016&pages=1629-1636&issue=9&author=P.+S.+Nosikauthor=S.+V.+Ryabukhinauthor=O.+S.+Artamonovauthor=O.+O.+Grygorenko&title=Synthesis+of+trans-disubstituted+pyrazolylcyclopropane+building+blocks&doi=10.1007%2Fs00706-016-1726-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of trans-disubstituted pyrazolylcyclopropane building blocks</span></div><div class="casAuthors">Nosik, Pavel S.; Ryabukhin, Sergey V.; Artamonov, Oleksiy S.; Grygorenko, Oleksandr O.</div><div class="citationInfo"><span class="NLM_cas:title">Monatshefte fuer Chemie</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1629-1636</span>CODEN:
                <span class="NLM_cas:coden">MOCMB7</span>;
        ISSN:<span class="NLM_cas:issn">0026-9247</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">Diastereoselective synthesis of trans-disubstituted pyrazolylcyclopropane building blocks (i.e. carboxylic acids and amines) is described starting from easily available pyrazolecarbaldehydes.  The key step of the synthesis was Corey-Chaikowsky cyclopropanation of the corresponding α,β-unsatd. Weinreb amides.  The title compds. were prepd. in four or six steps and 32-60 and 17-40 % overall yields, resp., on up to 50 g scale.  The building blocks obtained are good starting points for the design of lead-like libraries of peptidomimetic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5JO82cKC1R7Vg90H21EOLACvtfcHk0liL4mxo3skyaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFyksbg%253D&md5=1b4cd76fed0aa27fc3134d8bbe4a301f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs00706-016-1726-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00706-016-1726-6%26sid%3Dliteratum%253Aachs%26aulast%3DNosik%26aufirst%3DP.%2BS.%26aulast%3DRyabukhin%26aufirst%3DS.%2BV.%26aulast%3DArtamonov%26aufirst%3DO.%2BS.%26aulast%3DGrygorenko%26aufirst%3DO.%2BO.%26atitle%3DSynthesis%2520of%2520trans-disubstituted%2520pyrazolylcyclopropane%2520building%2520blocks%26jtitle%3DMonatsh.%2520Chem.%26date%3D2016%26volume%3D147%26issue%3D9%26spage%3D1629%26epage%3D1636%26doi%3D10.1007%2Fs00706-016-1726-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. P.</span></span> <span> </span><span class="NLM_article-title">Combinatorial synthesis of functionalized chiral and doubly chiral ionic liquids and their applications as asymmetric covalent/non-covalent bifunctional organocatalysts</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1039/B713843A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1039%2FB713843A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18219429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=567-576&issue=3&author=L.+Zhangauthor=S.+Luoauthor=X.+Miauthor=S.+Liuauthor=Y.+Qiaoauthor=H.+Xuauthor=J.+P.+Cheng&title=Combinatorial+synthesis+of+functionalized+chiral+and+doubly+chiral+ionic+liquids+and+their+applications+as+asymmetric+covalent%2Fnon-covalent+bifunctional+organocatalysts&doi=10.1039%2FB713843A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial synthesis of functionalized chiral and doubly chiral ionic liquids and their applications as asymmetric covalent/non-covalent bifunctional organocatalysts</span></div><div class="casAuthors">Zhang, Long; Luo, Sanzhong; Mi, Xueling; Liu, Song; Qiao, Yupu; Xu, Hui; Cheng, Jin-Pei</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-576</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A facile combinatorial strategy was developed for the construction of libraries of functionalized chiral ionic liqs. (FCILs) including doubly chiral ionic liqs. and bis-functional chiral ionic liqs.  These FCIL libraries have the potential to be used as asym. catalysts or chiral ligands.  As an example, novel asym. bifunctional catalysts were developed by simultaneously incorporating functional groups onto the cation and anion.  The resultant bis-functionalized CILs showed significantly improved stereoselectivity over the mono-functionalized parent CILs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hq6lB5tNW7Vg90H21EOLACvtfcHk0lh1CFE-0_yoLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWhs7o%253D&md5=4cec4a7bff2e3b65c7aac57156230d27</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2FB713843A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB713843A%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DMi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DJ.%2BP.%26atitle%3DCombinatorial%2520synthesis%2520of%2520functionalized%2520chiral%2520and%2520doubly%2520chiral%2520ionic%2520liquids%2520and%2520their%2520applications%2520as%2520asymmetric%2520covalent%252Fnon-covalent%2520bifunctional%2520organocatalysts%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2008%26volume%3D6%26issue%3D3%26spage%3D567%26epage%3D576%26doi%3D10.1039%2FB713843A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.%0AA.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lh1CFE-0_yoLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lh1CFE-0_yoLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB','PDB','5JHB'); return false;">PDB: 5JHB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6','PDB','4JT6'); return false;">PDB: 4JT6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZIM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZIM','PDB','3ZIM'); return false;">PDB: 3ZIM</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i116"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00972">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_31824"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00972">10.1021/acs.jmedchem.9b00972</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Syntheses of bromo derivative <b>44</b> (Scheme S1), bromo derivative <b>49</b> (Scheme S2), and compounds <b>3a</b>–<b>5a</b> and <b>3b</b>–<b>5b</b> (Scheme S3); plasma concentration of <b>7b</b> after a single po dose of 5 mg/kg in rats (Table S1); brain concentration of <b>7b</b> after a single po dose of 5 mg/kg in rats (Table S2); plasma concentration of <b>12b</b> after a single po dose of 5 mg/kg in rats (Table S3); brain concentration of <b>12b</b> after a single po dose of 5 mg/kg in rats (Table S4); stability of compound <b>11b</b> (5 μM) in primary mouse, rat, dog, and human hepatocytes (Table S5); CYP1A1 and CYP1A2 metabolites identification of <b>11b</b> (Table S6); proposed metabolic pathway for CYP-dependent metabolism of <b>11b</b> (Figure S1); chromatogram of compound <b>11b</b> incubated with CYP1A1 (60 min) (Figure S2); chromatogram of compound <b>11b</b> incubated with CYP1A1 (0 min) (Figure S3); chromatogram of compound <b>11b</b> incubated with CYP1A2 (60 min) (Figure S4); chromatogram of compound <b>11b</b> incubated with CYP1A2 (0 min) (Figure S5); activity data and standard errors of final compounds (Table S7); activity data and standard errors of compounds for modeling (Table S8); TREEspot data visualization of KINOMEScan interactions of compound <b>12b</b>, PQR620, and INK128 (Figure S6); selectivity profile calculated from KinomeScan data (Table S9); kinase interactions (KINOMEscan data) (Table S10); <sup>1</sup>H NMR, <sup>13</sup>C{<sup>1</sup>H} NMR, and NSI-HRMS spectra; HPLC chromatograms; chemical structures of final compounds and intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Compound <b>3a</b>-PI3Kγ (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>2a</b>-mTOR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>2b</b>-mTOR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>2a</b>-PI3Kα (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>2b</b>-PI3Kα (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_007.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_001.pdf">jm9b00972_si_001.pdf (15.39 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_002.pdb">jm9b00972_si_002.pdb (0.99 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_003.pdb">jm9b00972_si_003.pdb (1.73 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_004.pdb">jm9b00972_si_004.pdb (1.73 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_005.pdb">jm9b00972_si_005.pdb (1.05 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_006.pdb">jm9b00972_si_006.pdb (1.07 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00972/suppl_file/jm9b00972_si_007.csv">jm9b00972_si_007.csv (3.17 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB">5JHB</a> was used for docking of compound <b>3a</b> into PI3Kγ. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a> was used for docking of compounds <b>2a</b> and <b>2b</b> into mTOR kinase. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZIM">3ZIM</a> was used for docking of compounds <b>2a</b> and <b>2b</b> into PI3Kα.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00972%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-18%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00972" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997cec986b3d9a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
